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Activation of the N-methyl-D-aspartate(NMDA) receptor is important in both physiological
and pathological phenomena, including synaptogenesis, long-term potentiation,
neuroexcitotoxicity and epilepsy. Although implicated in postnatal formation of synaptic
connections, over-activation of the NMDA receptor in the neonate, as a result of say a
hypoxic-ischaemic insult, can lead to neuronal damage. Antagonists for specific sites on the
NMDA receptor complex may therefore prove to be novel therapeutic agents for preventing
excitotoxic neuronal damage. I have therefore investigated the ontogeny of the NMDA
receptor complex as well as modulation of the receptor in both adult and neonatal rat brain
tissue.
Radioligand binding studies were performed using high-affinity NMDA receptor antagonists.
[ H]3-((±)-2-carboxypiperazin-4-yl)propyl-l-phosphonoate ([ H]CPP) and [ H]D-2-amino-5-
phosphonopentanoate([ HJD-AP5), both competitive antagonists which bind to the NMDA
neurotransmitter recognition site, and [ H]dizocilpine a non-competitive antagonist which
binds to a site within the lumen of the NMDA-associated ion channel, were used. Optimal
experimental conditions were established for the binding of each ligand to membranes
prepared from rat brain tissue. This allowed reliable and reproducible measurements to be
made under different modulatory conditions. Using mature tissue the binding of [TfjCPP was
compared with that of [ H]AP5 in the presence of compounds active at the glycine modulatory
site including glycine, 7-chlorokynurenate and 3-amino-l-hydroxypyrrolid-2-one(HA-966).
Differential effects were seen on the binding of each ligand. The findings provide further
evidence for the hypothesis that the NMDA receptor exists in more than one conformational
state, these being regulated by glycine.
[3H]CPP and [3H]dizocilpine were used to investigate the ontogeny of their respective binding
sites. Each ligand bound to membranes prepared at various postnatal ages between birth and
adulthood. The binding of both ligands was detectable at the earliest ages examined,
increasing with postnatal age. [ H]CPP binding reached a level equivalent to that seen in
adult rats during the fourth week of life. [Tf|Dizocilpine binding was investigated in the
presence and absence of L-glutamate and/or glycine to try and elucidate underlying
modulatory changes resulting in alterations in postnatal binding. Binding was modulated by
both amino acids at all ages tested. Specific binding under each condition reached adult
equivalent levels at earlier ages than seen for [ H]CPP binding. For both ligands the
differences in binding between postnatal ages were due to an alteration in receptor density but
not to an alteration in receptor affinity. The receptor density for [ H]dizocilpine binding did
not alter significantly between experimental conditions, thus confirming that only the receptor
affinity is influenced by L-glutamate and/or glycine. As for adult tissue this was also true for
immature tissue.
Clearly both binding sites, as well as the glycine modulatory site, are present and functionally
coupled from an early stage of postnatal development. However, the neurotransmitter and the
ion channel sites have different developmental time-courses. Postnatal development of the
[ H]CPP site does however have a similar profile to the postnatal development of L-glutamate
levels as well as to the development of synaptic connections in rat brain. NMDA antagonists
active at any of the three mentioned sites could therefore play an important role in the
treatment of neonatal as well as adult excitotoxic damage caused by excessive activation of the
NMDA receptor.
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A wealth of evidence suggests that acidic amino acids are important endogenous
excitatory neurotransmitters in the mammalian central nervous system (CNS) although
the actual identity of the excitatory amino acid (EAA) neurotransmitter(s) remains
elusive. L-Glutamate and L-aspartate still remain the most likely candidates. Topical
application of the amino acids L-glutamate and L-aspartate to the mammalian cerebral
cortex was shown to cause convulsive behaviour in the mid 1950's (Hayashi, 1954).
Curtis and Watkins, pioneers in the field of EAA research, later demonstrated that L-
glutamate and other monoamino-dicarboxylic amino acids depolarised cat spinal
neurones, resulting in the generation of action potentials (Curtis and Watkins, 1960).
These initial findings have led to a great explosion of research in the EAA field,
especially in the last decade. Specific receptors for the EAA neurotransmitters) have
been identified in the mammalian CNS and physiological roles have been assigned to
them (Watkins et al, 1990). The N-methyl-D-aspartate (NMDA) receptor is the most
widely investigated EAA receptor. It has been implicated as having a number of
physiological and pathological roles and interest in the NMDA receptor lies in the
potential of NMDA receptor antagonists as therapeutically useful drugs in a wide range
of neurological dysfunctions (Collingridge and Lester, 1989). Paradoxically non-
NMDA receptors were cloned, and the molecular structure known, earlier than the
NMDA receptor (Hollman et al, 1989; Masu et al, 1991; Keinanen et al, 1990).
Recently however L-glutamate receptor subunits exhibiting typical NMDA receptor
characteristics have been cloned (Moriyoshi et al, 1991; Meguro et al, 1992). Work
can now proceed to determine the molecular mechanisms of both NMDA and non-
NMDA receptors.
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1.2 EAA NEUROTRANSMITTER CANDIDATES IN THE MAMMALIAN
CMS
Neurotransmitter substances may be classified either as excitatory or inhibitory,
depending on whether the substance causes a depolarisation or a hyperpolarisation of
the neuronal membrane. Glycine and y-amino-butyric acid (GABA) have been
identified and characterised as the major inhibitory neurotransmitters in the adult
mammalian CNS, whereas L-glutamate is thought to be the major excitatory
neurotransmitter (Graham et al, 1967; Fagg and Foster, 1983; Fonnum, 1984). It has
already been identified as the transmitter at the insect neuromuscular junction
(Usherwood, 1981). Other excitatory amino acid neurotransmitter candidates in the
mammalian CNS include L-aspartate, N-acetyl-L-aspartyl-L-glutamate (NAAG),
quinolinate and the sulphur containing analogues of L-glutamate and L-asparate such as
L-homocysteic acid (L-HCA) (Fig.l; Collingridge and Lester, 1989). To be classed as
a neurotransmitter a substance must satisfy a number of specific criteria. These criteria
were originally proposed for identification of peripheral transmitters but can also be
generalised to the CNS, (Orrega, 1979). These criteria state that the transmitter must
be present in presynaptic terminals with synthetic enzymes capable of synthesising the
neurotransmitter from precursors. The transmitter should be released in sufficient
quantities to elicit a postsynaptic response which can be mimicked by exogenous
application of the substance. The transmitter candidate should also have a regional
distribution in the CNS, with a mechanism for inactivation. It is difficult to prove that a
candidate substance satisfies all the criteria but the potential excitatory amino acid
candidates shall now be considered.
L-Glutamate
Most available evidence points to L-glutamate being the principle excitatory
neurotransmitter candidate in the mammalian CNS. L-Glutamate has the highest
concentration (lOmM) of all amino acids in the CNS (Perry et al, 1971), but shows no


























FIGURE 1 ; Chemical structures of endogenous EAA agonists
Abbreviations: L-HCSA, L-homocysteine sulphinic acid; L-HCA, L-homocysteic
acid; L-CSA, L-cysteine sulphinic acid; L-CA, L-cysteic acid; NAAG, N-acetyl-L-
aspartyl-L-glutamate
the dorsal and ventral roots of the spinal cord (Fonnum, 1984; Graham et al, 1967). It
plays an integral role in metabolic processes namely deamination, transamination and
amidation reactions which are involved in the detoxification of ammonia in the CNS
(Weil-Malherbe, 1950). This ubiquitous distribution and integral role in cell
metabolism makes it very difficult to separate the metabolic pool of L-glutamate from
the neurotransmitter pool. L-Glutamate is also a precursor of the inhibitory
neurotransmitter, GABA (Roberts and Frankel, 1950).
The synthesis of neurotransmitter L-glutamate has been shown to be extremely
complex (Fonnum, 1984). Glucose, acetate, glutamine, 2-oxyglutarate and ornithine
have all been proposed as putative precursors (Fig.2), (Potashner, 1978; Reijnierse et
al, 1975; Hamberger et al, 1979a,b; Fonnum, 1984; Yoneda et al, 1982).
Glutamine is probably the major precursor candidate for neurotransmitter L-
glutamate synthesis (Fig.2B; Shank and Campbell, 1983). Phosphate activated
glutaminase, which converts glutamine to L-glutamate, has been demonstrated in nerve
terminals (Kvamme, 1983; Ward et al, 1982). Double labelling release studies
resulted in four times more L-glutamate derived from glutamine being released as that
derived from glucose (Hamberger et al, 1979a,b; Bradford et al, 1978). A major
proportion of the glutamine is thought to originate from L-glutamate breakdown in glial
cells. Preloading synaptosomes with glutamine has been shown to increase L-
glutamate release indicating that newly acquired glutamine is readily converted into a
releasable pool of L-glutamate (Johansen et al, 1987).
Brain slice and synaptosomal membrane preparations are commonly used to
demonstrate both neurotransmitter release and re-uptake systems. Using a variety of
2+
depolarising stimuli, Ca -dependent release of radiolabelled L-glutamate has been
demonstrated (Potashner, 1978; Nadler et al, 1978; Toggenburger et al, 1982).
Release of endogenous L-glutamate has been measured both in vivo (Abdul-Ghani et
al, 1979) and in vitro (Malthe-Sorenssen et al, 1980; Collins, 1980). Depolarisation of
2+
glial preparations also results in release of L-glutamate but in a Ca -independent














FIGURE 2 : Synthetic and metabolic pathways of neurotransmitter L-glutamate
A. One of the many proposed synthetic pathways of neurotransmitter L-glutamate, in
this case the substrate is glucose. The relationship with the synthesis of L-
aspartate is clearly shown.
B. Diagrammatic representation of the L-glutamate-glutamine cycle in L-glutamate
releasing neurons and associated glial cells. Abbreviations: G, L-glutamate; Gn,
glutamine; Ca, calcium ions.
distinguish between the neurotransmitter and metabolic pools of L-glutamate.
Decortication of rats resulted in the selective loss of L-glutamate release from the
striatum, this is presumed to be the transmitter pool. The large reduction following
kainate lesioning of the striata probably reflects the metabolic pool (Butcher and
Hamberger, 1987).
Using synaptosomal preparations L-glutamate uptake into neurones was shown
to be Na+-dependent, requiring two Na+ ions per molecule of L-glutamate (Bennet et
al, 1973; Stallcup, 1979). Na+-Dependent glial cell uptake is also an important
process for removing L-glutamate from the synaptic cleft (Hertz, 1975) (Fig.2B).
Decreased L-glutamate uptake after lesioning of presumed glutamatergic pathways has
been demonstrated in the nucleus accumbens and caudate putamen (Walaas, 1981) as
well as other subcortical areas (Young et al, 1981). The neuronal and the glial cell
uptake system are both selective for L-glutamate and D and L-aspartate, with no other
amino acids being transported to any great extent (Davies and Johnston, 1976).
Glutamate-induced excitation is therefore prolonged in the presence of uptake
inhibitors (Johnston et al, 1980).
Finally, L-glutamate has been demonstrated to interact with specific receptors in
the mammalian CNS. Exogenous application of L-glutamate mimics the actions of
endogenous L-glutamate (Curtis and Watkins, 1960). The identification of antagonists
of L-glutamate induced excitations have helped in the definition of specific EAA
receptors (Watkins, 1986). Although three L-glutamate receptors were initially
classified (Watkins and Evans, 1981), five receptor subtypes (Table 2) have been
identified with the possibility of further subclasses (see Watkins, 1989; Monaghan et
al, 1988).
L-Aspartate
L-Aspartate (Fig.l) certainly cannot be discounted as a central excitatory
neurotransmitter although its effects cannot be easily separated from those of L-
glutamate, because they are metabolically related through a transamination reaction
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(Fonnum, 1984). L-Aspartate may be synthesised as a biprcxluct of a L-glutamate
synthetic pathway (Fig.2). Both amino acids are substrates for the same uptake carrier
(Davies and Johnston, 1976). In vivo they are both released upon stimulation and
interpretation of uptake and release studies is therefore very difficult (Watkins and
Evans, 1981). Most of what has already been discussed in the preceding section on L-
glutamate also applies equally to L-aspartate. Uptake studies show similar ratios
between L-aspartate and L-glutamate throughout the brain (McGeer et al, 1977).
Differences have, however, been clearly observed between the binding
3 3
specificities of [ H]L-aspartate and [ H]L-glutamate to synaptic membrane
preparations (Foster et al, 1981 a). Electrophysiological studies have also demonstrated
differences in responses to L-aspartate and L-glutamate (Duggan, 1974; Davies and
Watkins, 1973).
Other EAA transmitter candidates
Curtis and Watkins (1963) originally demonstrated the potency of sulphur
containing amino acids as neuronal excitants (Fig.l). Most evidence points to L-
homocysteate (L-HCA) as having an excitatory neurotransmitter role, since it is twelve
times more potent than L-glutamate as an excitant of central neurones and has a
selective action at the NMDA receptor (Mewett et al, 1983).
L-HCA release from brain slices was higher than for other sulphur containing
homologues with L-HCA-like immunoreactivity and L-HCA release both being highest
in brain areas containing a high density of NMDA receptors (Do et al, 1986b). (±)-B-p-
Chlorphenylglutamate an amino acid uptake blocker (Davies et al, 1985) prolonged the
depolarisation affect of L-HCA but did not effect the responses of other amino acids on
brain slices, indicating a specific uptake system for L-HCA (Zeise et al, 1988). The
NMDA antagonists 2-amino-5-phosphonopentanoate (AP5) and 2-amino-7-
phosphonoheptanoate (AP7) abolished the NMDA response, markedly reduced the L-
HCA response, but had no effect on the L-glutamate induced depolarisations (Do et al,
1986a; Knopfel et al, 1987). L-HCA has similar stimulatory actions to L-glutamate on
-5-
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[ H]dizocilpine binding, an effect blocked by CPP and potentiated by glycine (Schwarz
et al, 1990). This is an indication that the site of action is the L-glutamate
neurotransmitter site. The excitotoxic effect of L-HCA has a similar pharmacological
profile to that of NMDA but not kainate (KA) (Olney et al, 1987). No definitive
evidence exists yet as to the synthesis of L-HCA within the CNS but Griffiths et al
(1992) suggest that it may be analogous to the synthesis of L-cysteic acid.
Electrophysiological and biochemical evidence would certainly support the view that if
L-HCA and other sulphur containing amino acids are central neurotransmitters they act
specifically on the NMDA receptor. They may be responsible for the neurotoxic
effects caused by activation of the NMDA receptor (Olney et al, 1990).
N-Acetyl-L-aspartyl-L-glutamate (NAAG) is a dipeptide containing both L-
glutamate and L-aspartate within its structure (Fig.l). First identified around twenty
five years ago (Curatola et al, 1965), Zaczek et al (1983) have proposed it as a central
neurotransmitter candidate. NAAG is now well characterised as a potential excitatory
neurotransmitter. It has a defined regional distribution (Koller et al, 1984) and NAAG-
like immunoreactivity (NAAG-LI) exhibits a high degree of localisation within
glutamatergic neurones (Coyle et al, 1989), as well as co-localisation in groups of
cholinergic, serotonergic and noradrenergic neurones (Forloni et al, 1987; Guarda et
al, 1988). This may be suggestive of NAAG having a role as a neuromodulator rather
than a neurotransmitter. The actions of NAAG are terminated by enzymatic
hydrolyses with high affinity reuptake of breakdown products (Robinson et al, 1987;
Coyle et al, 1989). NAAG has been found to depolarise central neurones whilst its
breakdown product N-acetylaspartate (NAA) is inactive thereby suggesting excitatory
activity is due only to the peptide itself (ffrench-Mullen et al, 1985). However, L-
glutamate itself is also liberated (Coyle et al, 1989), and thus may be responsible for the
neurotransmitter actions of NAAG. Electrophysiologically NAAG has been shown to
have both NMDA and non-NMDA characteristics (ffrench-Mullen et al, 1985;
Westbrook et al, 1986).
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Quinolinic acid (Fig. 1) is an endogenous tryptophan metabolite and is a potent
excitant comparable with L-glutamate on single cortical neurones (Stone and Perkins,
1981). This excitatory activity is antagonised in parallel with NMDA by AP5, AP7
and HA-966 (3-amino-l-hydroxypyrrolidin-2-one) in vivo and in vitro (Perkins and
Stone, 1983; 1985). Wolfensberger etal (1983) have identified low concentrations of
endogenous quinolinate in both rat and human brain (<l|iM). Distinct regional
variations in quinolinate concentration have been measured as well as an increase in
concentration with age (Moroni et al, 1984a,b). Unusually, quinolinate does not
activate all NMDA-sensitive neurones, suggesting that it may be a selective agonist at a
specific subtype of NMDA receptor (Perkins and Stone, 1983). Herrling et al (1983)
provided further evidence for NMDA selectivity by observing that quinolinate
mimicked NMDA but not quisqualate responses. Quinolinate is not a substrate for the
3
L-glutamate uptake system and there is no evidence for uptake of [ H]-quinolinate into
synaptosomes or brain slices (Balcar and Johnston, 1972; Foster and Fagg, 1984;
Collins et al, 1985). The main argument against quinolinate being a neurotransmitter is
probably the lack of an uptake system to terminate its actions. Continual quinolinate
stimulation could lead to receptor desensitisation and potentially to neurotoxicity
mediated via the NMDA receptor, and so may therefore have greater pathological than
physiological importance (Stone and Connick, 1985). Quinolinate has indeed been
implicated as a mediator of neurodegeneration in Huntington's chorea (Beal et al,
1986), as well as in HIV-1 infected patients where increases in CSF quinolinate have
been detected (Heyes, 1990).
Identification of EAA receptors
The neurotransmitter candidates discussed in the preceding section elicit their
action by interacting with one or more of the identified postsynaptic EAA receptors
including the NMDA receptor. McLennan et al (1968) demonstrated
electrophysiologically a regional difference in the CNS in the potency of L-glutamate.
This was confirmed by Duggan (1974) and McCulloch et al (1974) who found that
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neurones in the dorsal horn of the spinal cord were more sensitive to L-glutamate than
L-aspartate and that NMDA and KA were acting on different receptors. Davies and
Watkins (1973) went on to demonstrate that HA-966 was more effective at blocking L-
aspartate elicited depolarisations than those of L-glutamate. This led to proposals of
2+
more than one EAA receptor. The later observation that Mg had a more profound
effect on NMDA and L-aspartate induced excitations than those elicited by kainate
(KA), quisqualate (QA) and L-glutamate (Evans et al, 1977; Ault et al, 1980) proved to
be of great importance in the differentiation of EAA receptors.
3A major step forward came when Monaghan et al (1983) using [ H]L-glutamate
demonstrated the existence of four separate EAA receptors autoradiographically, with
high affinities for NMDA, AMPA (a-amino-2-hydroxy-5-methyl-4-isoxazole
propionic acid), L-AP4 (2-amino-4-phosphonbutanoate) and KA. These studies
compared well with known electrophysiological and neurotoxicity data.
14
[ C]L-glutamate was the first radioligand used to study the binding of L-
glutamate to synaptic membranes, (Roberts, 1974; Michaelis et al, 1974). These two
independent studies found that the binding was saturable, of high affinity and was
displaced by other neuroexcitatory amino acids. This was the first indication of a
3
receptor interaction. L-glutamate binding studies were hampered until [ H]L-
glutamate of a higher specific activity became available and receptor selective drugs
were introduced. This led to the demonstration that detectable binding was specific for
the CNS and not the periphery (Biziere et al, 1980; Foster and Roberts, 1978). Not
only was binding specific for the CNS but it was specifically located in the synaptic
junction (Foster and Roberts, 1978; Foster et al, 1981b), indicating a synaptic role for
L-glutamate.
A wide range of values for binding site affinity (K^) and binding site density
3
(B ) have been reported for [ H]L-glutamate binding depending on the membranemax w
preparation used, the ions present in the assay and other alterations in assay conditions
-8-
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(see Foster and Fagg, 1984). Foster and Fagg (1984) have divided [ H]L-glutamate
binding up into high, medium and low affinity binding sites, subdivided by further ionic
specificity.
The advent of specific NMDA antagonists radiolabeled to a high specific
activity has enabled research on the NMDA receptor to proceed most rapidly. The
3
ligands used to identify the non-NMDA receptors apart from [ H]CNQX (Nielsen et al,
1990) however are still radiolabelled selective agonists (Table 1). The five EAA
receptors classified pharmacologically are shown in Table 2.
Over the past few years there have been rapid advances made in the cloning and
purification of L-glutamate receptor subunits. The G-protein linked metabotropic
receptor has been demonstrated to have similarities to other known G-protein coupled
receptors which stimulate phosphoinositide metabolism in that it possesses a large
amino-terminal extracellular domain and the putative 7 transmembrane segments
(Masu etal, 1991).
The ionotropic EAA receptors have also been cloned and in common with other
ligand-gated ion channels (Betz, 1990) they have four putative transmembrane
segments arranged in a similar conformation. However many structural features also
differ (Barnes and Henley, 1992). This may be suggestive of a superfamily of
ionotropic EAA receptors (Mayer, 1991). However, certain features do not appear to
be conserved even within the EAA receptor subgroup. There is certainly still much to
be investigated regarding the molecular structure of EAA receptors, which reveals a
wide diversity of EAA receptor subtypes and will help in the understanding of their
molecular mechanisms.
Physiological and pathological roles of EAA receptors
The NMDA receptor has been identified as playing a role in normal synaptic
transmission (Davies, 1989) as well as in the phenomenon of long term potentiation
(LTP; Collingridge et al, 1983). LTP is thought to be a good cellular correlate for
learning and memory. Morris et al (1986) have demonstrated that the NMDA
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TABLE 2 CLASSIFICATION OF THE EXCITATORY AMINO ACID
RECEPTORS















































* The AMPA receptor was previously named the quisqualate receptor.
Abbreviations: NMDA, N-methyl-D-aspartate; AP5, 2-amino-5-
phosphonopentanoate; AP7, 2-amino-7-phosphonoheptanoate; CPP, 3-((-)-2-
carboxypiperazin-4-yl)propyl-l-phosphonate; CGS 19755.1 (cis-2-carboxypiperidine-
4-yl)methyl-l-phosphonate; PCP, phencyclidine; TCP, N-[l-thienyl]-cyclohexyl-3,4-
piperidine; HA-966, 3-amino-l-hydroxypyrrolidin-2-one; ACC, 1-
aminocyclopentanecarboxylate; MNQX, 5,7-dintroquinoxaline-2,3-dione; AMPA, a-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; CNQX, 6-cyano-7-
nitroquinoxaline-2,3-dione; DNQX, 6,7-dinitroquinoxaline-2,3-dione; NBQX,6-

















FIGURE 3: Chemical structures of exogenous EAA agonists
Abbreviations: NMDA, N-methyl-D-aspartate; AMPA,x-amino-3-hydroxy-5-methyl-
4-isoxazole propionate.
t
antagonist D-AP5 impairs learning and memory. The NMDA receptor is also involved
in epileptiform burst discharges and has been implicated in the development of
neurones in the CNS (Ben-Ari and Represa, 1989). It is thought that inappropriate
activation of NMDA receptors may be responsible for neurodegeneration in a number
of identified pathological conditions including Alzheimer's disease, Huntington's
chorea (HC) and excitotoxic neural damage resulting from hypoxic ischaemic insults
(Bullock etal, 1990; Bridges etal, 1988; Woodruff etal, 1988). A more extensive list
of clinical conditions in which the NMDA receptor is implicated is given in Herrling
(1989). The non-NMDA receptors have also has roles assigned to them. KA and
AMPA receptors are also important in LTP and in fast synaptic transmission
(Collingridge and Lester, 1989). The KA/AMPA antagonist 2,3-dihyroxy-6-nitro-7-
sulfamyl-benzo (F) quinoxaline, (NBQX) has been demonstrated to act as a
neuroprotectant in cerebral ischaemia (Sheardown et al, 1990), thus these receptors are
important in mediating neurotoxic cell damage. The metabotropic receptor has been
implicated in neurodegenerative disease, and in neuronal developmental plasticity (Cha
et al, 1990; Nicoletti et al, 1988). Recent evidence also proposed a role for this
receptor in synaptic transmission (Miller, 1991a).
1.3 NON-NMDA EAA RECEPTORS
The four non-NMDA receptors are poorly characterised compared with the
NMDA receptor. This is due to the lack of compounds acting selectively at any one of
the non-NMDA sites. Agonists are still used in preference to the few non-selective
antagonists available, to investigate these receptors (Fig.3). Two of these receptors are
linked directly to ion channels (KA and AMPA receptors). The physiological
mechanism of the L-AP4 receptor is as yet poorly understood. KA and QA (Fig.3) are
both plant extracts and potent excitants of central neurons acting at EAA receptors
(Takemoto, 1978; Shinozaki et al, 1974; Biscoe et al, 1976). AMPA (Fig.3) is more
selective than QA at the ionophore linked QA receptor, thus the ionotropic QA receptor
is now termed the AMPA receptor (Krogsgaard-Larsen et al, 1980; Sugiyama et al,
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1988). Due to the lack of selective antagonists it has been difficult to separate KA and
AMPA responses. Both receptors are linked to low conductance ion channels which
conduct Na+ and K+ in a voltage independent manner (Ascher and Nowak, 1988b;
Crunelli et al, 1984; MacDonald et al, 1982). Radioligand binding studies have
demonstrated differences in receptor distribution using [^H]AMPA, [^H]CNQX and
[^H]KA (Nielsen et al, 1990; Slevin and Coyle, 1981). The distribution of AMPA
receptors resembles that of NMDA receptors (high in hippocampal CA1 area, outer
cortical layers and molecular layer of the cerebellum) as opposed to KA receptor
distribution (highest in the CA3 region of the hippocampus, deep cortical layers,
striatum and granule cell layer of the cerebellum) (Monaghan et al, 1983; 1985; Cha et
al, 1988). Although there are clear differences, there is a degree of response overlap
which has been explained as both responses being mediated through the same receptor-
channel complex with differences in desensitisation or conductance states accounting
for the varied responses (see Collingridge and Lester, 1989; Nicoll et al, 1990). Cross-
desensitisation studies may help to understand the situation fully. This doubt about the
KA/AMPA receptor(s) and ion channel(s) is still apparent even though a functional KA
receptor which is insensitive to QA and a family of AMPA-selective receptors have
been cloned (Hollman et al, 1989; Keinanen et al, 1990).
The quinoxalinediones are the most effective KA/AMPA antagonists available
to date (Honore et al, 1988; Blake et al, 1988; Drejer and Honore, 1988), although
they are also reported to interact with the NMDA glycine site (Birch et al, 1988a,b).
Electrophysiological studies have shown that 6-cyano-7-nitroquinoxaline-2,3-dione
(Fig.7; CNQX) and 6,7-dinitroquinoxaline-2,3-dione (DNQX) depress AMPA
responses to a greater, lesser or similar extent than to KA-responses (Neuman et al,
1988; Andreasen et al, 1989; Sheardown et al, 1988). It has again been suggested that
this mixed effect may be due to AMPA and KA acting at the same receptor. Selective
antagonists are required to investigate this possibility. They would also aid
investigation into the roles of the individual receptors in fast excitatory synaptic
transmission. NBQX has been reported to be more selective for AMPA than KA
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responses, and it has been recently suggested that argiotoxin may be used to separate
the responses (Lodge et al, 1990). Both receptors can mediate neurotoxic cell damage
therefore selective antagonists have a potential therapeutic use (Drejer and Honore,
1988).
Activation of the metabotropic receptor, which is linked to a G-protein, by L-
glutamate leads to the metabolism of inositol phosphate (IP). This was initially
demonstrated in Xenopus oocytes (Gundersen et al, 1984; Parker and Miledi, 1987;
Sugiyama et al, 1987). This effect was mimicked by L-glutamate and QA but not by
NMDA, KA or L-AP4 (Sugiyama et al, 1988). A similar response was later identified
in mammalian brain (Palmer et al, 1988). In cortical cell cultures this response was
also resistant to antagonism by CNQX (Patel et al, 1990). Thus a QA response had
been identified which was not mediated via the conventional QA/AMPA receptor.
7>m?-l-amino-cyclopentyl-1,3-dicarboxylate (ACPD) is the most selective agonist at
this receptor, evoking the rapid formation of IPp H^, IP3 and IP4 in a similar way
3
to QA (Monaghan et al, 1989). AMPA insensitive, QA sensitive [ H]L-glutamate
binding has been used to identify presumed metabotropic receptors. Highest densities
are observed in hippocampus, cortex and striatum. The receptor has been cloned,
revealing a family of metabotropic L-glutamate receptors which are linked to other
intracellular biochemical pathways in addition to IP metabolism and have differential
sensitivity to ACPD (Masu et al, 1991; Tanabe et al, 1992).
The L-AP4 receptor is named after the selective compound active at this site. L-
AP4 (Fig.3) unlike AP5 and AP7 is relatively inactive at the NMDA receptor
(Olverman and Watkins, 1989). No other compounds selective for this site have been
identified, thus precluding further investigations. L-AP4 does block synaptic
transmission to varying degrees in the hippocampus and the spinal cord with the
response being sensitive to broad spectrum EAA antagonists indicating a presumptive
receptor interaction (Evans et al, 1982; Koerner and Cotman, 1981). More recent
electrophysiological evidence points to the receptor being presynaptic with a role in
blocking neurotransmitter release though how this is achieved is unclear (Cotman et al,
- 12-
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1986. Binding studies using [ H]L-glutamate and [ H]L-AP4 indicate a post synaptic
interaction at a site where NMDA, AP5 and AP7 have no effect (Fagg et al, 1982;
3
Butcher et al, 1983; Monaghan et al, 1983). The studies using [ H]L-glutamate were
performed in the presence of CI" and it is now proposed that the binding is to a CI"
dependent L-glutamate transporter (Pin et al, 1984; Fagg and Lanthorn, 1985).
Clearly more work is necessary to fully understand the complexity of the response to L-
AP4 and its physiological relevance.
1.4 THE NMDA RECEPTOR
The NMDA receptor (Fig.4) is by far the best characterised EAA receptor in the
mammalian CNS. This is mainly due to the work of Watkins and colleagues who,
synthesised potent antagonists for EAA receptors, the NMDA receptor in particular.
Verification of the actions of the novel compounds was confirmed
electrophysiologically as well as by radioligand binding studies.
Although initial studies focussed on the neurotransmitter site of the NMDA
receptor it was found in due course to be a complex structure with multiple sites
available for pharmacological interaction (Fig.4). The main sites identified to date are
as follows:
1. Neurotransmitter recognition site.
2. Allosteric glycine modulatory site.
2+
3. Mg binding site.
4. PCP/Dizocilpine binding site.
2+
5. Zn /Tricyclic antidepressant (TCA) site.
6. Polyamine site.
Pharmacological characterization
NMDA (Fig.3) is a synthetic amino acid first synthesised around thirty years ago
(Watkins, 1962). Until the discovery of KA and QA it was the most potent
neuroexcitant known because it is not a substrate for the selective L-glutamate uptake
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1. Neurotransmitter binding site.
2. Allosteric glycine modulatory site.
3. Zn2+/TCA site.
4. PCP/Dizocilpine binding site.
5. Mg2+ binding site.
6. NMDA ion channel.
7. Proposed site of action of the polyamines.
FIGURE 4: Schematic representation of the NMDA receptor complex
Identified sites are clearly illustrated. Abbreviations: TCA, tricyclic antidepressant;
PCP, phencyclidine.
Modified from Wong, E.H.F. and Kemp, J.A. (1991) Annual Review of Pharmacology
and Toxicology, 21,401-425.
FIGURE 5: Chemical structures of competitive NMDA antagonists
Abbreviations: DAA, D-a-aminoadipate; DAS, D-a-aminosuberate; AP5, 2-amino-5-
phosphonopentanoate; AP7, 2-amino-7-phosphonoheptanoate; CGS, l-(cis-2-
carboxypiperidine-4-yl)methyI-l-phosohonate(CGS 19755); CPP, 3-(2-
carboxypiperazin-4-yl)propyl-l-phosphonate; CPP-ene,3-(2-carboxypiperazin-4-
yl)propyl-l-phosphonate; CGP 37849, 2-amino-4-methyl-5-phosphono-3-pentenoate;
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system (Balcar and Johnston, 1972). Apart from NMDA other exogenous agonists at
this receptor include ibotenate (Fig.3) and trans 2,3 piperadine dicarboxylate (trans-
2,3-PDA) (Curtis et al, 1979; Watkins and Olverman, 1988). Endogenous agonists at
the NMDA receptor have already been discussed (Section 1.2).
2+HA-996 and Mg were proposed as the first selective NMDA antagonists (see
Watkins, 1986). These were superceded by more selective NMDA antagonists of low
potency which were long chain analogues of L-glutamate. These included D-a-
aminoadipate (D-AA) and D-a-aminosuberate (D-AS) (Fig.5; Davies and Watkins,
1973; Evans et al, 1978, 1977; Collingridge and Davies, 1979; Watkins and
Olverman, 1988). These compounds were termed first generation NMDA antagonists
and helped to provide much of the evidence for the existence of NMDA and non-
NMDA receptors.
Second generation NMDA antagonists include the compounds D-AP5 and D-
AP7. Both are members of the a-amino-co-phosphonodicarboxylate homologous
series of compounds, being analogues of D-AA and D-AS respectively (Fig.5; Davies
et al, 1981; Watkins and Evans, 1981). The homologues, D-AP4, D-AP6 and D-AP8
were considerably less active as antagonists at the NMDA receptor (Evans et al, 1982;
Watkins and Olverman, 1988). The D or (-) isomer of AP5 was reported to be most
active (Davies and Watkins, 1982; Watkins and Olverman, 1987). It has been the
compound of choice for much of the functional characterisation of the NMDA receptor
3
having a higher affinity than D-AP7 for inhibition of [ H]AP5 binding (Watkins and
Olverman, 1988). K. values for inhibition of L-[ H]L-glutamate binding showed a
similar pattern (Fagg and Baud, 1988). D-AP5 has no effect on responses elicited by
other central neurotransmitters (Collingridge et al, 1983; Childs et al, 1988). It is also
without effect on responses elicited by KA, QA and AMPA (Davies et al, 1981).
Schild plot analysis of electrophysiological data revealed that D-AP5 is a competitive
antagonist at the NMDA receptor (Evans et al, 1982). Although D-AP5 is a very
useful experimental tool, potentially it has a very limited use as a therapeutic agent
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because of its relative inability to cross the blood brain barrier (BBB) (Meldrum et al,
1985). This led to a third generation of competitive antagonists which are generally
more lipophilic than AP5 and AP7.
The first effective compound was a conformationally restricted analogue of D-
AP7, 3-((-)-2-carboxypiperazine-4-yl)propyl-l-phosphonate (CPP) (Davies et al, 1986;
Murphy et al, 1987; Lehmann et al, 1987). CPP (Fig.5) is three times more potent
3
than D-AP5 as an antagonist at NMDA receptors as shown by inhibition of [ H]D-AP5
3
and [ HJCPP binding (K. values of 0.48pM and 0.35fiM respectively compared with
1.4jiM and 1.2fiM respectively for D-AP5; see Watkins and Olverman, 1988). The D-
isomer of CPP has since been reported to be most active (Herrling et al, 1989). Many
more competitive NMDA antagonists are now available, all analogues of AP5 or AP7
(Fig.5). These include CGS 19755 (Lehmann et al, 1988; Murphy et al, 1988),
CPPene (Herrling et al, 1989; Aebischer et al, 1989), CGP 39551, CGP 37849 and
CGP 40116 (Schmutz et al, 1989; Fagg et al, 1990). These compounds have K. values
for the inhibition of HJCPP binding of approximately 130nM, 40nM, 310nM, 35nM
and 19nM respectively. Clearly CGP 40116, an unsaturated analogue of D-AP5 and
the D isomer of CGP 37849 has the highest affinity for the NMDA neurotransmitter
recognition site. Since it is orally active it may prove to be not only a useful
pharmacologic tool, but also to be of benefit therapeutically.
Further characterisation
The NMDA receptor has been characterised as being a protein component of the
postsynaptic membrane (Fagg et al, 1986). The binding protein has been identified as
being 209KDa using [ H]CPP and molecular target size analysis (Honore et al, 1987).
This is further proof that it is a separate structure from the KA and AMPA binding sites
which have different molecular weights (Honore and Nielson, 1985; Honore et al,
1986). The same group also identified the NMDA sensitive ["^HJL-glutamate binding
protein as being 121KDa, much smaller than the CPP site but similar to the size of the
[^H]N-[l-thienyl]-cyclohexyl-3,4-piperidine ([^HJTCP) (118 kDa) and [^H]glycine
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sites (115 kDa) (Honore et al, 1987). They suggest that an additional macromolecule
may have to be associated with the agonist binding site in order to bind antagonists
(Honore et al, 1989). This evidence has been used in support of the suggestion that the
co-terminal of AP5 and AP7 bind to a site distinct from that at which agonists bind
although part of their binding sites must be common (Watkins and Olverman, 1988;
Fagg and Baud, 1988). The co-terminal of these compounds may therefore be
responsible for determining agonist or antagonistic properties.
An alternative view is that the recognition site exists in more than one
3
conformation. The binding pattern of NMDA sensitive [ H]L-glutamate (agonist)
3
shows clear differences to that of [ H]CPP (antagonist) although they are supposedly
thought to be binding to the same site on the receptor (Monaghan et al, 1988).
3
Originally, using NMDA sensitive [ H]L-glutamate binding, high densities of NMDA
receptors were found within the hippocampus, the nucleus accumbens and with a
defined regional distribution in the cerebral cortex (Monaghan et al, 1985). Areas of
lower NMDA receptor density include the globus pallidus and entorrhinal cortex.
Identified EAA using pathways such as the dentate gyrus to CA3 and the cerebellar
granule cell to purkinje cell had no detectable NMDA receptors. This is in agreement
with electrophysiological studies which have demonstrated the lack of activity of
NMDA antagonists at these synapses (Perkel et al, 1990).
In contrast, using [ H]CPP as a radioligand, a slightly different pattern of
binding was observed. While high levels of binding were still seen in the hippocampus
the cerebral cortex had a more uniform distribution of binding. Levels higher than seen
3
with [ H]L-glutamate were observed in the thalamus while lower levels were seen in
the medial and lateral septum. They concluded that there are agonist and antagonist
preferring sites and that they show regional variations in their ability to bind
radiolabeled agonists and antagonists (Monaghan et al, 1988). From this study it
could be proposed that the cortex has more antagonist preferring sites while the medial
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septum has more agonist preferring sites. Glycine is thought to play a modulatory role
modifying the agonist/antagonist preferring state (Johnston and Ascher, 1987;
Monaghan et al, 1988).
The NMDA associated ion channel and integral binding sites
The NMDA recognition site is linked and coupled to a cation conducting ion
channel which spans the plasma membrane (Fig.4). L-glutamate has been shown to
depolarise neurones by increasing Na+ conductance (Nistri et al, 1985; Zanotto et al,
2+
1983). Mg had been shown to decrease NMDA-induced depolarisations in spinal
cord (Evans et al, 1977; Davies and Watkins, 1977; Evans and Watkins, 1978). These
surprising results were later explained by the discovery that the NMDA channel is
2+blocked by extracellular Mg in a voltage dependent manner (Nowak et al, 1984;
Mayer et al, 1984). This was demonstrated in cultured neurons by the fact that the
current-voltage (I/V) relationship for NMDA responses was non-ohmic, i.e. non linear.
At potentials below -40mV a region of negative slope conductance was apparent. In
2+the absence of Mg the I/V relationship becomes linear again as it does when the
membrane is depolarised (Ascher et al, 1988a; Mayer and Westbrook, 1984). Single
2+
channel studies suggest that Mg binding site is located deep within the channel
(Ascher et al, 1988). It seems that under normal physiological conditions of ~lmM
2+
Mg , and at normal resting membrane potentials the NMDA receptors will probably
2+
be quiescent due to Mg blocking the channel. However, Davies (1989) puts forward
evidence suggesting that under normal physiological conditions NMDA receptor
activation may be involved in synaptic transmission. This may be synapse or pathway
selective.
EAA receptor agonists have been shown to activate a number of single channel
conductances although preferentially activating one conductance state (Jahr and
Stevens, 1987; Cull-Candy and Usowicz, 1987). NMDA preferentially opened
channels with the largest conductance states (40-50pS) which are the only conductances
2+ 2+ 2+
blocked by Mg , an effect mimicked by Co and Mn (Ascher and Novak, 1988).
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Unlike the AMPA and KA (but see Miller, 1991) ion channels, the NMDA channel in
+ 4* 2+
addition to conducting K and Na also conducts Ca (MacDermott et al, 1986;
2+ 2+
Mayer et al, 1987). Ca entry was studied using arsenazo III, a Ca indicator dye.
24* 24- 2+
Extracellular Mg blocked Ca entry indicating that the Ca originated
extracellularly and was not being released from intracellular stores. Single channel
2+
recordings showed that only the 40-50pS channels were permeable to Ca and the
2-j- _j_
Ca permeability of the NMDA channel is ten times higher than that of Na (Jahr and
Stevens, 1987). It has been postulated that one of the major functions of the NMDA
2+
receptor may be to increase intracellular Ca concentrations at select locations.
2+
Apart from the endogenous Mg block of the channel a number of exogenous
agents act as channel blockers. The first identified blockers were the a-opiates such as
cyclazocine and SKF10,047 (a naloxone-insensitive effect) and the dissociative
anaesthetics ketamine and phencyclidine (PCP; Fig.6) which selectively depressed
responses to NMDA (Lodge et al, 1982; Anis et al, 1983; Berry et al, 1984). These
channel blockers bind within the channel thereby decreasing channel open time
(Macdonald et al, 1987). Dizocilpine (MK-801; Fig.6) is the most potent NMDA
channel blocker found to date (Clineschmidt et al, 1982; Wong et al, 1986). These
compounds are all non-competitive antagonists, i.e. use-dependent blockers, where the
degree of antagonism can be enhanced by increasing the concentration of agonist
present (Lodge et al, 1989). The block is greater when the cell is depolarised
suggesting that the antagonist is trapped within the ion channel (Huettner and Bean
1988; MacDonald et al, 1987). Dizocilpine is thought to bind to a site distinct from
2+
that of Mg although they may be allosterically related (Reynolds and Miller, 1988b).
Further evidence for this is presented by Hori et al (1991). They demonstrated that
Mg^+ had a biphasic effect on [%]TCP (Fig.6) binding (a stimulatory effect at low
concentrations, EC^q = lljiM and an inhibitory effect at high concentrations, IC^q =
873|iM). Similar effects were seen in the presence of L-glutamate and glycine. Hori
2_L
et al (1991) go on to propose two Mg sites on the NMDA receptor complex, the




FIGURE 6: Chemical structures of non-competitive NMDA antagonists




nucleotides blocked the Mg stimulation. In the presence of agonist (L-glutamate)
the binding of [^Hjdizocilpine, [^H]TCP and [^H]PCP is enhanced as shown by an
increase in affinity for the binding site (Foster and Wong, 1987). Binding studies using
3
[ H]dizocilpine revealed that competitive antagonists had no effect on binding and
3likewise non-competitive antagonists have no effect on the binding of [ H]competitive
antagonists (Fagg and Baud, 1988; Wong et al, 1986). The regional distribution of
3
[ Hjdizocilpine binding as measured autoradiographically is very similar to that seen
for [^F1]AP5 (Bowery et al, 1988; Monaghan et al, 1986). This is a reflection of
transmitter recognition site and associated ion channel co-localisation. Since PCP and
dizocilpine bind with high affinity to their intra-channel site it could be that an
2+
endogenous compound (apart from Mg ) exists to modulate channel function (Zukin
et al, 1987).
The non-competitive NMDA antagonists are much more lipophilic than
competitive antagonists thereby having a higher bioavailability in the CNS after
systemic administration (Kemp et al, 1986). The problem with these compounds as
therapeutic agents is the incidence of side-effects as they interact with a number of
other neurotransmitter systems linked to ion channels (Halliwell et al, 1989; Amador et
al, 1991).
The Allosteric glycine modulatory site
The amino acid glycine has traditionally been classed as an inhibitory
neurotransmitter in the CNS, causing a hyperpolarisation when applied to central
neurones. This response is abolished by strychnine. Glycine has recently been
demonstrated to modulate responses elicited by the NMDA receptor by acting at a
strychnine insensitive site (Johnson and Ascher, 1987).
NMDA responses recorded electrophysiologically from cultured neurones were
smaller when a fast perfusion rate was used than when a slow perfusion rate was used.
This suggested that perhaps an important endogenous modulatory substance was being
washed away from the cell (Ascher and Johnston, 1989). Glycine was identified as this
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potentiating substance (Johnston and Ascher, 1987). Applied alone it has no effect but
co-application with NMDA led to an increase in the amplitude of the NMDA response.
Strychnine did not block the effect, therefore glycine was not acting at conventional
inhibitory strychnine sensitive glycine receptors. This basic concept of glycine
modulation resulted in the NMDA receptor complex being likened to the GABA^
receptor which is modulated positively by the benzodiazepine class of drugs (Ascher et
al, 1988b).
3
Strychnine insensitive [ H] glycine binding has revealed a distinct population of
3
sites in rat CNS. The distribution of sites matches that of [ H]AP5 and therefore
3 3
[ HJdizocilpine but not of [ H]strychnine indicating two populations of glycine
receptors (Bristow et al, 1986; Monaghan et al, 1986). The binding of the ligands
3 3 3
[ HJdizocilpine, [ HJTCP and [ HJPCP to membrane preparations are all enhanced by
addition of glycine (Ransom and Stec, 1988; Reynolds et al, 1987; Wong etal, 1987;
3
Snell et al, 1988). This effect is manifest as a change in the affinity of [ HJdizocilpine
binding (Reynolds and Miller, 1988c). These results suggest a link between the glycine
site and the NMDA channel.
The discovery of this glycine site coupled to the NMDA receptor has aided in the
understanding of the actions of kynurenate and HA-966 (Fig.7) on NMDA elicited
responses. HA-966 has been identified as a glycine site antagonist on rat cortical
wedge preparations (Fletcher and Lodge, 1988; Fletcher et al, 1989; Foster and Kemp,
1989). This effect can be reversed by addition of glycine. The effects of kynurenate
are still "broad spectrum" at high concentrations but at lower concentrations it is a
reasonably selective antagonist for the NMDA glycine site (Kessler et al, 1989). The
7-chloro derivative of kynurenate, 7-chlorokyunerate (7-Clkyn; Fig.7) and indole-2-
carboxylic acid are also potent and selective antagonists at the glycine site (Kemp et al,
1988; Huetnner et al, 1989). The quinoxalinediones, CNQX and DNQX (Fig.7)
should also be mentioned here. Apart from their activity at AMPA/KA receptors they
also antagonise NMDA responses non-competitively through an action at the glycine







N = < 'N^0
CNQX
FIGURE 7 : Chemical structures of compounds with actions at the NMDA-associated
glycine site
Abbreviations: HA-966, 3-amino-l-hydroxypyrrolidin-2-one; CNQX, 6-cyano-7-
nitroquinoxaline-2,3-dione
t
at this glycine site is L-689,560 which has been used successfully to characterise the
glycine site in both rat and human tissue (Grimwood et al, 1991a; Gulati et al, 1991).
3The tritiated radioligand shows a similar pharmacological profile to [ H]glycine
(Grimwood et al, 1991b).
NMDA receptors expressed in Xenopus oocytes from rat brain mRNA have
revealed an absolute requirement of glycine for activation (Kleckner and Dingledine,
1988). Glycine has also been proposed as the modulating substance responsible for
altering the relative affinities and proportions of agonist and antagonist binding at the
neurotransmitter recognition site (Monaghan et al, 1988; Monaghan and Cotman,
1989). Glycine is thought to promote an agonist preferring conformational state of the
receptor but the agonist/antagonist specific distribution of binding sites is still
maintained even in the presence of glycine or HA-966 (Monaghan and Cotman, 1989).
It is now suggested that there are two anatomically distinct binding sites which display
differing states depending on glycine interactions.
It is very difficult to estimate the glycine level in vivo especially in
electrophysiological experiments. Ascher and Johnson (1989) have proposed two
theories concerning the effect of glycine in vivo. Firstly, the glycine site may be
permanently saturated due to high endogenous levels of glycine. Endogenous
modulation would therefore only be due to other compounds active at the site (e.g.
serine). The second theory is that levels of glycine lower than required for saturation
are present normally and that fluctuations in the extracellular concentration can modify
synaptic transmission. It is thought that the first theory is most viable since glycine
levels in cerebrospinal fluid (CSF) indicate concentrations above l|iM (Skilling et al,
1988). Further supportive evidence comes from the fact that whole cell recordings
from mammalian brain slices are not modulated by glycine whereas NMDA responses
in torn-off patches are modulated by glycine (Llano et al, 1988). This would tend to
disagree with Monaghan et al (1988) who suggest regional variations in glycine
3
concentrations, as seen by the modulation of [ H]L-glutamate binding. The theory of
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Monaghan et al (1988) is supported by Thomson et al (1989) in electrophysiological
studies. However, this effect may be selective for different CNS regions (Thomson,
1989).
The NMDA glycine site may prove to be important therapeutically as a control
site for decreasing or increasing NMDA receptor activity and glycine antagonists
provide a novel angle for modulating NMDA responses.
The Zinc site
65 2+The presence of zinc has been demonstrated autoradiographically using Zn
in synaptic boutons in the mossy fibre of the CA3 region of the rat hippocampus
+ +
(Crawford and Conner, 1972). K -evoked release of Zn in rat hippocampus CA3
cells has shown that enough zinc is released to have an effect at the NMDA receptor in
2+ 2+
vivo (Aniksztejn et al, 1987). Like Mg , Zn has been shown to antagonise the
effects of NMDA by decreasing the channel open time and the channel conductance in
cultured cortical and hippocampal neurones (Westbrook and Mayer, 1987; Peters et al,
2+ 2+
1987). This effect does not show voltage dependence suggesting that Mg and Zn
2+
are acting at two distinct sites within the NMDA receptor complex. Zn also inhibits
3
[ H]-TCP binding in a non-competitive manner (Reynolds and Miller, 1988a,b) and
decreases NMDA-induced toxicity in cultured neurones (Peters et al, 1987). These
studies have led to the conclusion that zinc is not interacting with any of the identified
sites on the NMDA receptor complex, and that it is acting at a site outwith the channel
(Kushner et al, 1988).
The tricyclic antidepressant (TCA) class of drugs has been demonstrated to have
2+
an effect similar to Zn on NMDA responses (Reynolds and Miller, 1988a,d). They
3
demonstrated that the TCA's and derivatives inhibited [ HJdizocilpine binding in a
non-competitive manner. They do not compete with glycine or NMDA thereby ruling
out these domains as sites of action. Reynolds and Miller (1988d) have concluded that
2+
the TCA's may cause their actions at the NMDA receptor via the same site as Zn .
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2+The physiological relevance of this Zn fTCA site is still unknown but it is clear that
2+Zn and the TCA's decrease NMDA induced neurotoxicity in cultured cells (Leander
et al, 1989) a role that may be of use therapeutically.
The Polvamine site
3The polyamines spermine and spermidine potentiate [ H]dizocilpine and
3
[ H]TCP binding to rat synaptosomal membranes. Spermidine increased the affinity
3of the binding of [ H]dizocilpine from 45nM to 15nM. In the presence of L-glutamate
3and glycine, spermidine further increased the affinity of [ H]dizocilpine binding from
45nM to 2.2nM and 8.4nM respectively (Ransom and Stec, 1988; Williams et al,
1990). Polyamines were found to enhance [ HJCPP binding at high concentrations
(Carter et al, 1990). Further studies also revealed that polyamines enhanced binding of
3
[ H]glycine resulting in the value being altered from 189nM to 76nM (Ransom and
Deschenes, 1990). As yet the functional significance of these polyamine effects is
unclear but they are thought to act at a novel site in the NMDA receptor complex. In
addition arcaine, a competitive antagonist of the polyamine site has been identified
(Reynolds and Miller, 1990).
Since the polyamines are concentrated intracellularly, it seems most likely that
the binding site is located on the intracellular surface of the NMDA receptor protein
(Fig.4). Gangliosides have also been proposed as having an effect at an intracellular
site coupled to the NMDA receptor (Lodge et al, 1989). The ganglioside GTlb
(trisilalosylgangliotetraglycosylceramide) has been reported to decrease L-glutamate
induced cell death in neuronal cultures. A decrease in ^Ca^+ uptake suggests that
GTlb may be having an antagonistic effect at the NMDA receptor (Manev et al, 1989).
This effect may be due to a novel intracellular interaction with the NMDA receptor
2+
since classical Ca channel blockers are ineffective as are the NMDA antagonists.
The phenolethanolamine ifenprodil was originally described as a cerebral vasodilator
although it actually constricts isolated pial vessels (Cook and James, 1981). Ifenprodil
and its analogue SL82.0715 have now been described as novel antagonists at the
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NMDA receptor. A variety of techniques have been employed to demonstrate this,
both in vivo and in vitro (Carter et al, 1988; Gotti et al, 1988). Both compounds
3
displace [ H]CPP from its binding site in rat brain membranes with IC^q values of 0.1
and 0.3|iM for ifenprodil and SL82.0715 respectively. Slightly higher concentrations
also partially displace [ H]TCP binding and antagonise the stimulatory effect of L-
glutamate on such binding (Carter et al, 1989). These effects are all due to non¬
competitive antagonism. Both drugs also decrease the volume of damage seen in rat
and cat brain after a focal ischaemic insult (Carter et al, 1988). This is an effect very
similar to that seen with TCP. Available evidence suggests therefore that ifenprodil
and SL82.0715 are pure-competitive antagonists acting solely at the polyamine site,
although their actions are modulated by the polyamines. Ifenprodil may prove useful
in the characterisation of the mechanism of action of the polyamines (Williams et al,
1991).
1.5 EAA RECEPTORS IN THE DEVELOPING CNS
CNS Development
As an animal develops postnatally its nervous system must change and adapt in
order to maintain efficient function. The development of the mammalian CNS is an
ordered process and can be divided into four well defined phases (Kellaway, 1989).
1. Functional neurones are formed by differentiation from primitive neuroblasts.
2. Cellular contacts are formed when the differentiated neuronal elements move
from the site of genesis to appropriate loci.
3. Anatomic circuitry appropriate to an adult CNS is formed.
4. Functional transmission points within these circuits are formed.
CNS development is species dependent. For instance at birth the rat CNS is a
very immature structure while the human CNS is quite well formed. Whatever its state
at birth, the mammalian CNS continues to develop through these ordered phases until a
fully functional brain emerges. Neurones may gain or lose connections or alternatively
the structure and function of synapses may alter during maturation. The adult brain
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itself is not a finished product of this processing since it itself is in a continual state of
cytoarchitectural flux (Purves and Hadley, 1985; Purves, 1986). Plasticity in
adulthood is thought to be essential for processes such as learning and laying down
memory (Chang and Greenough, 1984; Lee et al, 1980).
The developing brain is very susceptible to influences from both endogenous
and exogenous sources, including other neurones, non-neuronal cells and other
environmental factors (Ribchester, 1986). The influences may lead to many changes in
brain structures such as alteration of neuronal sensitivity or modification of protein
synthesis resulting in changes in neuronal structure, circuitry or activity. These
influences on the brain will generally and ultimately manifest themselves in the
behaviour of the animal. The period of life when animals are most susceptible to such
defects coincides with the period of fastest neuronal growth (Cragg, 1975; Hubel and
Wiesel, 1970).
Developing neurones require neurotrophic factors to promote their viability.
Nerve growth factor (NGF) is necessary for promoting cell survival and for the
extension of axons and dendrites. Neurotransmitters released from nerve terminals
acting through defined receptors have also been shown to have neurotrophic properties
(Cowan et al, 1984). Mattson et al, (1988) put forward a hypothesis for the
involvement of neurotransmitters in neuronal development and degeneration based on
findings with the neurotransmitter L-glutamate. Their hypothesis states that:
"Neurodegeneration can result from the overactivity of a brain process (L-
glutamate transmission) which at lower levels of activation is involved in normal
developmental and functional events."
Apart from L-glutamate other central neurotransmitters have also been
implicated in similar processes namely acetylcholine (ACh), serotonin (5-HT) and
dopamine (DA) (see Lipton and Kater, 1989).
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Detection of L-glutamate/L-aspartate in the developing brain
The presence of the excitatory amino acids L-glutamate and L-aspartate has been
demonstrated in the developing brain. The levels of L-glutamate and L-aspartate in
cerebral cortex show differing time course profiles during postnatal development (Erdo
and Wolff, 1990b). Whereas L-aspartate is present at very low concentrations at
postnatal day 2 (PND2), rising gradually during development and peaking maximally at
PND30, L-glutamate at PND2 is already present at 50% of adult concentrations. L-
Glutamate levels rise from PND2 peaking maximally at PND16. Both L-aspartate and
L-glutamate are present at similar levels in adulthood. The developmental profile of L-
aspartate shows a great deal of similarity to the postnatal formation of synaptic
junctions as described by Aghajanian and Bloom in 1967. These results may therefore
indicate that Erdo and Wolff (1989) were measuring neurotransmitter L-aspartate
whereas the high level of L-glutamate detected may incorporate both the
neurotransmitter and metabolic pools. However, it should be noted that regional
differences in the postnatal development of amino acid content formation of synaptic
junctions are likely to exist.
High affinity uptake, as already mentioned in Section 1.2, is a good indication of
the presence of neurotransmitters. The presence of high-affinity uptake systems very
early in life may act as a controlling mechanism to limit precocious or ectopic
development of synapses (Fosse et al, 1989). Studies of [^Cjglutamine uptake during
postnatal development showed regional variations in the developing rat hippocampus
(Richter and Wolf, 1990). However, this pattern corresponded well to the uptake
profile seen using [ H]L-glutamate (Schmidt and Wolf, 1988). Both showed low
levels of uptake in newborn animals with a marked enhancement of uptake in
hippocampal neuropil areas during the first postnatal weeks. These developmental
profiles for EAA uptake systems correlate well with the development of enzymes
involved in glutamatergic neurotransmission such as phosphate activated glutaminase
(Wolf et al, 1988), L-glutamate dehydrogenase and L-aspartate amino transferase,
enzymes responsible for metabolising L-glutamate, (Rothe et al, 1983; Schmidt and
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Wolf, 1987). The development of high-affinity uptake of [^H]L-aspartate has also
been studied in the cat visual system (Fosse et al, 1989). Regional variations were seen
between the specific areas under study and as in the rat the development of the uptake
system closely paralleled postnatal changes in synaptogenesis and axonal/dendritic
arborization (Winfield, 1981; Cragg, 1975).
It therefore seems that the postnatal increases in L-aspartate and possibly L-
glutamate levels closely parallel the development of associated factors required to class
these substances as neurotransmitters (see Orrega, 1979), as well as the
cytoarchitectural development of the brain.
Ontogeny of EAA receptors
Ligand binding and autoradiography studies have been directed towards
ontogenic measurements of the EAA receptors. Over the last decade a number of
ligands have been utilised to measure EAA receptors in various brain regions.
(i) Cerebellum
3
The first reported studies of [ H]L-glutamate binding during postnatal
development used rat cerebellar membranes (de Barry, 1980 and Slevin and Coyle,
3
1981). Both studies found similar developmental profiles for [ H]L-glutamate
binding, with binding peaking at PND20 and concluded that this was due to a change in
receptor density rather than a change in affinity over time. These studies presumably
3
measured [ H]L-glutamate binding to many sites and not to specific receptors since the
original proposal of three EAA receptor subtypes was only being forwarded at this time
(Watkins and Evans, 1981). Slevin and Coyle (1981) measured [^H] KA binding and
found a similar developmental profile to [ H]L-glutamate, although KA sites
developed at a slower rate. The early appearance of KA sites supported previous
observations that iontophoretic application of KA to cerebellar neurones was





Baudry et al (1981), using Na independent [ H]L-glutamate binding, examined
the ontogeny of L-glutamate binding sites in hippocampal membranes at various
developmental stages. Binding increased gradually from PND4 to adult levels,
2+
reaching half maximal binding by PND13. They had already reported that Ca could
+ 3stimulate Na independent [ H]L-glutamate binding to adult hippocampal membranes
2+
(Baudry and Lynch, 1979) but could only detect Ca stimulation from PND9. Adult
levels however were reached by PND 16. These changes were all due to alterations in
receptor number and not to affinity changes. Interestingly they also found that LTP
could only be induced in CA1 cells from PND9 and was not apparent prior to this age.
2+ 3CI /Ca dependent [ H]L-glutamate binding sites have since been equated with the L-
AP4 receptor (Foster and Fagg, 1984). This may therefore have been measured in this
study. These results may also indicate similar underlying mechanisms controlling LTP
2+
and Ca stimulation.
Ben-Ari and co-workers have performed extensive studies comparing the
3
development of rat and human hippocampal EAA receptors using [ H]KA (Ben-Ari et
3
al, 1984; Represa et al, 1986) and NMDA-sensitive [ H]L-glutamate binding
(Tremblay et al, 1988; Represa et al, 1989) as markers for KA and NMDA
respectively. They have found transient increases in KA sites in the stratum lucidum
and the supragranule layer of the fascia dentata at birth which fall to adult levels of
approximately 73% and 50% respectively in human but not in rat hippocampi. KA
binding sites were maximal in man at foetal week 25 (FW25) before falling to adult
levels of approximately 60% of this maximum. NMDA sites both in rat and human
hippocampi also showed transient increases with maximum binding being detected at
PND8 (rat) and FW22 - 23 (human). Adult levels were 30% and 45% of this maximum
in human and rat respectively. In all cases changes observed were due to changes in
receptor number rather than affinity.
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3
Transient expression of [ H]L-glutamate binding has also been observed in the
globus pallidus of developing human brain an area which in the adult has no known
glutamatergic innervation (Greenamyre et al, 1987; Barks, 1988). This site was
insensitive to KA, AP7 and NMDA suggesting the transient expression of AMPA or
metabotropic receptors.
The exact physiological relevance of transient expression of EAA receptors is
unclear, but due to their involvement in neuronal growth and development, which will
be operating at peak levels of activity during very early life, it seems reasonable to
propose that EAA receptors are important in developmental plasticity during
synaptogenesis.
(iii) Other brain regions
The developing visual cortex is particularly malleable during the early postnatal
period. Development is subject to use-dependent modifications. This has been
demonstrated in the classic experiments of Hubel and Wiesel (1970). Bode-Greuel and
Singer (1989) have measured NMDA receptors in the developing cat visual cortex
3
autoradiographically using AP5 sensitive [ H]L-glutamate binding. Binding increased
from birth until PND14-28. Binding remained high throughout the second and third
month of life falling to adult levels of approximately 50% maximum binding levels.
This is an indication that the NMDA receptor may be involved in synaptic plasticity in
+ 3the kitten visual cortex. An earlier study measured Na independent [ H]L-glutamate
binding in visual structures from rat brain (Schliebs et al, 1986). Throughout
development the lateral geniculate nucleus (LGN) displayed highest levels of binding.
The LGN, visual cortex and superior colliculus had similar development patterns.
Initially binding was high, peaking at PND 15 then falling to adult levels at PND25.
Frontal cortex and retina had a similar profile to the previous mentioned structures but
peaked maximally at PND 10. This binding cannot be equated to any particular EAA
receptor but it does provide an indication of differential development in the visual
system perhaps highlighting the importance of these structures in synaptic plasticity.
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Erdo and Wolff (1990a) have investigated the postnatal development of distinct EAA
3
receptors in rat visual cortex. [ H]CPP binding was low at birth rising to peak at
PND14 - 21 with a slow decline up to the age of one year. In contrast both KA and
3 3AMPA (measured with [ H]KA and [ HJAMPA respectively) sites were high at birth
reaching a peak at PND6. KA and AMPA binding both reached adult levels of
approximately 80% and 50% of maximum binding at PND21-28. [ H]KA binding
3
was higher than [ H]AMPA binding. As in the cerebellum and hippocampus changes
were all due to receptor number rather than affinity with the exception of AMPA which
showed an alteration in receptor affinity as well as in receptor density throughout
development. A similar situation was found in the cerebral cortex of rats for [ H]KA
3and [ H]AMPA binding this may indicate a role other than in synaptic transmission
+ 3
(Erdo and Wolff, 1989). An early study of Na independent [ H]L-glutamate binding
to rat cerebral cortical membranes during development gave a biphasic profile
(Sanderson and Murphy, 1982). The first peak was at PND20 - 25 before falling off at
around PND30 before the second rise to adult levels. This effect cannot be assigned to
any specific receptor so it must be assumed to be a summation of all L-glutamate sites.
Electrophysiological studies
Electrophysiological studies have shown that the immature CNS is at all stages
an entirely different brain from that of the adult. Electroencephalogram (EEG) can
provide an overview of the differences in electrical activity between the mature and
immature brain. Noebels (1989) states that "EEG recordings obtained from the
immature human CNS would be considered sufficiently abnormal if derived from the
scalp of an adult to indicate imminent demise". The ionic dependence of action
2+
potentials also alters postnatally in some cortical neurones, with shifts from Ca to
+ +
Na selective currents with similar changes seen in relation to K channels (Mori-
Okamoto et al, 1983). The hippocampus is a seizure-prone brain structure. A brief
seizure can set in motion a cascade of events including neural growth and formation of
new synaptic contacts (Ben-Ari and Represa, 1990). Ben-Ari and co-workers have
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studied the electrophysiological properties of immature rat hippocampal CA3
pyramidal cells. Using intracellular recording they have revealed the involvement of
NMDA receptors in bursting phenomena.
During PNW1 they consistently detected spontaneous giant depolarizing
potentials (GDP) in CA3 cells (Corradetti et al, 1988). This spontaneous bursting
could be blocked or reduced by AP5 and CPP, thus indicating NMDA receptor
involvement The GDP's disappeared during the second postnatal week. This time
scale agrees with that of Tremblay et al, (1988) who demonstrated a high level of
binding to NMDA receptors during the first postnatal week which was followed by a
decrease during the second postnatal week. Further work actually showed the GDP's
to be mediated by GABA released from interneurones under NMDA receptor control
(Ben-Ari et al, 1989). This was demonstrated by the ability of picrotoxin and
bicucculine to block the GDP's. The actual mechanism of this phenomena is unknown
but may be due to an immature excitatory state of the GABAergic system. This may
not mature until the second week of life (Cherubini et al, 1991), thus reverting to
exerting an inhibitory influence as reflected by the decrease seen in the frequency of
GDPs. Gaiarsa et al (1990) have shown that modulation of the NMDA response by
effects exerted at the glycine modulatory site on these receptors also influences the
GDP's. Glycine and D-serine cause an increase in GDP frequency but only until
PND10 an effect which is blocked by AP5. Co-application of NMDA and glycine has
a stimulatory effect blocked by 7-Clkyn. This effect again falls off during the second
week of life. These findings indicate that the glycine site on the NMDA receptor is not
only present but is also functional from a very early stage of postnatal development
Other interesting observations made by the same group are that immature CA3
cells have a different current voltage relationship from adult CA3 neurons (Ben-Ari et
al, 1988). NMDA stimulation does not invoke a region of negative slope conductance
2+
on immature I/V plots. This would seem to suggest that the voltage dependent Mg
block as seen in adults (Nowak et al, 1984; Mayer et al, 1984) is less consistently
2+
present in immature cells. Following NMDA receptor activation, more Ca will
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therefore be able to flow through the channel which may be used to promote growth
cone development (Kater et al, 1988) and increase synaptogenesis. This effect has
recently been confirmed in hippocampal CA1 cells by two groups (Bowe and Nadler,
1990; Morrisett et al, 1990). Both groups although using different recording
2+
techniques, demonstrated that Mg was less active in young rats than in adults as an
antagonist of NMDA induced depolarisations. Ben-Ari's group has also shown that
NMDA receptors are present from PND1 and therefore presumably develop prenatally
(King et al, 1989). CA3 cells became more sensitive to NMDA as measured by burst
firing from PND1 - PND10.
Few electrophysiological experiments involving developmental aspects of EAA
receptors have been carried out in other regions of the brain. Hamon and Heinneman
(1988) have looked at developmental changes in the hippocampus but in the CA1
2+
subpopulation of cells. They found by measuring [Ca ] decreases extracellularly that
the NMDA receptors in striatum pyramidale are most sensitive to NMDA during the
age range PND5 - 9 and that between ages PND12 - 30 receptors in the stratum
radiatum were most sensitive indicating that pyramidal cell dendrites became more
sensitive to NMDA with increasing age, perhaps by an increase in receptor number or
by a maturational aspect of receptor development. LTP in CA1 cells has been shown to
be reliably detected from PND8 (Baudry et al, 1981) but to be at maximal levels at
PND15 (Harris and Teyler, 1984). There may therefore be a correlation between
receptor number, receptor sensitivity and induction of LTP in the CA1 region of the
hippocampus.
The visual system
The role of EAA receptors in the plasticity of the developing visual system has
received much attention in the past few years. Until the second or third month of life
(the "critical" period), cells in kitten striatal cortex are responsive to visual stimulation
through either eye (Wiesel and Hubel, 1965). During the "critical" period binocular
connections are readily modified by visual experience (Hubel and Wiesel, 1970).
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NMDA receptors are implicated in synaptic plasticity not only in the hippocampus
(Collingridge et al, 1983) but also the visual cortex (Artola and Singer, 1987). The role
of the NMDA receptor in experience dependent plasticity in the visual cortex has been
examined. Kittens were subjected to intracortical infusions of AP5 during the "critical"
period. Visual responses in 71% of cortical cells were suppressed compared with 33%
in adult cats. It was suggested that the NMDA receptor participates in synaptic
responses of visual cortical neurones in kittens but not so readily in cats. Results using
kynurenate also suggest the involvement of a non-NMDA receptor component in visual
system plasticity (Tsumoto et al, 1987). These findings resulted in the hypothesis that
"NMDA receptors in the visual cortex of young kittens were more effective than those
of adult cats" (Artola and Singer, 1987).
Similar findings were reported in kitten monocular deprivation studies.
Activation of the NMDA receptor in the visual cortex is important for synaptic
plasticity dependent on visual experience with the study also proposing the important
2+role of Ca in plasticity (Kleinschmidt et al, 1987). By infusing AP5 into the left
visual cortex (the right receiving saline) after monocular deprivation, Gu et al (1989)
were able to prevent the vision dependent recovery of deprived pathways. These
studies highlight the importance of NMDA receptor activation in the developing CNS,
in particular, the necessity for NMDA receptor activation in the facilitation of use-
dependent modifications of synaptic circuitry.
1.6 SUMMARY OF STUDY OBJECTIVES
The first aim of this study was to establish radioligand binding assays which
could be used to examine the neurotransmitter binding site and the associated ion
channel of the NMDA receptor in tissue obtained from mature and immature rats.
[^HjCPP, [^H]D-AP5 and [^Hjdizocilpine were used, all having a high affinity and
specificity for their respective binding sites.
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The interaction between the glycine site and the neurotransmitter site is still
poorly understood. Glycine is thought to regulate agonist and antagonist states of the
NMDA receptor (Monaghan et al, 1988). The effects of glycine, HA-966 and 7-Clkyn,
all compounds previously demonstrated as having activity at the glycine site (Foster
3
and Kemp, 1989; Kemp et al, 1988), have been investigated on the binding of [ H]CPP
3
and [ H]D-AP5. The findings are discussed in relation to both known
electrophysiological and biochemical effects of the compounds, and are compared with
reciprocal binding studies.
The main objective of the study was however to use the two main radioligand
3 3
binding assays ([ H]CPP and [ Hjdizocilpine) to create ontogenic profiles of then-
respective binding sites, the neurotransmitter site and the ion channel site, on the
NMDA receptor complex. The NMDA receptor is clearly important in CNS
development, however, no study yet has investigated the postnatal development of sites
on the NMDA receptor using radioligand binding to the same membrane preparation
with radioligands of high specificity and affinity for individual sites. Modulation of
[ Hjdizocilpine binding by L-glutamate and glycine throughout postnatal development
was also examined. This was to determine not only whether these sites were present
and functionally coupled early in life but also to see if they behaved as has been
previously demonstrated in the mature brain. These findings along with those of
functional studies may help to establish the therapeutic usefulness of NMDA
antagonists in pathological conditions which are thought to occur early in life as a
consequence of NMDA receptor activation. The findings are compared and related to
those of other EAA receptor ontogeny studies both biochemical and






The technique of radioligand binding has been used in the present study to
investigate the NMDA receptor. Paton and Rang (1965) pioneered this technique.
They investigated the binding of [ H]atropine to membranes prepared from guinea-pig
ileum. Although most of the resultant binding was actually to non-muscarinic sites
some muscarinic sites were in fact specifically labelled. Radioligand binding very
simply involves the incubation of a radiolabeled ligand with an homogenate prepared
from the tissue under study. The ligand is usually the putative neurotransmitter under
study or an agonist/antagonist derivative of a neurotransmitter. Antagonists are
preferable to agonists because they generally have a higher affinity and higher
specificity for discrete receptor types (Olverman et al, 1988). Ideally the radioligand
should be highly selective for the system under investigation, radiolabelled to a high
specific activity and have a long half life, hence [^H] and [^C] are ideal radioisotopes
to use. Taking these factors into account enables the use of low concentrations of
ligand since high affinity sites will be saturated at nanomolar concentrations and only a
small fraction of the ligand will be bound (Hrdina, 1986). The availability of
biologically active compounds labelled to a high specific activity has since led to
important advances, not only in the understanding of drug-receptor/neurotransmitter-
receptor interactions at the molecular level and the mechanisms underlying the effects
but also in receptor purification, distribution and structure-activity studies. This
technique has led to the discovery of high-affinity binding sites in relevant tissues for
known psycho-active drugs such as the benzodiazepines, opiates, neuroleptics and the
antidepressants.
2.2 ANIMALS USED
Male Cob (Wistar) rats of 10-12 weeks of age were routinely used. In the
developmental study male Cob rats of 90 days of age were used as adult comparisons,
to tissue obtained from Cob pups of either sex (PND0-PND28). The day of birth was
regarded as PNDO. Adult and pup brains were treated identically.
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2.3 MEMBRANE PREPARATION
Two membrane preparations were used in these studies. The preparation of
whole membranes is described in Fig.8 and of synaptosomal membranes in Fig.9.
Whole membranes (adapted from Biziere et al, 1980)
Rats were killed by stunning and decapitation, pups by decapitation only. The
whole brain was then carefully but rapidly removed and placed in ice-cold 0.9% (w/v)
saline solution. The appropriate brain areas were dissected out on an ice-cold block
and blotted dry. This tissue was then homogenised in 40 volumes (w/v) ice-cold assay
buffer in a teflon-glass homogenizer, 3mm clearance, 12 strokes at 800 rpm. The
homogenate was centrifuged at 50,000g for 10 min at 4°C in an ultracentrifuge
(Centrikon T-2070). The supernatant was discarded and the resultant pellet was
resuspended in 40 volumes ice-cold assay buffer and incubated at 35°C for 30 min
followed by centrifugation at 50,000g for 10 min at 4°C. This was followed by a
further two washing steps, i.e. resuspension in 40 volumes buffer followed by
centrifugation at 50,000g. The final pellets were then either resuspended in an
appropriate volume of assay buffer for use as fresh membranes or resuspended in 10
volumes of assay buffer and frozen at -20°C until the day of the assay. On the day of
the assay frozen membranes were thawed slowly on the bench at room temperature
before increasing the volume from 10 to 40 volumes with assay buffer. The
membranes were centrifuged at 50,000g for 10 min at 4°C before the final resuspension
into assay buffer. For adult whole membranes the final resuspension resulted in
approximately lOmg of original tissue being added to each test incubation tube. Pup
membranes were prepared in an identical manner but the final resuspension volume was




Homogenise in 40 vol (w/v) assay buffer,
centrifuge (50,000g; 10 min)
4'
Discard supernatant; resuspend pellet in 40 vol assay buffer,
incubate (35°C; 30 min) followed by centrifuge (50,000g; 10 min)
Discard supernatant; resuspend pellet in 40 vol assay buffer,
centrifuge (50,000g; 10 min)
*
Discard supernatant; resuspend pellet in 40 vol assay buffer,











(see text for details)
Resuspend in 10 vol
assay buffer
Store at -20°C. On day
of experiment thaw slowly
at room temperature.
Increase to 40 vol
with assay buffer,
centrifuge (50,000g; 10 min).
Final resuspension as for
fresh membranes.
FIGURE 8 : Flow diagram to illustrate the routine preparation of whole membranes
from rat tissue
Preparation of membranes subjected to extensive washing included three extra washing
steps prior to use either fresh or previously frozen.
Rat Brain Tissue
4^
Homogenize in 15 vol; 0.32M sucrose
centrifuge (l,000g : 10 min)
4'
Discard pellet (Pj): Recentrifuge supernatant
centrifuge (17,000g : 20 min)
*
Discard supernatant; resuspend pellet (P2) in 40 vol ^O,
incubate (35°C; 30 min),
centrifuge (50,000g; 10 min)
Discard supernatant; resuspend in 40 vol f^O;
centrifuge (50,000g; 10 min)
4'
Discard supernatant; resuspend in 40 vol H2O;
centrifuge (50,000g; 10 min)
Discard supernatant
FRESH FROZEN
Resuspend in 10 vol assay
Final resuspension into assay buffer. Store at -20°C.
buffer for direct use On day of experiment thaw
(see text for details) slowly at room temperature.






FIGURE 9 : Flow diagram to illustrate the routine preparation of synaptosomal
membranes from rat tissue
Preparation of membranes subjected to extensive washing included three extra washing
steps prior to use either fresh or frozen.
i
Synaptosomal membranes (Olverman et al, 1984)
Rats were killed by stunning and decapitation, pups by decapitation only. The
whole brain was then carefully and rapidly removed and placed in ice-cold 0.9% saline
solution. The appropriate brain areas were then dissected out on an ice-cold block and
blotted dry. The tissue was homogenised in 15 volumes (w/v) of ice-cold isotonic
sucrose (0.32M) using a teflon-glass homogenizer, 3mm clearance; 12 strokes at
800rpm. The resulting homogenate was centrifuged at lOOOg for 10 min at 4°C in a
bench-top centrifuge (Burkard Koolspin). The supernatant was carefully decanted off
and recentrifuged at 17,000g for 20 min at 4°C in the bench-top centrifuge. The
pellet containing blood vessels and myelin was discarded. The resultant pellet (P2)
was then resuspended in 40 volumes of distilled and deionised water and incubated at
35°C for 30 min followed by centrifugation at 50,000g (Centrikon ultracentrifuge) for
10 min at 4°C. The membranes were washed a further twice in distilled and deionised
water (40 volumes) and centrifuged (50,000g; 10 min; 4°C). The final resuspension
was into assay buffer. In the filtration and centrifugation assay approximately 16mg of
original tissue was added to each test incubation tube. Pup membranes were prepared
in an identical manner but the final resuspension was adjusted to give a suitable protein
concentration according to age.
2.4 RADIOLIGAND BINDING ASSAYS
Centrifugation Assay
Binding assays were routinely performed in 0.7ml polythene micro-centrifuge
tubes (Sarstedt). Membranes were added to the tubes containing 50}il aliquots of
buffer or drugs under test and allowed to incubate in a water bath at optimum assay
temperature for 3 min before addition of a 50pl aliquot of radiolabelled ligand resulting
in a final assay volume of 500|il. Following an incubation period during which the
binding process reached equilibrium the process was terminated by high-speed
centrifugation (15,000g) for 1.5 min in a maxi-fuge (Whyteleaf). The clear supernatant
was carefully aspirated off with a fine pasteur pipette and the pellets were washed
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rapidly with cold distilled water. The insides of the micro-centrifuge tubes were
carefully wiped dry using cotton buds to remove any excess radioactivity without
touching the pellet. Each tube containing a pellet was placed in a scintillation vial
(Packard). The pellet was then solubilised using concentrated formic acid (100p.l).
Following the addition of liquid scintillation fluid (3.5ml; Unisolve E, Koch-Light)
bound radioactivity was measured in a liquid scintillation analyser (Packard 1900CA).
Filtration assay
Binding assays were routinely performed in 5ml plastic test tubes (Sterilin).
Membrane aliquots were added to tubes containing lOOpl aliquots of drugs or buffer
and allowed to incubate in a water bath at the assay temperature for 3 min before
addition of a lOOpl aliquot of radiolabelled ligand. The final assay volume was
lOOOp.1. After an incubation period during which the binding process reached
equilibrium the process was terminated by rapid filtration over glass fibre filters
(Whatman GF/B) using a 24 well cell harvester (Brandel Gaithersburg M.D.). The
filters were washed with two 5ml aliquots of buffer. The whole filtration process took
10-15 sees. Filters were then placed in scintillation vials (Packard). Concentrated
formic acid (100|il) was added to each filter to solubilise the trapped proteins before
addition of liquid scintillation fluid (2ml; Unisolve E, Koch Light). Bound
radioactivity was measured in a scintillation analyser (Packard 190QCA).
Routine Binding Assays
Except where indicated binding assays were performed as follows:-
(i) 13H1CPP and r3H!D-AP5
3 3
Binding of [ H]CPP and [ H]D-AP5 was routinely carried out using a
centrifugation assay. Synaptosomal membranes (0.4ml; 25 vol made up in 50mM
Tris-HCl buffer; pFl 7.75) were incubated in triplicate at 25°C for 25 min before the
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binding reaction was terminated. The volume and concentration of membranes was
altered depending on drugs and/or buffer which were to be included in the assay. All
further steps are fully described in the section "Centrifugation assay".
(ii) r3HlDizocilpine
3
Binding of [ HJdizocilpine was routinely performed using a filtration assay.
Whole membranes (0.6ml; 80 vol made up in 5mM Tris-HCl buffer, pH 7.4) or
synaptosomal membranes (0.6ml; 37.5 vol made up in 5mM Tris-HCl; pH 7.4) were
incubated in duplicate at 25°C for 45 min prior to termination of the binding reaction.
As previously the volume and concentration of membranes was altered depending on
the amount of drugs, buffer or modulating agents which were to be included in the
assay. All further steps are fully described in the section "Filtration Assay".
2.5 PROTEIN ASSAY
Protein concentrations for each membrane preparation used were determined to
account for daily variations. The method of Bradford (1976) was used. This assay
eliminates the problem of interference by Tris and other reagents encountered in the
standard procedure of Lowry et al (1951). The reagent used is Coomassie Brilliant
Blue G-250 which exists in red and blue forms. Upon binding of the dye to protein the
red form is converted to the blue form. This reaction takes place within 2 min and is
stable for 60 min. Briefly, samples of membrane homogenate (lOOp.1) were incubated
at room temperature for 20 min with protein reagent (5ml), (0.01% (w/v) Coomassie
Brilliant Blue G-250, 4.7% (w/v) ethanol and 8.5% (w/v) phosphoric acid) in
disposable cuvettes (BDH). Absorbence was measured at 595nM in a Cecil
spectrophotometer. A standard curve was constructed using bovine serum albumin as
the standard protein and a new curve was constructed for each assay and each new
batch of protein reagent using a multipurpose line-fitting program (Polyfit).
Absorbence readings from the membrane preparations were then converted to mg of
protein by reference to the standard curve.
-40-
2.6 PURIFICATION OF RADIOLIGANDS
Even under recommended storage conditions radioligands are extremely
susceptible to decomposition. Therefore regular checks must be made on the state of
3the radioligand. [ H]D-AP5 has been reported to decompose such that a radioactive
3
impurity, more acidic than D-AP5, interfered with [ H]D-AP5 binding (Olverman et
al, 1988). The method for purifying and thus separating [ H]D-AP5 from the
3 • 3
[ H]impurity is now described, as is a method for purifying [ H]CPP.
3
[ HJDizocilpine (NEN-DuPont) was bought in quantities such that it lasted for three to
six months, after which a new batch was purchased.
i3hicpp
Unlabelled CPP was synthesised in the laboratory of Dr J.C. Watkins, University
3
of Bristol (Davies et al, 1986). The [ H]CPP used in the current study was obtained by
custom nidation of an unsaturated precursor of CPP (Amersham International, Bucks.,
UK). This was stored in distilled and deionised water under liquid nitrogen (-180°C)
pending purification on Dowex AG-1 acetate ion-exchange resin. The resin was
purchased in the chloride form and was prepared for use in the acetate form. Fresh
resin (5ml) contained within a glass column was prepared by washing with 2M sodium
acetate (105ml) until no chloride was detected. The resin was then eluted with distilled
and deionised water (35ml) before NaOH (M, 0.5ml) was added to the resin. The
column was further eluted with distilled and deionised water (45ml) until a neutral pH
3
was reached. [ H]CPP (2.5|iCi in 2.5ml distilled and deionised water) was added
dropwise to the resin followed by distilled and deionised water (2.5ml). The resin was
further eluted with distilled and deionised water (35ml) and fractions (5ml) were
3
collected. This was to eliminate any [ HIE^O from the resin. Subsamples were taken
for scintillation counting for detection of radioactivity (Packard Tricard 1900CA). The
3
resin was next eluted with 0.1M acetic acid (50ml) to collect [ HjCPP. Fractions
(2.5ml) were collected. Subsamples were diluted in distilled and deionised water and
taken for scintillation counting. This resulted in one peak of radioactivity being eluted
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(Fig.lOA). This radioactivity accounted for 76.6% of that added to the column. The
fractions corresponding to [ H]CPP were combined and ffeeze-dried. The residues
were resuspended in distilled and deionised water to give a final stock concentration of
3
[ H]CPP. Finally the resin was eluted with acetic acid (40ml) and fractions (5ml)
collected. This process should strip the resin of anything remaining on it. Subsamples
were taken for scintillation counting.
3
lOOjiCi of the purified [ H]CPP was added to a fresh Dowex AG-1 acetate resin
3column. The above process was repeated to confirm that it was authentic [ H]CPP.
Again one peak of radioactivity was eluted, corresponding to that in Fig.lOA, with
0.1M acetic acid (Fig. 10B). This radioactivity accounted for 98% of that added to the
3column. Aliquots of [ H]CPP (100-200|il) were stored under liquid nitrogen where the
ligand remained stable for at least three months. For each binding experiment a fresh
aliquot was removed from storage and diluted with assay buffer to the required
concentration (usually IOOjiM) and stored on ice prior to addition to the membrane
suspensions.
I3HJD-AP5
Unlabelled D-AP5 was synthesised in the laboratory of Dr J.C. Watkins,
University of Bristol (Davies and Watkins, 1982). The [3H]D-AP5 used in the present
study was obtained by custom tritiation of an unsaturated precursor of D-AP5
(Amersham International, Bucks, UK). This was stored at a stock concentration of
lOmCi/ml in distilled and deionised water under liquid nitrogen (-180°C) pending
purification on Dowex AG 50W x 8 ion-exchange resin. The method of Olverman et
al (1988) was used. Briefly, fresh resin (5ml) contained within a glass column was
prepared by washing with NaOH (N, 50ml) followed by distilled and deionised water
until a neutral pH was reached. HC1 (N, 50ml) followed by distilled and deionised
water were then washed through until pH 5 was reached. [ H]D-AP5 (3mCi in 0.5ml
distilled and deionised water) was added to the column and the resin eluted with
distilled and deionised water (80ml). Fractions (1ml) were collected and subsamples
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FIGURE 10: Ion exchange purification of FHICPP
[3H]CPP was added to a column of Dowex AG-1 ion exchange resin (5ml; 1 bed
volume). The resin was prepared for use by elution with 2M sodium acetate(25 bed
volumes), distilled and deionised water (7 bed volumes), M NaOH (0.5ml) and finally
distyled and deionised water(9 bed volumes). After addition of the unpurified sample
of [h]CPP to the resin it was further eluted with distilled and deionised water (7 bed
volumes), 0.1M acetic acid (10 bed volumes) and M acetic acid(8 bed volumes).
Fractions (1ml) were collected and the radioactivity in each determined and expressed
as a percentage of radioactivity added to the column.
(A). 2.5 mCi of a sample of unpurified [ H]CPP resulted in radioactivity being eluted in
one peak by 0.1 M acetic acid.
(B). One hundred microcuries of [ H]CPP collected from the peak in (A) above was
retested by addition to fresh column of resin. Only one peak was obtained
corresponding to that seen in (A) above with 0.1M acetic acid.
In (A) the fractions corresponding to CPP when combined accounted for 76.6% of










FIGURE 11: Ion exchange purification of F~H1D-AP5
[TI]D-AP5 was added to a column of Dowex AG 50W x8 resin (5ml; 1 bed volume).
The resin was eluted with distilled and deionised water (16 bed volumes). Fractions
(lml) were collected and the radioactivity in each determined and expressed as a
percentage of radioactivity added to the column.
(A). Three millicuries of a sample of unpurifxed |/TflD-AP5 resulted in radioactivity
being eluted in two peaks with distilled and deionised water.
(B). One hundred microcuries of [ HJD-AP5 collected from the second peak in (A)
above was retested by addition to a fresh column of resin. Only one peak was
eluted with distilled and deionised water, corresponding to the second peak in (A).
The second peak in (A) corresponds to [ H]D-AP5 (Olverman et al 1988) and
accounts for 12.8% of radioactivity added to the column. 95% of radioactivity











(l-2|il) were taken for scintillation counting (Packard Tricarb 1900CA). This resulted
in two peaks of radioactivity being eluted (Fig. 11 A). The second peak corresponded to
3
[ HD-AP5 (Olverman et al, 1988), and accounted for 12.8% of the radioactivity added
3
to the column. Fractions corresponding to [ H]D-AP5 were combined and freeze
dried. The residues were resuspended in distilled and deionised water to give a final
concentration of 20(iM [^H]D-AP5.
100(iCi of the purified [^H]D-AP5 was added to a fresh AG 50W x 8 resin
column, and was subjected to the steps described above to confirm that it was authentic
3
[ HJD-AP5. This resulted in one peak of radioactivity being eluted with distilled and
deionised water (Fig. 1 IB). This peak corresponded to the second peak in Fig.l 1A and
accounted for 95% of the radioactivity added to the column. Aliquots of [ H]D-AP5
(100-200|il) were stored under liquid nitrogen where the ligand remained stable for at
least three months. For each binding experiment a fresh aliquot was removed from
liquid nitrogen storage and diluted with assay buffer to the required concentration
(usually 200nM) and stored on ice prior to addition to the membrane suspensions.
2.7 DATA ANALYSIS
Disintegration experiments have shown that lp.Ci of radioactivity is equivalent
to 2.22 x lO^dpm's. Knowing both this and the specific activity of the radioligand
under study (in Ci/mmol), it is simple to transform specific binding (expressed in
dpm's) into an amount of ligand specifically bound (moles). This value can be
expressed as the number of moles per weight of tissue or protein to take into account
variations in membrane preparations between experiments.
Kinetic parameters of K^ (receptor affinity) and Bmax (number of receptors
present) were calculated. A computer curve fitting programme was used to fit raw
experimental data. ("Polyfit", an IBM multipurpose programme written by Dr. R.B.
Barlow; see Bowmer, 1992). This allowed consistent handling of complex binding
data. This program allows the fitting of values of Y by the least squares method to
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values of X. The logistic expression below (Equation 1) was used where: Y =
response, X = ligand concentration, M = maximum effect and, IC^q is the concentration
of inhibitor producing half maximum effect and P defines the slope.
Equation 1
When X is plotted logarithmically the curve is S-shaped, with a slope determined
by P. It can be used therefore to assess whether results obey the Law of Mass Action.
If they do P should be equal to 1. In inhibition studies P is negative with the curve
being "reverse S-shaped" relating the amount of ligand bound to varying concentrations
of competing unlabelled ligand. P is therefore equivalent to n^, the Hill Co-efficient,
where n is the slope of the line at the midpoint (Barlow and Blake, 1989). The Hill Co¬
efficient is an indication of the existence of co-operativity. A Hill number of close to
unity indicates either a lack of co-operativity or binding site heterogeneity.
The dissociation constant K. was calculated graphically in some instances using
the findings of Cheng and Prussoff (1973; Equation 2) where [L] = ligand
concentration, IC^q is the concentration of inhibitor producing half maximal effect and
K, in the dissociation constant.
When assay conditions are such that [L]/Kd « 1 then Ki ~ IC^q. Ligand-
receptor interactions are saturable therefore a finite number of receptors must exist in a
given tissue. The term Bmax is used to define the maximum number of receptor sites
present in a tissue. Therefore if specific binding follows the Law of Mass Action the
relationship between the amount of ligand bound (SB) and ligand concentration [L] is
as shown in Equation 3.
d
Ki = ^50
1 + [L]/Kd Equation 2
gg _Bmax [L]
[L] + Kd Equation 3
-44-
A plot of SB/[L] against SB gives a straight line from which both B and K,max q
can be calculated (Scatchard Plot), but this method was not routinely used in the present
study.
Statistical Analysis
Mean values and standard error of mean (s.e.m.) were calculated where
appropriate. Developmental data were subjected to one-way or two-way analysis of
variance as appropriate (Monk and Hall, 1980). Analysis of variance (anova) allows
the reliability of a difference between means to be assessed in the light of the overall
variability of the data. An F ratio was computed from mean squares (C.L.R. Anova;
Clear Lake Research Incorporated, 1985; 1986). A low F ratio generally signifies a
lack of significance between means. A larger F ratio makes it more likely that a
significant effect exists. One-way anova (between subject) can be successfully applied
to the data presented in the present study where the groups are of unequal numbers.
Differences between ages were investigated using this method. Two-way analysis of
variance was used to look for differences between conditions and age. This also
indicates whether an interaction is occurring. This refers to the way in which the
effects of one independent variable are influenced by the other independent variable.
Since the F ratio gives no indication as to where the difference lies, an a
posteriori comparison must be made (i.e. post hoc test). In these studies a t-test was
used to locate significant (p < 0.05) differences. All possible pairwise comparisons
between means were made. Analysis of variance results are expressed as follows: F
(degrees of freedom) = x; p < 0.05. Student's t-test was applied where appropriate to
rrr» jr
other data (Statworks ). Lines of best fit were fitted to data using Polyfit.
-45-
Developmental Study
Adult (PND90) comparisons were routinely included in each experiment using
immature tissue (PND0-PND28). The reason being to control for the assay itself. If
for any reason binding to the PND90 tissue was not as expected the whole experiment
was discarded.
Specific binding, K^, Bmax and EC^q values were calculated, where
appropriate, for adult and immature binding and subjected to analysis of variance (as
described above) to look for differences between ages. Since data were grouped in age
intervals (see Section 3.5.1) any slight variation in receptor affinity or EC^q may be
undetected using analysis of variance. Therefore two alternative methods were used to
investigate the variation in and EC^q values. The first simply involved plotting all
data points against individual ages and fitting a straight line to them using the method of
least squares. The second method involved calculating the ratio of specific binding
(SB)/B and then plotting this against respective age. The ratio should be anIllaX
indication of since from Equation 4, [L] is fixed, therefore SB/Bmax must
approximate K^. A straight line was again fitted to these data as above. If the slope of
these lines was close to zero it was assumed that no changes were occurring in EC^q or
postnatally. However, lines with a sharp gradient may be an indication of postnatal
alteration. Plots of SB/B ov were constructed for binding expressed both per mgmax




[ HJMK801 (specific activity 24.8Ci/mmol) was purchased from New England
Nuclear (NEN-DuPont). CPP and D-AP5 were synthesised in the laboratory of Dr J.C.
Watkins (Department of Pharmacology, University of Bristol). The ligands were
prepared by custom tritiation (Amersham International, Bucks) to specific activities of
20Ci/mmole and 40Ci/mmole for [^HjCPP and [^H]D-AP5 respectively. HA966,
-46-
AP7 and 7-chlorokynurenate were also synthesised in the laboratory of Dr Watkins.
(+)Dizocilpine (MK(+)), (-)dizocilpine (MK(-)) and (±)dizocilpine (MK(±)) were
obtained from Fujisawa Pharmaceutical Company (Japan).
All other reagents and compounds used were purchased from routine laboratory






The first objective of this study was to establish binding assays for [ H]CPP and
3
[ Hjdizocilpine to the same membrane preparation which could be used to generate
reliable information about their respective binding sites on the NMDA receptor
3
complex. The aims were (a) to use the [HjCPP assay to investigate interactions
between the neurotransmitter binding site and the NMDA associated glycine site and
(b) to use both radioligand binding assays to study the ontogeny of the NMDA receptor
complex in the rat CNS between birth (PNDO) and adulthood (PND90).
NMDA receptors are present in highest densities in the hippocampus and the
cerebral cortex (Wong et al 1986; Monaghan et al 1985; Olverman et al 1988).
Therefore to maximise binding under conditions when it may be very low, such as in
neonatal tissue, membrane preparations were prepared from pooled hippocampal and
cerebral cortical tissue. Two membrane preparations were investigated; (i) a whole
membrane preparation, and (ii) a crude synaptosomal preparation, as described in
Section 2.3.
3.2 CHARACTERISATION OF f3H1CPP BINDING
33.2.1 Timecourse of f H1CPP binding to synaptosomal membranes
3
Using the standard centrifugation assay (Section 2.4) [ HjCPP (15nM) bound to
freshly prepared synaptosomal membranes from rat cerebral cortex. Binding to freshly
prepared whole membranes was not successful, resulting in low specific binding
making accurate measurements difficult. For this reason synaptosomal membranes
were used in all further experiments concerned with characterising [ HjCPP binding.
At 25°C [ HjCPP (15nM) binding was rapid, reaching equilibrium within 5 minutes
(Fig. 12). The non-specific component of the binding measured with L-glutamate
(ImM) was essentially instantaneous varying very little during the incubation. Specific
binding at equilibrium was around 180fmol/mg protein, accounting for approximately
40% of total binding. Binding was reversible since addition of L-glutamate (ImM)




FIGURE 12: Timecourse of pHlCPP binding
Synaptosomal membranes were incubated with [Tl]CPP (15nM) at 25° at pH7.5 using
50mM Tris-HCl for various times(circles; Assoc) in the absence or presence of L-
glutamate(lmM) to measure total and non-specific binding respectively. In replicate
control samples L-glutamate (ImM) was added after 15min incubation (squares;
Dissoc). Specific binding was determined by subtracting non-specific binding from
total binding. Specific binding accounted for 40% of total binding. Each point is the
mean of triplicate determinations.
33.2.2 The effect of varying experimental conditions on the binding of f H1CPP
3The proportion of total [ H]CPP binding to rat synaptosomal membranes
accounted for by specific binding (~ 40%) is relatively low compared with say
3
[ H]dizocilpine binding (see Section 3.3.1). It was therefore important to try and
optimise experimental conditions to increase specific binding.
Effect of Ca2+
2+Inclusion of Ca in the assay buffer may result in reduced non-specific binding
2+
(Olverman et al, 1988). Inclusion of a physiological concentration of Ca (2.5mM)
in the standard assay buffer (50mM Tris-HCl, pH 7.5) in the form of CaC^ resulted in
specific binding accounting for 31% of total binding. This was no better than in the
2+absence of Ca (40%) and was therefore not included in further assays.
Effect of Tris-acetate buffer
50mM Tris-acetate buffer (pH 7.4), was compared with 50mM Tris-HCl buffer
(pH 7.5). No differences were seen between the proportion of specific binding under
each condition. This lack of effect was further confirmed by calculation of and
I^max values. values of 0.79|iM and 0.63(iM were seen with Tris-acetate and Tris-
HCl with corresponding II Qv values of 3.5 and 3.3 pmol/mg protein.max
Effect of extra washing of membrane preparations
Extra washes of membrane preparations should lead to a lowering of
endogenous neurotransmitters. This should result in improved binding. However
longer preparation time may be deleterious to the membranes. Extra washing (x 2 extra
3
washes) of this membrane preparation had no beneficial effects on [ H]CPP binding
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FIGURE 13: Inhibition of P^HICPP binding using filtration to terminate the assay
Synaptosomal membranes were prepared from pooled cortical and hippocampal tissue
and incubated with [ H]CPP (10nM) at 25°C for 25 min using 5mM(circles) or 50mM
Tris HCl(triangles), (pH 7.5). Binding was inhibited with increasing concentrations of
CPP (0.01-100|iM). Non-specific binding was measured with L-glutamate (ImM).
The assay was terminated using filtration as described in Section 2.4. Each point
represents the mean of duplicate determinations. Non-specific binding using 5mM or
50mM buffer accounted for 95.5% and 91.3% of total binding respectively.
TABLE 3 THE EFFECT OF pH ON THE BINDING OF f3HlCPP
Synaptosomal membranes were incubated at 25°C for 25 min with [^HJCPP (lOnM)
using 50mM Tris HC1 of increasing pH (6.5 - 8.5). Non-specific binding was
measured with L-glutamate (ImM). Specific binding was calculated by subtracting
non-specific binding from total binding.


















n = 5 or 6
Values represent mean ± s.e.m.
levels of binding were seen at pH 7.75 at 25°C, with lower binding seen towards the
3
extremes of the pH range. K. and El v values were calculated for [ H]CPP bindingfl niaX
at pH 7.75.
3.3 CHARACTERIZATION OP [3IIIDIZOCILPINE BINDING
33.3.1 Timecourse of [ Hjdizocilpine binding to synaptosomal membranes
3The binding of [ H]dizocilpine (InM) to synaptosomal membranes prepared
from pooled rat cerebral cortices and hippocampi in the presence of L-glutamate and
glycine (both IOjiM) reached equilibrium by 45min of incubation at 25°C. This level
of binding remained stable until at least 60 min of incubation (Fig. 14). Non-specific
binding was defined using unlabelled dizocilpine (30}iM). Although the use of the
same compound in unlabelled form is not ideal, no other compound is currently
commercially available which shows the same degree of specificity and affinity for the
3 3
[ H]dizocilpine binding site. At equilibrium, unlike [ HJCPP, specific binding
accounted for approximately 92% of total binding.
3.3.2 Determination of KdJjmax and nH values
K, and B values were to be routinely estimated from concentrationd max J
dependent inhibition curves by fitting data to Equation 1 (Section 2.7). However to
confirm that this method was reliable these parameters were also initially calculated
using Scatchard and Hill plots (Fig.15). The specific binding in the presence of
increasing concentrations of [ H]dizocilpine (0.5 - lOnM) was measured as described
in Section 3.4.1. These data were transformed into Scatchard (Fig.l5A) and Hill
(FIg,15B) plots for the estimation of Bmax, and n^ values. The calculated
from Fig.l5A is 4.6nM with a corresponding B of 1.83pmol/mg protein. The K,max ci
value calculated from Fig.l5B is 5.0InM, which correlates well with the value
derived from Fig. 15A. The n^ value of 1.009 indicates a single population of binding
sites. These values compare well with those calculated by fitting binding data obtained






















FIGURE 14: Timecourse of P^HIdizocilpine binding
Synaptosomal membranes were prepared from pooled cortical and hippocampal tissue.
They were incubated at 25°C with [ H]dizocilpine (InM) using 5mM Tris-
HCl(pH7.4) in the presence or absence of dizocilpine (30|iM) for various times to
measure non-specific and total binding respectively. Binding was measured in the
presence of L-glutamate and glycine (both 10(iM). Specific binding was calculated by
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B
FIGURE 15: ScatchardCA) plot and HilKBi plot of I~H1dizocilpinc binding
Synaptosomal membranes prepared as described in Fig. 13 were incubated with
increasing concentrations of [HJdizocilpine (0.5-10nM) for 45min in the absence or
presence of dizocilpine (30|iM) to measure total and non-specific binding. Binding
was measured in die presence of L-glutamate and glycine (both lOjiM). Specific
binding was calculated and transformed into a Scatchard plot(A), from which a Ka of
4.6nM and a Bmax of 1.83pmol/nig protein were estimated for [ H]dizocilpine binding.
Data were further transformed into a Hill plot (B) from which a Hill co-efficient (nH) of
1.009 was estimated along with an ICso of 5.01nM.
Abbreviation: SB, specific binding








































dizocilpine, to the equation Y = MX*5 /(Xp +IC^q P) (Equation 1). Under identical
experimental conditions a of 6.8 ± l.OnM (n = 13) was calculated with a
corresponding Bmax of 1.7 ± 0.3pmol/mg protein (n = 13) with n^ being 1.1 ± 0.09 (n
= 13). This inhibition method was used in all further experiments.
3.3.3 Effects of buffer concentration
3
Binding of [ H]dizocilpine (InM) to whole and synaptosomal membrane
preparations subjected to normal washing (3 x washes) was investigated in the presence
of 5mM and 50mM Tris-HCl (pH 7.4). The results are from a representative
experiment whereby a single whole and a single synaptosomal membrane preparation
were halved during preparation such that one half was prepared with 5mM buffer and
the other half was prepared with 50mM buffer. Binding was inhibited using increasing
concentrations of dizocilpine (O.Ol-lOOnM), and this data was used to calculate and
Bmax va^ues- L-Glutamate (0.01-100|J.M) was used to modulate binding and EC^q
values were calculated for this effect (Table 4).
Control binding
In the presence of 50mM buffer it proved difficult to demonstrate reliable
inhibition of [ H]dizocilpine binding. and Bmax values could not be measured.
However, in the presence of 5mM buffer and Bm values were calculated for each
membrane preparation (Table 4). The value for binding to whole membranes was
lower than that for synaptosomal membranes. Bmax values indicated a higher density
of binding sites in synaptosomal membranes than in whole membranes.
L-Glutamate modulation
3
L-Glutamate modulation of [ H]dizocilpine binding was apparent regardless of
the buffer concentration. A concentration dependent increase in specific binding was
observed, and maximum binding was measured in the presence of 10(iM L-glutamate
under both conditions. The ability of L-glutamate to cause this enhancement of
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binding as measured by the EC^q values, was similar in the presence of 5 or 50mM
buffer to both membrane preparations. The percentage increase in specific binding, in
the presence of IOjiM L-glutamate compared to control binding was however greater in
the presence of 5mM buffer and was greatest for synaptosomal membranes(Table 4).
3.3.4 The effects of extensive membrane washing
Extensive washing of a membrane preparation may prove advantageous since a
greater proportion of endogenous modulators should be removed. This is important for
3
[ H]dizocilpine binding since it will allow measurements of exogenous modulation to
be made. However the extended preparation time may ultimately be harmful to the
membrane preparation and may lead to the removal of important cellular elements.
The effects of extensive washing (6 x washes) were investigated on the binding of
3
[ Hjdizocilpine (Washed membranes; Table 4). Since binding in the presence of
50mM Tris-HCl was unreliable all further assays were carried out in the presence of
5mM Tris-HCl. As in section 3.3.3 results are from the single representative study
whereby one whole and one synaptosomal membrane preparation were prepared, with
one half subjected to normal washing (3 x; normal membranes, as already described
above), and the other half subjected to extensive washing (6 x; washed membranes).
Kd> Bmax and EC^q values were calculated as described in Section 3.4.3 and are
displayed in Table 4 (washed membranes).
Control binding
Extensive washing decreased the amount of specific binding detected for each
membrane preparation compared to normal membranes. The largest decrease in
binding was seen for synaptosomal membranes (75%). This effect is further reflected
in the calculated values. The values for [ Hjdizocilpine binding to both whole
and synaptosomal membranes increase with extensive washing indicating that the
affinity of [ Hjdizocilpine for its binding site has decreased. Bmax values increase for
both membrane types after extensive washing compared to normal conditions.
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L-Glutamate modulation
3L-Glutamate increased [ H]dizocilpine binding dose-dependently to both
membrane preparations with normal and extensive washing. EC^q values however did
not alter with extensive washing for either membrane preparation, washed or normal.
Maximum levels of binding were again seen in the presence of 10|iM L-glutamate for
each membrane preparation. The extent of the L-glutamate modulation was greater for
synaptosomal membranes, both with normal and extensive washing. Greatest
modulation was measured in extensively washed membranes.
3.3.5 Effects of freezing and thawing membrane preparations
Freezing membrane preparations prior to use can be advantageous since they can
be prepared in advance and stored in usable aliquots. This would be extremely useful
for neonatal tissue which was to become available at short notice. In addition freezing
and thawing can be beneficial to membrane preparations since this process can allow
the disruption of vesicles containing endogenous neurotransmitters and
neuromodulators. As described above (Section 3.3.4) one whole and one
synaptosomal membrane preparation was prepared. Half was frozen for at least 24
hours prior to use, the other half was used fresh. Binding, examined under control
conditions and in the presence of L-glutamate and glycine (both 10(iM), was inhibited
with increasing concentrations of dizocilpine (O.Ol-lOOnM). In addition, binding was
positively modulated with increasing concentrations of L-glutamate (0.01 - 100pM) or
glycine (0.01- lOOpM). K^, Bmax and EC^q values were calculated.
Control binding
Specific binding of [ H]dizocilpine to both membrane preparations which had
been previously frozen was reduced compared to fresh membranes (Table 5). Under
control conditions and Bmax values did not vary greatly between fresh and frozen
membranes (Table 6). Concentration dependent inhibition of [ H]dizocilpine binding
was measured with dizocilpine in both fresh and previously frozen membranes (Fig. 16).
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TABLES THE EFFECTS OF FREEZE/THAWING ON rHIDIZOCILPINE
BINDING
Membranes, fresh or previously frozen, were incubated with [3H]dizocilpine (InM) for
45 min at 25°C. Non-specific binding was measured with dizocilpine (30|iM).
Specific binding was calculated. Replicate samples were incubated in the presence of
L-glutamate and glycine (both 10|iM). Modulated binding was expressed as a
percentage of that measured under control conditions.
MEMBRANE TYPE SPECIFIC BINDING
(fmol/mg protein)




whole 51.90 90.91 175
Synaptosomal 45.36 149.38 329
FROZEN
whole 39.35 191.79 487
Synaptosomal 29.41 431.37 1466
L-glu: L-glutamate (lOpM)
gly: glycine (lOpM)
TABLE6BINDINGCHARACTERISTICSOFf^HIDIZOC LP NETFR HNDF ZENMEMBRA EP EPARA ONS [^HjDizocilpinebind gwascarr edutdet iliTabl5bhp es ncefincr asingoncentrationsdizoc pine(0.01- lOOnM)indieabs nceorpresencefL-glutamata dglycin(bothl p ).Re li atea pleswerincub dth p rencef increasingconcentrationsfL-glut materglyc(0.01-lOOfiM).D awerfitt dhl gi icqu t onY=M /(X+IC o),Kd,Bm«andECsovalueswerecalculat d. Control+L-glu&g yL-gl MEMBRANETYPEKdBnmw*xECso (nM)(pmol/mgpr tein)(pmol/mgpr tein)|l FRESH Whole8.320.486 50.610 Synaptosomal26.801.245 10.9318 FROZEN Whole6.210. 82 92.75136 Synaptosomal39.801 22.9570 819 L-glu;-glutamate(10|iM) gly;lycine(lOpM)
Modulation of binding
L-Glutamate and glycine each increased the binding of [ H]dizocilpine to whole
and synaptosomal membranes, fresh and previously frozen, in a concentration
dependent manner with maximal binding being seen at lOpM glycine and at lOjiM L-
glutamate (Table 5; Fig. 16 and 17). L-glutamate enhanced binding to both membrane
preparations, fresh and frozen, to a greater extent than glycine (Fig. 17). The increase
in binding seen with L-glutamate alone was comparable to the increase in binding seen
with both L-glutamate and glycine (Table 5; Fig. 17).
3The EC^q values for L-glutamate and for glycine modulation of [ H]dizocilpine
binding did not vary greatly between fresh and previously frozen, whole and
synaptosomal membranes.
Likewise Bmax values obtained from previously frozen membranes did not
greatly differ from those calculated for fresh membranes in the absence or presence of
L-glutamate and glycine. values were reduced in both fresh and frozen membranes
in the presence of L-glutamate and glycine (Fig. 16; Table 6).
3
3.3.6 Inhibition of [ H]dizocilpine binding to the two membrane preparations chosen
to be used in the present study
The inhibition of [ HJdizocilpine (InM) binding to fresh synaptosomal
membranes and previously frozen whole membranes was investigated in the absence
3
and presence of L-glutamate (10|iM). [ H]Dizocilpine ((+)dizocilpine) binding was
inhibited with the(+) isomer(MK(+)) the (-)isomer(MK(-)) and compared with the
racemic(±) mixture (MK(±)) of dizocilpine. Inhibition curves are displayed in Figs. 18
and 19, for whole and synaptosomal membranes respectively, with corresponding K.
values in Table 7. The rank order of potency of these compounds for inhibition of
3
[ HJdizocilpine binding was, MK(+) > MK(±) > MK(-) for synaptosomal membranes
and MK(±) > MK(+) > MK(-) for whole membranes. Hill constants are near to unity
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FIGURE 16: Inhibition of F^Hldizocilpine binding to fresh and previously frozen
synaptosomal membranes
One membrane preparation was prepared and halved with one half used fresh and the
other half used after being frozen for at least 24 hours. Membranes, fresh (A) and
previously frozen (B), were incubated with[3H]dizocilpine (InM) at 25°C for 45min in
the presence of increasing concentrations of dizocilpine (0.01-300nM). Binding was
measured in the absence(CONTROL) or presence of L-glutamate and
glycine(+GLU/GLY;both lOpM). Non-specific binding was measured with
dizocilpine (30|iM). Specific binding was calculated and expressed as a percentage of
binding under control conditions. Each point is the mean of duplicate determinations.
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FIGURE 17: Modulation of f%ldizocilpine binding to synaptosomal membranes
One membrane preparation was used as described in Fig. 16. Membranes, fresh (A)
and previously frozen (B), were incubated with [ H]dizocilpine (InM) at 25°C for 45
min in the presence of increasing concentrations of L-glutamate(GLU) or
glycine(GLY);,(0.01 - 100(iM). Dizocilpine (30jiM) was used to determine non¬
specific binding. Specific binding under each modulatory condition was calculated and
expressed as a percentage of binding under control conditions. Each point is the mean
of duplicate determinations.
Abbreviations: GLU, L-glutamate; GLY, glycine.
B
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FIGURE 18: Inhibition of f%fldizocilpine binding to whole membranes
previously frozen whole membranes prepared from cortical tissue were incubated with
[ H]dizocilpine (InM) at 25°C for 45 min. Binding was inhibited with increasing
concentrations of MK(-), MK(+) or MK(+) (see text for explanation of abbreviations),
in the absence (A) or presence(B) of L-glutamate (IOjiM). Non-specific binding was
measured with dizocilpine (30fiM). Specific binding was calculated and expressed as a
percentage of binding under control conditions. Data were fitted by least squares to the





FIGURE 19: Inhibition of faldizocilpine binding to synaptosomal membranes
Fresh synaptosomal membranes prepared from cortical tissue were incubated with
[HJdizocilpine (InM) at 25°C for 45 min. Binding was inhibited with increasing
concentrations of MK(-), MK(+) or MK(±) (see text for explanation of abbreviations),
in the absence(A) or presence(B) of L-glutamate (IOjiM). Non-specific binding was
measured with dizocilpine (30|iM). Specific binding was calculated and expressed as a
percentage of binding under coptrolpConditions. Data were fitted by least squares to the
logistic expression: Y = MX /(X + ICso). Each point represents the mean of two
separate observations.
TABLE 7 INHIBITION CONSTANTS FOR THE DISPLACEMENT OF
LHIDIZOCILPINE FROM SYNAPTOSOMAL (A) AND WHOLE
(B1 MEMBRANES BY STEREOISOMERS OF DIZOCILPINE
[^HJDizocilpine binding was measured as described in Table 5 to fresh synaptosomal or
previously frozen whole membranes, in the presence of increasing concentrations of
MK+, MK- or MK± (0.01 - lOOnM). Binding was measured in the absents or nresence
of L-glutamate (lOpM). Data were fitted to die logistic equation Y = MX /(X + ICso),
Ki values were calculated.
Control +L-glutamate (IOjiM)
Ki nH Ki nH
(nM) (nM)
A: Synaptosomal Membranes
MK+ 9.4 0.96 3.7 0.93
MK- 85.1 0.82 17.9 0.98
MK± 25.6 0.73 6.9 0.96
B: Whole Membranes
MK+ 18.7 0.94 11.3 1.14
MK- 24.0 0.92 17.3 1.02
MK± 14.3 0.99 8.2 0.93
Values are the means of two experiments.
3.3.7 Summary of optimal assay conditions used in all further studies
Since an ontogenic study was to be carried out using both [^H]CPP and
3
[ H]dizocilpine it was important to evaluate binding of both ligands to identically
3
prepared membranes to enable direct comparisons of binding parameters. As [ H]CPP
bound most reliably to fresh synaptosomal membranes not subjected to extensive
3
washing this preparation was used in all further [ HjCPP binding studies. The
calculated K. was 0.25|iM (0.2, 0.3) with a corresponding Bmov of 2.6pmol/mgg max
protein (2.2, 2.9). All further binding assays were carried out at 25°C in the presence
of 50mM Tris-HCl (pH 7.75) using a centrifugation assay to terminate the binding
process.
However, a synaptosomal preparation may not be entirely appropriate for an
ontogenic binding study due to the low numbers of synaptic junctions in early life
3
(Aghajanian and Bloom, 1967). Therefore the ontogeny of [ Hjdizocilpine binding
throughout postnatal development was also investigated using a whole membrane
3
preparation. As freezing and thawing did not adversely influence [ Hjdizocilpine
binding, previously frozen membranes were used. These were prepared without
extensive washing which was shown to alter the B„ .° max
3.4 MODULATION OF I3H1CPP AND r3H!D-AP5 BINDING VIA THE NMDA
GLYCINE SITE
3.4.1 Introduction
[3H]CPP and [3H]D-AP5 are specific, high affinity ligands both binding to the
NMDA receptor neurotransmitter recognition site (Olverman et al, 1988; Murphy et al,
1987). It has been reported that glycine is an essential requirement for the activation of
the NMDA receptor by L-glutamate (Kleckner and Dingledine, 1988). The mechanism
responsible for the link between these two sites is still unknown. Monaghan et al
(1988) however propose two possibilities, multiple NMDA receptor subtypes or
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distinct conformational states, which are regulated by glycine. Studies were carried out
to investigate the effects of glycine, HA-966 and 7-Clkyn, compounds which all act at
the NMDA glycine site, on the binding of [3H]CPP and [3H]D-AP5.
3.4.2 Inhibition of [3H1CPP binding
[3H]CPP (lOnM) binding was inhibited by CPP, L-glutamate and D-AP5 in a
3
concentration dependent manner (Fig.20; Table 8). The calculated for [ H]CPP
binding was 0.44 ± 0.04|iM with a corresponding E$ ov of 2.68 ± 0.45 pmol/mg proteinIXlaX
(n = 5; Table 8).
3.4.3 Inhibition of r3H!D-AP5 binding
[3H]D-AP5 binding was inhibited by L-glutamate, D-AP5 and CPP (Fig.21).
The for [3HJD-AP5 binding was 0.82 ± 0.19(lM with a corresponding Bmax of 3.2
± 0.82pmol/mg protein (n = 3). IC^q values of 0.1 (iM and 0.89|J,M were calculated for
CPP and L-glutamate inhibition respectively.
3.4.4 The effect of glycine
[3H]CPP binding
The effect of increasing concentrations of glycine were investigated on the
3
binding of [ H]CPP. A slight potentiation in the amount of specific binding was
measured in the presence of 0.01 - 30|iM glycine but at higher concentrations (> 30(iM)
a slight reduction in binding was seen when compared to control binding (Fig.22).
Binding was increased to a maximal level of 120.7 ± 5.1% of control binding in the
presence of 3|iM glycine. At higher concentrations (> 30pM) binding decreased dose-
dependently, reaching 83.3 ± 5.9% of control levels in the presence of ImM glycine.
Glycine therefore exhibits both weak stimulatory and weak inhibitory effects on the
binding of [3H]CPP.
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FIGURE 20: Inhibition of P^HICPP binding
Synaptosomal membranes were incubated with [ H]CPP (lOnM) at 25°C for 25 min
using 50mM Tris-HCl with increasing concentrations of CPP (n=5), L-glutamate (n =
5; GLU) or D-AP5 (n = 3, AP5), (0.03 - 100p.M). Non-specific binding was measured
with L-glutamate (ImM). Specific binding in the presence of inhibitor was expressed
as a percentage of binding under control conditions. Raw data were fitted by least
squares to the logistic expression: Y = MX /(X + ICso), Kd, Ki and Bmax values were
estimated.
Each value represents mean ± sem.
t
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FIGURE 20: Inhibition of F^HICPP binding
Synaptosomal membranes were incubated with [ H]CPP (lOnM) at 25°C for 25 min
using 50mM Tris-HCl with increasing concentrations of CPP (n=5), L-glutamate (n =
5; GLU) or D-AP5 (n = 3, AP5), (0.03 - 100pM). Non-specific binding was measured
with L-glutamate (ImM). Specific binding in the presence of inhibitor was expressed
as a percentage of binding under control conditions. Raw data were fitted by least
squares to the logistic expression: Y = MX /(X + ICso), Ka, Ki and Bmax values were
estimated.
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FIGURE 21: Inhibition of LH1D-AP5 binding to synaptosomal membranes
[ H]D-AP5 binding was measured as described for [ H]CPP binding in Fig.20, in the
presence of increasing concentrations of D-AP5(AP5), CPP or L-glutamate (GLU)
(0.03-100pM). Non-specific binding was measured with L-glutamate (ImM).
Specific binding in the presence of inhibitor was expressed as a percentage of binding
under cc^ptrol^conditions. Data were fitted by least squares to the logistic expression:
Y = MX /(X + ICso), Kd, Ki and Bmax values were estimated. Each value is the mean
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FIGURE 22: The effect of compounds active at the NMDA glycine site on the binding
QffHICPP
Membranes were incubated with [ H]CPP(10nM) at 25°C for 25 min with increasing
concentrations of glycine (n = 5; GLY), HA-966 (n = 5; HA966) and 7-Clkyn (n = 3;
7-C1), (0.01 - 1000|iM). Specific binding in the presence of inhibitor was expressed as
a percentage of binding under control conditions. Data were fitted by least squares to
the logistic expression: Y = MX /(X + ICso), Ki and ECso values were estimated as
appropriate.
Each value represents mean ± sem.
i
r3H!D-AP5 binding
Increasing concentrations of glycine had a markedly different effect on the
binding of [3H]D-AP5 from the effect already described for [3H]CPP binding (Fig.23).
3
Glycine only inhibited [ H]D-AP5 binding. However, glycine could not totally inhibit
binding. Maximum inhibition (37.6%) was seen in the presence of 3pM glycine with
no further inhibition seen even at higher glycine concentrations. This is a
concentration dependent inhibitory action which has an IC^q of approximately 0.6|iM.
3.4.5 The effect of HA-966
HA-966 has been described as both an antagonist and a partial agonist at the
NMDA associated glycine site (see Thomson, 1990).
r3H!CPP binding
3
HA-966 markedly increased the binding of [ H]CPP in a concentration
dependent manner over the concentration range 0.03-1000JJ.M, (Fig.22). In the
presence of 100|iM HA-966 binding reached a maximum level of 204.5 ± 6.% of
control binding. The EC^q for this modulating effect was 6.3 ± 1.6(iM.
r3H1D-AP5 binding
3
HA-966, like glycine also had a very different effect on [ H]D-AP5 binding
from that seen on [ H]CPP binding. No potentiation of binding was seen. Binding
was in fact inhibited (Fig.23). As with glycine binding could not be completely
inhibited with around 70% of [3H]D-AP5 binding remaining insensitive to HA-966
inhibition. The IC^q for this inhibition is estimated as 5(iM.
3.4.6 The effect of 7-chlorokvnurenate
7-Clkyn is reported as being either an antagonist or an inverse agonist at the


















- - - - GLY
- -O - 7-CI
6
- 8
T I I I
7 - 6 - 5 - 4
CONCENTRATION LOG[M]
- 2
FIGURE 23: The effect of glycine .HA-966 and 7-Clkvn on the, binding of i%TD-AF5
Binding was measured as previously described in Fig.21 but in the presence of
increasing concentrations of glycine (GLY), HA-966(HA966) or 7-Clkyn (7-CI), (0.03
- IOOOjiM). Specific binding in the presence of inhibitor was expressed as a percentage
of binding under control conditions. Raw data were fitted by least squares to the
logistic expression: Y = MX /(X + ICso), Ka and Bmax values were estimated. n = l




7-Clkyn had a different effect on [ H]CPP binding from both glycine and HA-
3966. Increasing concentrations of 7-Clkyn inhibited [ H]CPP binding, in a
concentration dependent manner, although the inhibition was incomplete (Fig.22). In
the presence of ImM 7-Clkyn 28 ± 4.8% of [3H]CPP was not inhibited. The IC^q
value for this inhibition was calculated as 104.1 ± 16.3|iM (n = 3).
r3H!D-AP5 binding
7-Clkyn unlike HA-966 and glycine had a very similar effect on [3H]D-AP5
binding as the effect already reported for [ H]CPP. 7-Clkyn inhibited the binding in a
concentration dependent manner. Around 40% of binding remained insensitive to
inhibition even by ImM 7-Clkyn (Fig.23). The IC^q for this inhibition is
3
approximately 100|iM, similar to that calculated for inhibition of [ H]CPP binding.
3
3.4.7 The effect of glycine on the inhibition of [HICPP binding
One proposal of the actions of glycine is that it may promote the "agonist" state
of the NMDA receptor (Monaghan et al, 1988). The effect of 3pM glycine, a
3
concentration producing maximal stimulation of [ HJCPP binding, was investigated on
the inhibition of [3H]CPP binding by CPP (Fig.24A), L-glutamate (Fig.24B), D-AP5
(Fig.24C) and 7-Clkyn (Fig.24D).
3
Glycine (3|iM) had no significant effect on the inhibition of [ HjCPP binding by
L-glutamate and CPP (Table 8; Fig.24A and 24B). The and Bmax values were not
significantly different from binding in the absence of glycine. The IC^q for D-AP5
inhibition was however affected, with it becoming less effective as an inhibitor of
[3H]CPP binding (P < 0.05; Table 8). Glycine had no significant effect on inhibition
by 7-Clkyn. 27.4 ± 6.5% of binding still remained in the presence of ImM 7-Clkyn
and 3|iM glycine. This is not significantly different from in the absence of glycine
(Section 3.5.6).
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FIGURE 24: The effect of glycine on the inhibition of FH)CPP binding
[ H]CPP binding was measured as described in Fig. 20, but in the presence of glycine
(+GLY; 3|lM) and increasing concentrations of (A), CPP (n = 5): (B), L-glutamate (n =
3; GLU): (C), D-AP5 (n = 3; AP5) and (D), 7-Clkyn (n = 3; 7-C1), (0.03 - 1000[iM).
Specific binding was calculated and expressed as a percentage of binding under cpntro^
conditions. Data were fitted by least squares to the logistic expression: Y = MX /(X
+ ICso), Ka, Ki and Bmax values were estimated.
Each value represents mean ± sem.
In the presence of low concentrations of D-AP5 and 7-Clkyn, glycine increased
binding to around 120% of control values. This was not seen with CPP or L-glutamate.
3.4.8 The effect of HA-966 on the inhibition of pHlCPP binding
The effect of lOOjiM HA-966 was examined on the inhibition of [^H]CPP
binding by CPP (Fig.25A), L-glutamate (Fig.25B), D-AP5 (Fig.25C) and 7-Clkyn
(Fig.25D). Concentration dependent inhibition by each of these four compounds was
still seen in the presence of HA-966 (IOOjiM). HA-966 significantly increased the
affinity of [^H]CPP for its binding site resulting in a of 0.21 ± 0.04|iM (Table 8; P
< 0.05). The B was reduced although not significantly.IIldA
3The affinity of L-glutamate for the [ H]CPP binding site was significantly
decreased compared to control conditions in the presence of HA-966. The affinity of
D-AP5 was also decreased compared to control (Table 8).
The IC^q for inhibition by 7-Clkyn was significantly decreased in the presence
of HA-966 compared to control conditions, showing an increase in affinity for the
[^H]CPP binding site (p < 0.05; Table 8). 32.6 ± 4.4% of binding remained in the
presence of ImM 7-Clkyn and lOOjlM HA-966.
3.4.9 The effect of HA-966 and glycine on pH]CPP binding
3
l|i.M HA-966 did not have a significant effect on [ H]CPP binding compared to
3
control, and did not effect [ H]CPP binding in the presence of increasing concentration
of glycine (Fig.26). The weak stimulatory and inhibitory effects were still apparent.
100|lM HA-966 resulted in 200% of control [^H]CPP binding at low glycine
concentrations. However as the glycine concentration increased the proportion of
binding increased by HA-966 was inhibited to control levels of binding. The IC^q for
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FIGURE 25:^ The effect of HA-966 on the inhibition of PHICPP binding
Binding of [ H]CPP was carried out as described in Fig.20 but in the presence of HA-
966(+HA966:100|iM) and increasing concentrations of (A),CPP (n = 3), (B), L-
glutamate (n = 3; GLU); (C), D-AP5 (n = 1; AP5) and (D), 7-Clkyn(n = 3; 7-C1), (0.03
- IOOOjiM). Specific binding was calculated and expressed as a percentage of binding
under control conditions. Data were fitted by least squares to the logistic expression: Y
= MX /(X + IC50), Kd, Ki and Bmax values were estimated.
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FIGURE 26: The effect of HA-966 and glycine on the binding of FH1CPP
Binding of [ H]CPP was carried out as described in Fig.20 but in the presence of HA-
966 (+HA966 1 or lOOpM) and increasing concentrations of glycine (gly), (0.01-
IOOOjiM). Specific binding was calculated and expressed as a percentage of binding
under control conditions. Data were fitted by least squares to the logistic expression:
Y = MX /(XP + IC50), Ki values were estimated.
Each value is the mean ± sem of 3-5 individual experiments.
3.4.10 The effect of glycine and 7-Clkvn on falCPP binding
3
The effect of ImM 7-Clkyn was tested on the binding of [ H]CPP in the
presence of increasing concentrations of glycine (Fig.27A). Binding was reduced to
approximately 20% of control levels at all concentrations of glycine tested (0.01 -
1000|iM). This is equivalent to binding in the presence of 7-Clkyn alone. Thus
3
glycine does not modulate the binding of [ H]CPP which remains in the presence of
ImM 7-Clkyn.
3.4.11 The effect of HA-966 and 7-Clkyn on f^HlCPP binding
7-Clkyn (ImM) reduced [^H]CPP binding to around 30% of control levels.
Increasing concentrations of HA-966 led to complete inhibition of this component of
binding which was normally insensitive to 7-Clkyn (ImM). An IC^q of 1.4|iM was
calculated for this effect (Fig.27B).
3.5 AN INVESTIGATION INTO THE ONTOGENY OF THE NMDA
RECEPTOR
3.5.1 Introduction
The objective of the study was to investigate the ontogeny of the NMDA
3
receptor in the rat CNS. This was carried out by measuring the binding of [ H]CPP
3and [ Hjdizocilpine to the neurotransmitter site and the ion channel site on the NMDA
receptor complex respectively. Membranes were prepared from rats of postnatal ages
between PND0-PND28 and also from rats at PND90. PND90 in this study has been
classed as adult and is used as a comparison to data obtained between PND0 and
3
PND28. [ HjDizocilpine binding was measured using both whole membranes
3
(previously frozen) and synaptosomal membranes (fresh). [ H]CPP binding was
measured using only a synaptosomal membranes preparation since binding to whole
membranes was unsuccessful (Section 3.2). Specific binding at a single ligand
3 3
concentration was measured for [ H]CPP and [ Hjdizocilpine. Binding of
3
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FIGURE 27: The effect of glycine .HA-966 and 7-Clkvn on the binding of falCPP
Binding was measured as previously described in Fig.20 but in the presence of
increasing concentrations of glycine (A; GLY) or HA-966(B; HA966),(0.03-1000jiM)
in the presence of 7-Clkyn (+7-Cl;lmM). Specific binding in the presence of inhibitor
was expressed as a percentage of binding under control conditions. Raw data were
fitted by least squares to the logistic expression: Y = MX /(X + ICso), Kd and Bmax
values were estimated, n = 1 for glycine and 7-Clkyn and n = 3 for HA-966.
• HA966
- - A -
investigate underlying regulatory mechanisms which may alter during postnatal
development. Binding data were expressed both per mg protein and per mg wet weight
tissue, since the protein content of the brain alters postnatally. The alteration in protein
content may have some bearing on the resultant postnatal profile of binding. Using
both plots, binding can be compared and the influence of protein alteratins assessed.
The alteration in postnatal protein content of the membranes used in this study is shown
in Fig.28 for whole and synaptosomal membranes. Whole membranes have the higher
protein content throughout postnatal development.
Specific binding at one ligand concentration is not an ideal method of expressing
binding data. Therefore and Bmax values were calculated for both ligands thus
giving an indication of receptor affinity and receptor number. This was not always
possible however when at young ages, (e.g. at ages less than PND8) dose-dependent
inhibition and modulation could not be reliably measured. In such circumstances
specific binding at a single ligand concentration was the only measurement available
for comparisons between ages, membranes or experimental conditions. The effects of
3
L-glutamate and glycine were investigated on the binding of [ H]dizocilpine, at
different postnatal ages. Calculation of EC^q values provided a quantitative parameter
describing their ability to modulate binding.
3
Fig.29A shows an example of data for [ HJdizocilpine binding throughout
postnatal development. Although the increase in binding with postnatal age can be
seen it is difficult to compare data between ages since at some ages only one
measurement was made. Figure 29B shows the alternative method of presenting this
data which allows statistical analysis to be carried out. The data is grouped at four day
age intervals and is presented in the form of a histogram. One way analysis of variance
can be applied to the data. Ages where binding is significantly different from that at
PND90 are indicated. All further binding data is therefore presented in this format.
3 3
The postnatal development of [ Hjdizocilpine and [ H]CPP binding, at a single ligand
concentration, to the NMDA receptor neurotransmitter site and associated ion channel
















FIGURE 28: Protein content of membrane samples used in nostnatal binding studies
The protein content of membrane samples was measured using the method of
Bradford(1978). An increase in protein concentration was seen with increasing age
in both whole(A) and synaptosomal(B) membranes. Whole membranes have the
higher protein content at all ages tested. A smooth curve was fitted to the data showing
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FIGURE 29: Comparison of a plot of all data points and a plot of grouped data for
postnatal binding
Whole membranes were incubated at 25°C for 45 min with [ H]dizocilpine (InM) in
the presence or absence of dizocilpine (30joM), to measure total and non-specific
binding. Binding was measured in the presence of L-glutamate (10|iM). Specific
binding was calculated by subtracting non-specific binding from total binding and
expressed per mg protein. Individual points were plotted against age(A) or grouped at
four day age intervals (B). One-way analysis of variance was applied to (B). This
revealed a significant difference between binding at different postnatal ages.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column. i
described previously. The data shall be presented as follows; (i) [^H]Dizocilpine
3
binding to whole membranes (Section 3.7), (ii) [ H]Dizocilpine binding to
3
synaptosomal membranes (Section 3.8) and (iii) [ H]CPP binding to synaptosomal
membranes (Section 3.9).
3.5.2 Brain and body development
Brain tissue and body weights were recorded during postnatal development in
Wistar Cob rat pups (PNDO - PND28). No distinction was made between males and
females. Body weights increase gradually until PND28 but increase at a more rapid
rate after 3 weeks of age (Fig.30A). Tissue weight as illustrated in Figure 30B
represents the combined weight of cerebral cortices and hippocampi (wet weight) as
used for membrane preparations. In contrast to whole body weight, tissue weight
increases rapidly until PND17-20. After this age growth is much slower, as it
approaches adult weight. Brain weight is therefore approaching adult levels at an
earlier age than body weight. However, this is no reflection of the postnatal
development of brain constituents.
3.6 [3HlDIZOCILPINE BINDING TO WHOLE MEMBRANES
3.6.1 Control Conditions
3
Specific binding of [ H]dizocilpine at a single ligand concentration was
measured at various postnatal ages in the absence of L-glutamate and glycine (Fig.31).
Specific binding was detected from PNDO and at all ages tested throughout postnatal
development. Binding was lowest during the age range PNDO-4 (Fig.31 A; mean age
1.2d; 46.02 ± 7.44 fmol/mg protein; n = 8) and was less than half the amount of
specific binding detected in adult tissue (PND90; 106.5 ± 6.01fmol/mg protein; n =
15). Binding remained low until PND9-12 after which it increased to levels higher
than at PND90. Maximum binding was reached at PND25-28 (mean age 26.0d; 215.1
± 29.6fmol/mg protein; n = 3). Binding at PND25-28 was approximately 200% of the
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FIGURE 30: Rat brain and tissue weights during postnatal development
The increase in rat body weight (A) is slower than that of brain tissue weight (B) during
the first four weeks of life. Tissue weight plateaus by PND25-28 while body weight is
still increasing. Brain tissue weight is defined here as the tissue wet weight of pooled
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FIGURE 31: Postnatal binding of feldizocilpine to whole membranes
Membranes (previously frozen) were incubated at 25°C for 45 min with [ H]dizocilpine
(InM) in the absence or presence of dizocilpine (30|iM) to measure total and non¬
specific binding. Specific binding was calculated and expressed per mg protein (A)
and per mg wet weight tissue (B). Values were grouped and meaned as explained in
the text. Statistical analysis using one-way analysis of variance followed by a t-test
revealed a significant difference in binding between different ages (p < 0.05), see text
for details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
at different ages; F(7) = 14.385, p < 0.01. Further analysis using a t-test showed that
3until PND9-12 [ H]dizocilpine binding was significantly lower than at PND90 (p <
0.05). At PND17-20 and PND25-28 binding was significantly higher than at PND90
(p < 0.05). At all other ages binding was not significantly different from at PND90.
When the data were expressed per mg tissue a different profile was seen.
Binding increased gradually with increasing age (Fig.31B) unlike the sudden increase
seen after PND9-12 when expressed per mg protein. Lowest specific binding was
observed at PNDO-4 (mean age 1.2d; 1.37 ± 0.19 fmol/mg tissue; n = 8). This
accounts for a much smaller proportion (18%) of adult binding (PND90; 7.38 ± 0.45
fmol/mg tissue; n = 15) compared to when the data were expressed per mg of protein.
Binding increased gradually reaching a maximum level at PND25-28 (mean age 26.0d;
10.74 ± 1.2fmol/mg tissue; n = 3). This level of binding was almost 150% of the
PND90 value. A significant difference between binding at different postnatal ages was
revealed with analysis of variance, F(7) = 10.773, p < 0.01. Further analysis revealed
that binding between PND0 and PND12 was significantly lower than at PND90, while
at PND25-28 it was significantly higher (p < 0.05). Binding at all other ages was not
significantly different from binding at PND90.
3
3.6.2 Effect of L-glutamate on specific binding of \ Hldizocilpine
L-glutamate modulation resulted in an increase in the specific binding of
3
[ H]dizocilpine compared to control binding (Section 3.3). This effect was measured
throughout postnatal development from PND5-8 onwards (Fig.32).
The binding profile (Fig.32A) for postnatal binding was almost identical to that
observed in the absence of L-glutamate. No increase in specific binding compared to
control conditions could be measured at PNDO-4. Binding remained low until PND9-
12 thereafter increasing to levels higher than measured at PND90 (196.9 ± 11.8fmol/mg
protein; n = 13). Maximal binding was seen at PND25-28 (mean age 26.0d; 326 ±
39.2fmol/mg protein; n = 3). Analysis of variance revealed a significant difference
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FIGURE 32: The effect of L-glutamate on the postnatal binding of F-FT|dizncilpine, to
whole membranes
Membranes(previously frozen) were incubated at 25°C for 45 min with [ H]dizocilpine
(InM) and L-glutamate (10fiM). Dizocilpine (30|iM) was used to measure non¬
specific binding. Specific binding was calculated and expressed per mg protein (A)
and per mg wet weight tissue (B). Values were grouped and meaned as explained in
the text. Statistical analysis using one-way analysis of variance followed by a t-test
revealed a significant difference in binding between different ages (p < 0.05), see text
for details.
*, P<0.05 when compared to PND90 value. Number of observations are indicated
above each column.
i
between PNDO-12 was significantly lower and binding at PND25-28 was significantly
higher than that at PND90 (p < 0.05). Further analysis revealed that levels of binding
not significantly different from PND90 occurred between PND13-24.
Data expressed per mg tissue (Fig.32B) again show a gradual increase in binding
postnatally. Lowest binding was seen at PNDO-4 (mean age Id; 2.6 ± 0.19 fmol/mg
tissue; n = 6) rising to peak binding levels at PND25-28 (mean age 26d; 16.09 ± 0.56
fmol/mg tissue; n = 3), representing around 20% and 120% of PND90 levels (13.39 ±
0.6 fmol/mg tissue; n = 13) respectively. A significant increase in binding was
detected at PNDO-4 compared to control conditions (p < 0.05). Significant differences
between binding at different ages were revealed by analysis of variance, F(7) = 33.409,
p < 0.01. Further analysis revealed that binding between PND0 and PND 16 was
significantly less than at PND90 (p < 0.05).
3.6.3 Extent of L-glutamate modulation
3
The extent to which [ H]dizocilpine specific binding was enhanced by L-
glutamate (lOpM) during postnatal development is illustrated in Fig.33. At PNDO-4,
when expressed per mg protein (Fig.33A) L-glutamate appeared to reduce binding
compared to control. From PND5 binding is increased at all ages compared to control
conditions, to a similar extent. When expressed per mg tissue (Fig.33B) binding is
enhanced at all ages to a similar extent. Analysis of variance was applied to both sets
of data. WTien expressed per mg protein (Fig.33A), F(7) = 2.478, p < 0.05 a significant
difference was found between ages. Further analysis revealed that the modulation at
PNDO-4 was significantly less than the modulation at all other ages (p < 0.05). The
amount of binding was not significantly different from that seen under control
conditions. No other differences were found. When expressed per mg tissue analysis
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FIGURE 33: Extent of L-glutamate modulation of FHldizocilpine binding to whole
membranes
Each determination of binding in Fig.32 was expressed as a percentage of binding under
control conditions both per mg protein (A) and per mg tissue (B), to evaluate whether
the extent of modulation by L-glutamate altered during postnatal development.
Statistical analysis was performed using one-way analysis of variance followed by a t-
test for each set of data. A significant effect was seen in (A), (p < 0.05), see text for
full details.
*, P<0.05 when compared to all other values. Number of observations are indicated
above each column.
33.6.4 The effect of glycine on specific binding of \ Hldizocilpine
3The ontogenic binding profile for [ H]dizocilpine binding during postnatal
development in the presence of glycine (IOjiM), (Fig.34A), is almost identical to that
seen in the presence of L-glutamate (Fig.32A). Binding was lowest at PNDO-4 (mean
age 1.7d; 51.95 ± 6.8 fmol/mg protein; n = 3) which unlike L-glutamate shows an
increase compared to control conditions. Binding remained low until PND9-12 (mean
age 9.3d; 84.2 ± 14.5 fmol/mg protein; n = 3) after which it increased. A peak level of
binding was reached at PND25-28 (mean age 26.0d; 310.5 ±4.1 fmol/mg protein; n =
3) declining thereafter to PND90 levels (185.8 ± 10.2 fmol.mg protein; n = 13).
Analysis of variance revealed a significant difference between ages F(7) = 15.597, p <
0.01. Further analysis showed identical differences to those revealed in the presence of
L-glutamate with binding between PNDO and PND12 being significantly lower than
PND90 levels and binding at PND25-28 being significantly higher (p < 0.05).
When expressed per mg tissue (Fig.34B) the profile is also almost identical to
that seen in the presence of L-glutamate (Fig.32B). At PNDO-4 (mean age 1.3d; 2.9 ±
0.26fmol/mg tissue; n = 5) binding is lowest, being just over 20% of the adult value
(13.27 ± 0.42 fmol/mg tissue; n = 13). Binding increases gradually with increasing
age until a maximum level is reached, at PND25-28 (mean age 26.0d; 14.62 ± 0.45
fmol/mg tissue; n = 3). Analysis of variance revealed a significant difference between
binding at different ages, F(7) = 31.271, p < 0.01. Binding between PND0-PND16 was
significantly lower than that seen at PND90 (p < 0.05). Binding at all other ages was
not significantly different to binding at PND90.
3.6.5 Extent of glycine modulation
3
The extent to which [ Hjdizocilpine binding was enhanced by glycine (lOpM)
during postnatal development is illustrated in Fig.35. Glycine modulation was seen at
all ages. The extent of modulation did not vary at different postnatal ages regardless of
the method of data expression. Analysis of variance was applied to both sets of data.
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FIGURE 34: The effect of glycine on the postnatal binding of f%11dizocilpine to whole
membranes
Membranes(previously frozen) were incubated at 25°C for 45 min with [ HJdizocilpine
(InM) and glycine (10JJ.M). Dizocilpine (30ji.M) was used to measure non-specific
binding. Specific binding was calculated and expressed per mg protein (A) and per mg
wet weight tissue (B). Values were grouped and meaned as explained in the text.
Statistical analysis using one-way analysis of variance followed by a t-test revealed a
significant difference in binding between ages (p < 0.05), see text for details.
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FIGURE 35: Extent of glycine modulation of F^HIdizocilpine binding to whole
membranes
Each determination of binding in Fig.34 was expressed as a percentage of binding under
control conditions both per mg protein (A) and per mg tissue (B),to evaluate whether
the extent of modulation by glycine altered during postnatal development. Statistical
analysis was performed using one-way analysis of variance followed by a t-test for each
set of data. No significant differences were seen between ages.
Number of observations are indicated above each column.
respectively. These very low F values indicated that no significant differences exist
between ages and that the extent of modulation by glycine did not alter significantly
with increasing age.
33.6.6 The effect of L-glutamate and glycine on \ Hldizocilpine binding
3As well as enhancing the binding of [ Hjdizocilpine when administered
individually, these two amino acids increase binding when present in combination.
The basic profiles gained for the individual amino acids (Figs.32 and 34) have
paralleled the control profiles (Fig.31). Fig.36A shows that the developmental profile
for [ H]dizocilpine binding in the presence of both L-glutamate and glycine is also
similar to these profiles. Binding at PNDO-4 (Fig.36A; mean age 0.8d; 59.2 ± 11.4
fmol/mg protein; n = 6) was approximately one quarter of the final adult value
(PND90; 224.9 ± 22.04 fmol/mg protein; n = 13). The greatest amount of binding was
seen at PND25-28 (mean age 26.0d; 339.9 ± 47.7 fmol/mg protein; n = 3), when
binding peaked at around 150% of the PND90 level. Analysis of variance revealed
significant differences between binding at different ages in the presence of both amino
acids which were equivalent to those seen with each individual amino acid, F(7) =
10.333, p < 0.01. Binding between PND0 and PND12 was significantly lower and
binding at PND25-28 significantly higher than binding seen at PND90 (p < 0.05).
Expressing data per mg tissue (Fig.36B) resulted in a profile whereby binding
increased to PND90 levels. Binding at PNDO-4 (mean age l.ld; 1.77 ± 0.16 fmol/mg
tissue; n = 7) represents only 11% of PND90 binding (15.93 ± 0.7 fmol/mg tissue; n =
13). An F value of F(7) = 6.478, p < 0.01 was found when analysis of variance was
applied to the data. Binding between PND0 and PND20 was significantly less than that
at PND90. Adult levels of binding were reached at the age of PND21-24 (mean age
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FIGURE 36: The effect of T.-glntamate and glycine on the postnatal binding of
F^Hldizocilpine to whole membranes
Membranes(previously frozen) were incubated at 25°C for 45 min with [ HJdizocilpine
(InM) and L-glutamate and glycine (both 10|iM). Non-specific binding was measured
with dizocilpine (30}iM). Specific binding was calculated and expressed per mg
protein (A) and per mg wet weight tissue (B). Values were grouped and meaned as
explained in the text. Statistical analysis using one-way analysis of variance followed
by a t-test revealed a significant difference in binding between different ages (p <
0.05),see text for details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
3.6.7 Extent of modulation bv L-glutamate and glycine
The extent of modulation by L-glutamate and glycine is shown in Fig.37. When
expressed per mg protein (Fig.37A), as with glycine, the extent of modulation does not
vary postnatally. However, this is different to L-glutamate (Fig.33A) when at PNDO-4
no modulation was observed. Analysis of variance revealed no significant differences
between ages, F(7) = 1.151 when expressed per mg protein. When expressed per mg
tissue a significant effect is found F(7) = 2.328; p < 0.05. Further analysis revealed
that modulation at PND9-12 and PND21-24 was equivalent to that seen at PND90
while at all other ages the degree of modulation was significantly lower.
3.6.8 Comparison of specific binding between control and modulatory conditions
Binding at each age was compared with binding in each other experimental
condition using two way analysis of variance to find out whether binding was
significantly increased compared to control conditions by L-glutamate and/or glycine.
A significant difference was found between conditions, F(3) = 17.096, p < 0.01 and
F(3) = 33.575, p < 0.01 for data expressed per mg protein and per mg tissue
respectively. Binding in the presence of L-glutamate and/or glycine was significantly
greater than under control conditions (p < 0.05). Binding in the presence of glycine
was significantly less than seen with L-glutamate and glycine (p < 0.05). A similar
analysis was performed for all measurements of percentage modulation between
treatments. No significant effect was found, F(2) = 2.096 and F(2) = 0.577 for data
expressed per mg protein and mg tissue respectively. L-Glutamate, glycine and the
3
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FIGURE 37: Extent of modulation of F^Hldizocilpine binding to whole membranes by
L-glntamate and glycine
Each determination of binding in Fig.36 was expressed as a percentage of binding under
control conditions both per mg protein (A) and per mg tissue (B), to evaluate whether
the extent of modulation by glycine altered during postnatal development. Statistical
analysis using one-way analysis of variance followed by a t-test revealed a significant
difference in binding between different ages in (B), (p < 0.05), see text for details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
3.6.9 Determination of the differences in specific binding during postnatal
development
3It is clear therefore that [ H]dizocilpine binding to a whole membrane prepared
from rat brain tissue varies in amount throughout postnatal development. This binding
can be modulated by the amino acids L-glutamate and glycine. It is therefore important
3
to try and find the underlying reasons for the changes in [H]dizocilpine binding. To
this end and Bmax values under control and modulatory conditions have been
measured. EC^q values were also measured for L-glutamate and glycine modulation
of binding.
33.6.10 Determination of Kj values for r Hldizocilpine binding during postnatal
development
Increasing concentrations of unlabelled dizocilpine were used to inhibit
3
[ H]dizocilpine in an attempt to measure the affinity of this compound for its binding
3
site. Throughout postnatal development dizocilpine inhibited [ H]dizocilpine binding
to whole membranes in a dose-dependent manner in the absence and presence of amino
acid modulators (Fig.38), as previously demonstrated in mature tissue. values are
displayed in Table 9A for binding throughout postnatal development under control
3
conditions. Reliable and reproducible inhibition of [ H]dizocilpine binding was not
easily measured at PNDO-4 because of the low specific to total binding ratio.
Therefore it was not always possible to analyse data to obtain and Bmax values at
this age. values do not alter between ages during development as indicated by
analysis of variance , F(6) = 0.785. Analysis of variance revealed that n^ does not
change significantly between ages, F(6) = 0.663. All values were very close to unity.
3
3.6.11 The effect of L-glutamate on Kj values for \ Hjdizocilpine binding
L-glutamate (lOpM) increased the affinity of the receptor for dizocilpine from
PND5-8 compared to control conditions (Table 9B). As under control conditions
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FIGURE 38: Inhibition of pHldizocilpine binding to whole membranes at two
iystnatal ages
[ jH]dizocilpine binding was measured as previously described(Fig.31), in the presence
of increasing concentrations of dizocilpine(O.Ol-lOOnM) in the absence or presence of
L-glutamate and glycine(both 10|iM). Binding was expressed as a percentage of
binding under control conditions.
A. Binding at PND8, Kd values of 7.9nM and 5.0nM were calculated in the absence and
presence of L-glutamate and glycine respectively.
B. Binding at PND14, Ka values of 3.4nM and 2.6nM were calculated in the absence
and presence of L-glutamate and glycine respectively.
TABLE 9 Kd VALUES FOR I3H1DIZQCILPINE BINDING TO WHOLE
MEMBRANES IN THE ABSENCE OR PRESENCE OF L-
GLUTAMATE
Membranes were incubated with [3H]dizocilpine (InM) at 25°C for 45 min in the
presence of increasing concentrations of dizocilpine (0.01 - lOOnM), in the absence (A)
or presence (B) of L-glutamate (lOj^M). Non-specific binding was measured with
dizocilpine (30|iM). Data were fitted to the logistic expression Y = MX /(X + ICso),
Kd values were calculated. No significant differences between ages were revealed by
one-way analysis of variance under control conditions.
A: Control
AGE RANGE Kd n nH MEAN AGE
(days) (nM) (days)
0-4 NM
5-8 4.7 ± 0.77 8 1.02 ±0.08 6.3
9-12 3.5 ±0.56 3 1.08 ±0.13 9.5
13-16 4.6 ±0.95 6 0.99 ± 0.08 14.3
17-20 3.9 ±1.56 3 0.92 ±0.1 17.7
21-24 6.9 ±1.95 3 1.37 ±0.17 22.3
25-28 4.6 ±0.54 3 1.26 ±0.32 26.0
90 4.9 ± 0.42 15 1.11 ±0.56 90.0
B: +L-Glutamate (10|iM)
AGE RANGE Kd n nH MEAN AGE
(days) (nM) (days)
0-4 7.9(7.9; 7.9)* 2 NM 1.0
5-8 3.6 ±0.89 6 1.07 ±0.08 6.4
9-12 3.0 ±0.38 4 1.24 ±0.10 9.5
13-16 2.8 ±0.23 6 1.10 ±0.03 14.3
17-20 2.9 ± 0.43 3 1.01 ±0.04 17.7
21-24 2.8 ± 0.27 3 1.07 ±0.08 22.3
25-28 2.6 ±0.14 3 1.07 ±0.07 26.0
90 3.5 ±0.39 13 1.13 ±0.08 90.0
P < 0.05 when compared to PND90
Values represent mean ± s.e.m.
NM: not measured
PND5-PND90. Analysis of variance however revealed a significant difference
between ages, F(7) = 6.96; p > 0.05. The at PNDO-4 (7.9nM; n = 2) was
significantly higher than at PND90 (3.5 ± 0.4nM; n = 13) and all other ages. This is
however in agreement with the lack of effect of L-glutamate modulation of specific
binding at PNDO-4 (Fig.33A). However specific binding was low and this may not be
reliable. As under control conditions (Table 9A) n^j values were not significantly
different from PND90 values during postnatal development, F(6) = 2.103. All n^
values were close to unity.
33.6.12 The effect of glycine on Kj values for [ HI dizocilpine binding
Glycine (10}iM) also increased the affinity of dizocilpine for its binding site
(Table 10A), compared to control conditions throughout postnatal development.
Reliable values could not be measured at PNDO-4. Analysis of variance revealed
no significant differences between ages, F(6) = 2.01. The Hill Coefficients (n^)
throughout postnatal development for binding in the presence of glycine do not vary
significantly, F(6) = 1.371. All values are close to unity.
3
3.6.13 The effect of L-glutamate and glycine on Kj values for f Hldizocilpine binding
L-Glutamate and glycine increased the affinity of dizocilpine for its binding site
compared to control conditions (Table 10B). The values calculated throughout
postnatal development from PND5-PND28 do not vary from the PND90 value (2.7 ±
0.14nM; n = 13). Analysis of variance however revealed a significant difference
between ages, F(7) = 5.429, p < 0.01 with the at PNDO-4 (4.9nM; n = 2) being
significantly higher than at PND90 (p < 0.05). This difference corresponds to that seen
in the presence of L-glutamate alone. In the presence of both amino acids n^ was close
to unity at all ages. No significant differences were found between ages, F(7) = 1.641.
TABLE 10 Kd VALUES FOR I3H1DIZOCILPINE BINDING TO WHOLE
MEMBRANES IN THE PRESENCE OF GLYCINE OR GLYCINE
AND L-GLUTAMATE
Membranes were incubated with [^jdizocilpine (InM) at 25°C for 45 min in the
presence of increasing concentrations of dizocilpine (0.01 - lOOnM) in the presence of
(A), glycine (IOjjM) or (B), L-glutamate and glycine (both 10|iM). Non-specific
binding was measured with dizocilpine (30pM). Data were fitted to the logistic
equation Y = MX / (X + ICso) from which Kd values were calculated. No significant
differences were revealed with analysis of variance for binding in the presence of
glycine.
A: + Glycine (lOjiM)
AGE RANGE Kd n nH MEAN AGE
(days) (nM) (days)
0-4 NM
5-8 3.9 ±0.65 6 1.07 ±0.11 6.0
9-12 4.1 ±0.68 4 1.22 ±0.15 9.5
13-16 2.9 ± 0.26 6 1.05 ±0.07 14.3
17-20 4.3 ±1.2 4 0.94 ±0.08 17.7
21-24 3.3 ±0.33 3 0.96 ±0.12 22.3
25-28 3.2 ±0.3 3 1.00 ±0.11 26.0
90 3.2 ±0.12 13 1.14 ±0.03 90.0
B: + L-Glutamate and Glycine (10|iM)
AGE RANGE Kd n nH MEAN AGE
(days) (nM) (days)
0-4 4.9(5.5; 4.3)* 2 1.15(1.3; 1.0) 1.7
5-8 1.2 ±0.54 4 1.01 ±0.07 6.3
9-12 3.4 ±0.43 4 1.34 ±0.11 9.5
13-16 2.4 ±0.11 6 1.09 ±0.04 14.3
17-20 2.5 ± 0.26 4 1.07 ±0.03 18.0
21-24 2.6 ±0.04 3 1.07 ±0.08 22.3
25-28 2.8 ±0.11 3 1.09 ±0.03 26.0
90 2.7 ±0.14 13 1.08 ±0.02 90.0
P < 0.05 when compared to PND90
Values represent mean ± s.e.m.
NM: not measured
3.6.14 Comparison of Kj and nn values between control and modulatory conditions
All values obtained under each experimental condition were compared with
each other at the same age ranges using two-way analysis of variance. This revealed
that the values obtained in the presence of one or both amino acids were
significantly smaller than those obtained under control conditions, F(3) = 11.497, p <
0.01, indicating an increase in affinity. A similar analysis was carried out for
respective n^ values. No significant differences between conditions were found, F(3)
= 0.485.
3.6.15 Alternative evaluations of the variance in Kj
Plots of all values and specific binding/Bmax (SB/Bmax) were constructed
for each set of data. These are shown in Figs.39 and 40. Straight lines were fitted to
all plots. Each had a slope close to zero indicating a lack of variance postnatally. This
is in agreement with the findings using analysis of variance. Due to the low number of
measurements at PNDO-4, the significant effects seen with analysis of variance could
not be detected. Data between PNDO and PND28 only are shown when PND90 data
were included, the slopes of all lines were still close to zero.
3.6.16 B values under control conditions
IIldA
These values are displayed in Fig.41. A similar postnatal profile to that
observed for specific binding under control conditions (Fig.31A) was seen. Analysis
of variance revealed a significant difference in receptor density between ages, F(6) =
5.847; p < 0.01. Further analysis revealed that the Bmax at PND25-28 (mean age
26.0d; 1.096 ± 0.16pmol/mg protein; n = 3) was significantly higher (p < 0.05) than at
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FIGURE 39: Alternative evaluation of the postnatal variance in the Kd for
FHldizocilpine binding to wh^le membranes. 1
Individual Kd values for [ H]dizocilpine binding (PNDO-28) under control(A)
conditions and in the presence of L-glutamate(10|iM; B), glycine(10|iM; C) and both
amino acids(D) have been plotted against age and fitted, using least squares, with a
straight line using the equation: y=mx+c. The slope of the line may reveal an alteration
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FIGURE 40: Alternative evaluation of the variance in postnatal Kd variance for
rHldizocilpine binding to whole membranes. 2
Plots of specific binding/Bmax (both calculated per mg protein) were constructed for
individual data points at each postnatal age. Straight lines were fitted using the method
of least squares and the equation' y=mx+c. Under each condition the lines had
gradients very close to zero. This may be an indication that the Kd is not altering
postnatally.
FIGURE 41: Bmax values for postnatal f%ldizocilpine binding to whole membranes
Bmax values were calculated as explained in the text from specific binding(SB), ligand
concentration!!.] and Kd. Values were fitted to the equation: Bmax = SB (Kd +
[L])/[L]. Bmax values were estimated under control conditions (CONTROL) in the
presence of L-glutamate (-tGLU), glycine (+GLY) and both amino acids (+GLU/GLY).
Statistical analysis was performed using one-way analysis of variance followed by a t-
test for each set of data. A significant effect was seen when p < 0.05, see text for full
details.





3.6.17 The effect of L-glutamate (TOpMl on B^
Bmax values in the presence of L-glutamate (10|iM) are presented in Fig.41,
revealing a similar developmental profile to specific binding (Fig.32A). Lowest
receptor density was measured at PND9-12 (mean age 9.5d; 0.375pmol/mg protein; n
= 4) rising thereafter to a peak level at PND25-28 (mean age 26.0d; 1.14 ±
0.18pmol/mg protein; n = 3) before declining to the PND90 level (0.918 ±
0.1 lpmol/mg protein; n = 15). Analysis of variance revealed a significant difference
between ages, F(7) = 2.248, p < 0.05. The B values at PNDO-4 and PND9-12 weremax
significandy lower than at PND90.
3.6.18 The effect of glycine (TOp-NT) on B values
UiOA
®max va^ues in t^e presence of glycine (10pM) are shown in Figure 41. The
lowest Bmax was at PND5-8 (mean age 6.0d; 0.391 ± 0.13pmol/mg protein; n = 6).
The B thereafter increases with increasing age, as for specific binding (Fig.34A) toIIlaA.
a maximum level at PND25-28 (mean age 26.0d; 1.25 ± 0.15pmol/mg protein; n = 3)
before reaching the PND90 level (0.774 ± 0.05pmol/mg protein; n = 13). Analysis of
variance revealed a significant difference between ages, F(6) = 5.899; p > 0.01, with
receptor density at PND5-8 and PND25-28 being significantiy different lower and
higher respectively, from that at PND90 (p > 0.05).
3.6.19 B values in the presence of L-glutamate and glycine (both 10pM)
max
B
o values in the presence of both amino acids (Fig.41) have a similarmax
developmental profile to that seen for specific binding (Fig.36A). Analysis of variance
revealed a significant difference between ages, F(7) = 2.916; p < 0.05. No values were
significantiy different from the B at PND90. However, receptor density at PND0max
to PND16 was significantiy less than that measured at PND25-28 (p > 0.05).
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3.6.20 Comparison of Blliax values between control and modulatory conditions
All Bmax values obtained under each experimental condition were compared
with each other at the same age ranges using two-way analysis of variance. This
revealed that the Bmax values did not alter significantly between control and modulated
conditions, F(3) = 0.799.
3
3.6.21 EC-q values for L-glutamate and glycine modulation of j Hldizocilpine binding
EC^q values for both L-glutamate and glycine were measured throughout
postnatal development (Tables 11A and B). L-Glutamate modulated binding in a dose-
dependent manner at all ages tested from PND5 (Fig.42A). As L-glutamate (lOpM)
induced increase in specific binding at PNDO-4 could not be measured (Fig.33A) it was
not surprising that a reproducible dose-dependent modulation in membranes prepared
from this age range could not be obtained. Analysis of variance revealed a very low F
value (F(6) = 1.022) for the EC^q value of L-glutamate modulation indicating no
significant differences with age. These data indicate that the ability of L-glutamate to
modulate [ H]dizocilpine binding does not alter during postnatal development from
PND5.
As for L-glutamate, glycine induced a dose-dependent modulation of
3
[ H]dizocilpine binding during postnatal development (Fig.42B) with maximum
binding seen at IOjjM both in immature and adult (PND90) membranes. EC^q values
for glycine modulation during postnatal development do not vary significantly from
each other as shown using analysis of variance, F(6) = 0.407.
3.6.22 Alternative evaluation of the variance in ECLq values
Plots of all EC^q values were made for L-glutamate and glycine with respect to
age (Fig.43A and B). The lines fitted to the data have gradients very close to zero.
This would indicate that the ability of L-glutamate and glycine to modulate
3
[ H]dizocilpine binding is unaltered during postnatal development. Data is shown for
PNDO-28 only. Inclusion of PND90 data did not influence the gradient of the line.
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TABLE 11 Egso VALUES EQR L-GLUTAMATE AND GLYCINE
MODULATION OF F^IDIZOCILPINE BINDING TO WHOLE
MEMBRANES
Membranes were incubated with [^dizocilpine (InM) at 25°C for 45 min in the
presence of increasing concentrations of L-glutamate (A), or glycine (B), (0.01 -
100}iM). Non-specific binding was measured with dizocilpine (30pM). Data were
fitted to the logistic equation Y = MX /(X + ECso). Analysis of variance revealed no
significant differences between ages.
A. L-Glutamate
AGE RANGE ECso n MEAN AGE
(days) (BM) (days)
0-4 NM
5-8 0.18 ±0.05 4 6.8
9-12 0.27 ±0.17 4 9.5
13-16 0.13 ±0.02 6 14.3
17-20 0.30 ±0.09 4 18.0
21-24 0.15 ±0.02 3 22.3
25-28 0.12(0.12; 0.12) 2 25.0
90 0.24 ±0.03 13 90
B. Glycine
AGE RANGE ECso n MEAN AGE
(days) OtM) (days)
0-4 NM - .
5-8 0.21 ±0.07 4 7.3
9-12 0.13 1 9.0
13-16 0.10 ±0.05 6 14.3
17-20 0.32 ±0.1 3 18.3
21-24 0.28 ± 0.23 3 22.3
25-28 0.33 ± 0.21 3 26.0
90 0.23 ±0.04 13 90
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FIGURE 42: Modulation of hHldizocilpine binding to whole membranes at two
postnatal ages
Binding of [ H]dizocilpine was measured as previously described in Fig.31, but in the
presence of incresasing concentrations of L-glutamate(A) or glycine(B: O.OI-IOOjjM).
Binding was expressed as a percentage of binding under control conditions.
A.ECso values of 0.16(iM and 0.13|iM were calculated for L-glutamate modulation at
PND7 andPND 14 respectively.





















































~i 1 1 1 1 1
5 1 0 1 5 20 25 30
POSTNATAL AGE (days)
FIGURE 43: Alternative evaluation of the ECso values for L-glntamate and glycine. 1
Individual ECso values for L-glutamate(A) and glycine(B), have been plotted against
postnatal age and fitted using the method of least squares with a straight line, using the
equation; y=mx+c, to estimate the ivariance. Both lines have gradients close to zero
indicating a lack of postnatal change.
3.7 r3HIDIZOCILPINE BINDING TO SYNAPTOSOMAL MEMBRANES
3.7.1 Control conditions
3
Fig.44A illustrates specific binding measured with [ H]dizocilpine (InM) in
synaptosomal membranes prepared freshly, from pooled cortices and hippocampi, in
3the absence of added L-glutamate and glycine. Binding of [ H]dizocilpine, although
very low, was detected at PNDO-4 and at all ages tested throughout postnatal
development. Specific binding gradually increased from PNDO-4 (Fig.44A; mean age
0.4d; 9.35 ±1.6 fmol/mg protein; n = 5) with increasing age until PND13-16 when a
peak level of binding was reached. Analysis of variance was applied to this data,
revealing a significant difference between ages, F(6) = 6.794; p < 0.01. Only binding
at PNDO-4 was significantly less than at PND90 (P < 0.05). At PND13-16 binding was
significantly greater than at PND90 (P < 0.05).
Fig.44B illustrates specific binding but expressed per mg wet weight tissue.
Binding was low at PNDO-4 (mean age 0.9d; 0.095 ± 0.02 fmol/mg tissue; n = 0)
increasing to peak levels at PND13-16 (mean age 14.5d; 2.77 ± 0.22 fmol/mg tissue; n
= 4). This was around 195% of the adult amount (PND90; 1.75 ± 0.26 fmol/mg tissue;
n = 13) and was significantly higher than binding at PND9-12. After this peak level
binding decreased to PND90 levels. Analysis of variance revealed a significant
difference between ages F(7) = 7.536; p < 0.01. Binding was significantly lower than
at PND90 between PND0 and PND8 (P < 0.05). Peak binding at PND13-16 was not
significantly greater than at PND90.
3
3.7.2 The effect of L-glutamate on \ Hldizocilpine binding
3
Figure 45A illustrates the specific binding of [ H]dizocilpine when maximally
modulated by L-glutamate during postnatal development. The effect of L-glutamate
was not examined at PNDO-4 due to very low specific binding, making measurements
unreliable. When expressed per mg protein (Figure 45A) binding increased from the
lowest level at PND5-8 (mean age 6.4d; 149.5 ± 18.6 fmol/mg protein; n = 4), when it
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FIGURE 44: Postnatal binding of F^HIdizocilpine to synaptosomal membranes
Membranes (fresh) were incubated at 25°C for 45 min with [ H]dizocilpine (InM) in
the absence or presence of dizocilpine (30pM) to measure total and non-specific
binding. Specific binding was calculated and expressed per mg protein (A) and per mg
wet weight tissue (B). Values wjere grouped and meaned as explained in the text.
Statistical analysis using one-way analysis of variance followed by a t-test revealed a
significant difference in binding between different ages (p < 0.05), see text for details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
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FIGURE 45; The effect of L-glutamate on the postnatal binding of F^Hldizocilpine to
synaptosomal me.mhr^neq
Membranes (fresh) were incubated at 25°C for 45 min with [3H]dizocilpine (InM) and
L-glutamate (lOjiM). Dizocilpine (30|iM) was used to measure non-specific binding.
Specific binding was calculated and expressed per mg protein (A) and per mg wet
weight tissue (B). Values were'grouped and meaned as explained in the text.
Statistical analysis using one-way analysis of variance followed by a t-test revealed a
significant difference in binding between different ages (p < 0.05), see text for details.
Binding was not measured at PNDO-4.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
continues to increase until a peak is reached at PND21-24 (mean age 23d; 390.2
fmol/mg protein; n = 1) before adult levels are reached. This peak represents 130% of
adult binding. Analysis of variance revealed no significant differences between ages,
F(5) = 1.798. It must therefore be assumed that adult levels of binding are present from
PND5-8 (mean age 6.4d).
When this data is expressed per mg tissue (Fig.45B) a different developmental
3
pattern is seen. Binding of [ H]dizocilpine increased gradually and with increasing
age during development until PND90 levels are reached. At PND5-8 (mean age 6.4d;
1.83 ± 0.27 fmol/mg tissue; n = 4) binding is almost 20% of adult levels (PND90; 9.4 ±
0.65 fmol/mg tissue; n = 3). Analysis of variance revealed a significant difference
between ages, F(6) = 5.39; p < 0.01. Binding at PND5-8 and 9-12 is significantly
lower than PND90 binding (p < 0.05). At PND13-16 binding reaches a level not
significantly different from that at PND90.
3.7.3 Extent of L-glutamate modulation
3
The maximum extent of [ H]dizocilpine modulation compared to control
conditions is illustrated in Fig.46. Application of analysis of variance to these data
reveal no significant differences between ages. F(5) = 1.439 when expressed per mg
protein and, F(6) = 1.831 when expressed per mg wet weight. L-Glutamate modulation
is therefore not altering postnatally from PND5 in this membrane preparation.
3
3.7.4 The effect of glycine on \ HT|dizocilpine binding
Binding in the presence of glycine is illustrated in Fig.47. Binding was only
measured from PND5-8 as it was difficult to obtain reliable results at younger ages due
to the low specific binding. PND5-8 (Fig.47A; mean age 6.4d; 95.51 ± 15.9 fmol/mg
protein; n = 5) binding is approximately 48% of that seen in adult membranes (PND90;
199.1 ± 15.9 fmol/mg protein; n = 3). This is almost identical to the proportion of
binding measured in the presence of L-glutamate at this age range (Fig.45A). Binding
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FIGURE 46: Extent of L-plutamate modulation of pHldizocilpine binding to
synaptosomal membranes
Each determination of binding in Fig.45 was expressed as a percentage of binding under
control conditions both per mg protean (A) and per mg tissue (B), to evaluate whether
the extent of modulation by L-glutamate altered during postnatal development.
Statistical analysis was performed using one-way analysis of variance followed by a t-
test for each set of data. No significant effects were seen between ages. L-Glutamate
is therefore modulating binding to a similar extent throughout postnatal development.
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FIGURE 47: The effect of glycine on the postnatal binding of pHldizocilpine to
synaptosomal membranes
Membranes (fresh) were incubated at 25°C for 45 min with [ H]dizocilpine (InM) and
glycine (10|iM). Dizocilpine (30}iM) was used to measure non-specific binding.
Specific binding was calculated and expressed per mg protein (A) and per mg wet
weight tissue (B). Values were grouped and meaned as explained in the text.
Statistical analysis using one-way analysis of variance followed by a t-test revealed a
significant difference in binding between different ages (p < 0.05), see text for details.
Binding was not measured at PNDO-4.
*, P<0.05 when compared to PND90 value. Number of observations are indicated
above each column.
fmol/mg protein; n = 1) before falling to the adult value. Analysis of variance revealed
no significant differences between ages, F(6) = 2.225, a similar profile to that seen for
L-glutamate modulation. Therefore binding in the presence of glycine (lOpM) as in
the presence of L-glutamate (10pM) reached levels not significantly different from
those at PND90 by PND5-8 (mean age 6.4d).
When expressed per mg tissue binding increased from PND5-8 to PND13-16
when a level similar to that at PND90 was reached (Fig.47B). At PND5-8 (mean age
6.4d; 1.20 ± 0.24 fmol/mg tissue) binding was approximately 20% of adult levels (5.63
± 0.42 fmol/mg tissue; n = 3). Analysis of variance revealed a significant difference
between ages, F(6) = 6.206; p < 0.01. Binding not significantly different from PND90
levels was reached from PND13-16 (mean age 14.5d; 5.29 ± 0.96 fmol/mg tissue; n =
3). Prior to this age, binding was significantly lower than at PND90 (P < 0.05).
3.7.5 Extent of glycine modulation
The extent of glycine modulation compared to control conditions is shown in
Fig.48. Analysis of variance revealed no significant differences between ages, F(6) =
0.791 and F(5) = 1.068 when expressed per mg protein (Fig.48A) and per mg tissue
(Fig.48B) respectively. Therefore the ability of glycine to modulate binding does not
vary postnatally from PND5.
3
3.7.6 The effect of L-glutamate (lOp-Ml and glycine (TOfiMi on \ Hjdizocilpine
binding
Modulation of binding by both amino acids was seen throughout postnatal
development. Specific binding measured in the presence of both L-glutamate and
glycine is shown in Fig.49. When expressed per mg protein (Fig.49A), binding was
lowest at PNDO-4 (mean age 0.4d; 60.34 ± 17.4 fmol/mg protein; n = 3) representing
approximately 20% of adult levels (PND90; 304.4 ±31.8 fmol/mg protein; n = 13).
There was a gradual increase in binding until maximum binding was reached at
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FIGURE 48: Extent of glycine modulation of hHldizocilpine binding t" synaptosomal
membranes
Each determination of binding in Fig.47 was expressed as a percentage of binding under
control conditions both per mg protein (A) and per mg tissue (B), to evaluate whether
the extent of modulation by glycine altered during postnatal development. Statistical
analysis was performed using one-way analysis of variance followed by a t-test for each
set of data. No significant effects were seen between ages. Glycine is therefore
modulating binding to a similar extent throughout postnatal development.
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FIGURE 49: The effect of L-glntamate and glycine on the postnatal binding of
FHldizocilpine to synaptosomal membranes
Membranes (fresh) were incubated at 25°C for 45 min with [ H]dizocilpine (InM), L-
glutamate and glycine (both lOpM). Dizocilpine (30|iM) was used to measure non¬
specific binding. Specific binding was calculated and expressed per mg protein (A)
and per mg wet weight tissue (B). Values were grouped and meaned as explained in
the text. Statistical analysis using one-way analysis of variance followed by a t-test
revealed a significant difference in binding between different ages (p < 0.05),see text
for details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
to adult binding. Analysis of variance revealed a significant difference between ages,
F(6) 4.518; p < 0.01. Binding between PNDO and PND8 was significantly lower than
that at PND90 (p < 0.05). Adult levels were therefore reached from PND9-12.
When expressed per mg tissue (Fig.49B), binding is lowest at PNDO-4 (mean
age 0.9d; 0.94 ± 0.07 fmol/mg tissue; n = 10). Binding increased to a maximum level
at PND90 (9.69 ± 0.52 fmol/mg tissue; n = 13). Analysis of variance revealed a
significant difference between ages F(7) = 13.795; p < 0.01. Further analysis revealed
that binding was significantly lower than PND90 levels between PNDO and PND24 (p
< 0.05) apart from PND25-28.
3.7.7 Extent of modulation by L-glutamate and glycine
The extent of modulation by both amino acids is shown in Fig.50. Expressed
per mg protein, analysis of variance revealed a significant difference between ages, F(6)
= 3.541; p < 0.05. The extent of modulation seen at PNDO-4 was significantly higher
from that at all other ages except PND90 (p < 0.05). Binding at PND90 was
significantly greater than that between PND13 and PND28 (p < 0.05). Expressed per
mg tissue a significant difference between ages was also found; F(7) = 4.31; p < 0.01.
Binding between PND13 and PND28 was significantly lower from that at PND90 (p <
0.05) and PNDO-4 (p < 0.05).
3.7.8 Comparison of specific binding between control and modulatory conditions
Specific binding at each age was compared with binding in each other condition
using two way analysis of variance. Data expressed per mg protein revealed a
significant difference between conditions, F(3) = 36.287; p < 0.01. Further analysis
revealed that specific binding in the presence of L-glutamate and/or glycine was
significantly greater than that seen under control conditions (p < 0.01). A similar
finding was seen for data expressed per mg tissue with F(3) = 39.165; p < 0.01. L-
Glutamate and/or glycine are therefore significantly increasing binding compared to





































FIGURE 50: Extent of L-gliitamgt? «nd glycine modulation of pXr^iyr^ilpin^ hinging
to synaptosomal membranes
Each determination of binding in Fig.49 was expressed as a percentage of binding under
control conditions both per mg protein (A) and per mg tissue (B), to evaluate whether
the extent of modulation by both!L-glutamate and glycine altered during postnatal
development. Statistical analysis was performed using one-way analysis of variance
followed by a t-test for each set of data. A significant effect was seen when p < 0.05,
see text for full details.
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FIGURE 51 : Inhibition of [^Hldizocilpine binding to syaptosomal membranes at two
postnatal ages
[ Hjdizocilpine binding was measured as previously described(Fig.44), in the presence
of increasing concentrations of dizocilpine(0.01-300nM) in the absence or presence of
L-glutamate and glycine(both 10|iM). Binding was expressed as a percentage of
binding under control conditions.
A. Binding at PND8, Kd values of 15.5nM and 8.5nM were calculated in the absence
and presence of L-glutamate and glycine respectively.
B. Binding at PND11, Kd values of 32.5nM and 5.1nM were calculated in the absence
and presence of L-glutamate and glycine respectively.
TABLE 12 Kd VALUES FOR ^HIDIZQCILPINE BINDING TO
SYNAPTOSOMAL MEMBRANES IN THE ABSENCE OR
PRESENCE OF L-GLUTAMATE
Membranes were incubated with [^HJdizocilpine (InM) at 25°C for 45 min in the
presence of increasing concentrations of dizocilpine (0.01 - lOOnM), in the absence (A)
or presence (B) of L-glutamate (lOpM). Non-specific binding was measured with
dizocilpine (30|iM). For data obtained under control conditions (A), ICso values were
estimated graphically and Kd values were calculated using Equation 2 (Section 2.7).
Data in the presence of L-glutamate (B) were fitted to the logistic expression Y =
MX /(X + ICso) from which Kd values were calculated. No significant differences









5-8 20.6 ±4.2 4 5.8
9-12 10.9 ± 6.7 4 10.3
13-16 13.2 ±3.2 4 14.5
17-20 11.9 ±5.6 4 18.8
21-24 19.0 ±3.7 3 23.3
25-28 23.6 ± 10.6 4 27.8






n nH MEAN AGE
(days)
0-4 NM
5-8 3.8 ±0.54 4 1.25 ±0.02 6.0
9-12 3.1 ±0.69 3 0.91 ±0.16 10.0
13-16 4.1 ±0.62 3 0.96 ±0.11 14.3
17-20 2.9 ±0.19 3 0.96 ±0.14 19.0
21-24 4.4 1 1.11 23.0
25-28 4.3 ± 0.08 3 1.12 ±0.27 27.7
90 4.9 ±0.19 4 0.85 ± 0.07 90
Values represent mean ± s.e.m.
NM: not measured
TABLE 13 Kd VALUES FOR [3H1DIZQCILPINE BINDING TO
SYNAPTOSOMAL MEMBRANES IN THE PRESENCE OF
GLYCINE OR L-GLUTAMATE AND GLYCINE
Membranes were incubated with [^dizocilpine (InM) at 25°C for 45 min in the
presence of increasing concentrations of dizocilpine (0.01 - lOOnM) in the presence of
(A) glycine (lOpM) or (B) L-glutamate and glycine (both IOjiM). Non-specific
binding was measured with dizocilpine (30|iM). Data were fitted to the logistic
equation Y = MX / (X + ICso) Kd values were calculated. No significant differences
were revealed with analysis of variance.
A: +Glycine (lOpM)
AGE RANGE Kd n nH MEAN AGE
(days) (nM) (days)
0-4 NM
5-8 9.5 ± 2.54 4 1.11 ±0.23 6.0
9-12 2.7 ± 0.69 3 0.66 ±0.07 10.0
13-16 5.7 ± 0.98 3 0.94 ±0.09 14.3
17-20 6.7 ± 0.79 3 1.18 ±0.16 18.8
21-24 6.1 1 1.7 23.0
25-28 5.3 ±1.83 3 0.97 ±0.22 27.7
90 5.6± 1.14 4 0.91 ±0.12 90
B: +L-Glutamate and glycine (lOpM)
AGE RANGE Kd n nH MEAN AGE
(days) (nM) (days)
0-4 4.1 ±1.1 3 0.78 ±0.16 2.7
5-8 4.7 ± 1.0 6 0.98 ± 0.02 6.2
9-12 3.2 ±0.7 4 1.17 ±0.1 10.3
13-16 6.3 ± 1.1 4 1.14 ±0.09 14.5
17-20 3.9 ±0.6 4 0.92 ±0.1 18.8
21-24 5.8 (5.3; 6.3) 2 1.09 23.0
25-28 5.9 ± 1.2 3 0.94 ±0.01 27.7
90 6.8 ± 1.0 13 1.1 ±0.06 90
Values represent mean ± s.e.m.
NM: not measured
The extent of modulation was also subjected to two way analysis of variance
under each method of data expression. Expressed per mg protein significant
differences were seen between treatments F(2) = 5.429; p < 0.01. The extent of
modulation in the presence of glycine was significantly lower from that seen with either
L-glutamate or L-glutamate and glycine (p < 0.05). Expressed per mg tissue F(2) =
11.996; p < 0.01. Modulation by L-glutamate and by glycine was significantly less
than modulation by both amino acids (p < 0.01).
33.7.9 Determination of Kj values for I Hldizocilpine binding
In the absence of added L-glutamate and glycine binding was very low at PND0-
34 (see Fig.44), consequently values for [ Hjdizocilpine binding were not calculated
3
(Table 12A). At all other ages inhibition of [Hjdizocilpine was measured in the
absence and presence of L-glutamate and glycine (Fig.51). values were calculated
using Equation 2 (see Section 2.7). Application of analysis of variance to the from
each age range revealed no significant differences between ages, F(6) = 0.622.
3
3.7.10 The effect of L-glutamate on the Kj values for \ Hjdizocilpine binding
The values in the presence of L-glutamate are presented in Table 12B. As
for whole membranes, analysis of variance revealed no significant differences between
ages, F(5) = 2.036. The Hill Co-efficients (n^) at all ages are very close to unity and
do not significantly differ from each other, F(6) = 0.798.
3
3.7.11 The effect of glycine on the Kj values for T Hldizocilpine binding
3
values for [ Hjdizocilpine binding in the presence of glycine during
postnatal development are presented in Table 13A. Analysis of variance revealed no
significant differences between ages F(5) = 1.127. The Hill Co-efficients (n^) were
not significantly different between ages F(5) = 1.563.
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33.7.12 The effect of L-glutamate and glycine on the Kj T ffldteocilping binding
Inhibition of [^H]dizocilpine binding was measured in the presence of both
amino acids (Fig.51) values were measured (Table 13B). values were estimated
at PNDO-4 due to the higher levels of binding in the presence of both amino acids.
Analysis of variance revealed that did not alter significantly between ages F(7) =
0.698. In the presence of both amino acids n^ also does not vary significantly between
ages, F(7) = 0.985.
3.7.13 Comparison of Kj and n^ values between control and modulatory conditions
All ICj and n^ values obtained under each experimental condition at each age
range were compared with each other using two-way analysis of variance. This
revealed that the values obtained in the presence of L-glutamate and/or glycine were
significantly smaller than in control conditions, F(3) = 6.179, p < 0.01. A similar
analysis was carried out for n^ values. No significant differences between conditions
were found, F(2) = 0.140.
3.7.14 Alternative evaluation of the variance in Kj
Plots of all K, values and SB/B values were constructed for each set of datad max
(Figs.52 and 53). Straight lines were fitted to all plots. For plots of all values the
line of best fit had a gradient close to zero in all conditions, apart from control and in the
presence of L-glutamate. This is also apparent for the plots of SB/Bmax under control
conditions and in the presence of L-glutamate. It is possible therefore that the is
changing postnatally although analysis of variance has not detected it. Data between
PND0 and PND28 only is shown. When PND90 data were included, the slopes of the
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FIGURE 52 : Alternative evaluation of the postnatal variance in the Kd for
F^HIdizocilpine binding to synaptosomal membranes. 1
Individual Kd values for [ HJdizocilpine binding (PND0-28) under control(A)
conditions and in the presence of L-glutamate(10p.M; B), glycine(10|iM; C) and both
amino acids(D) have been plotted against age and fitted, using least squares, with a
straight line(using the equation: y=mx+c). The slope of the line may reveal an alteration
in Kd with age. In the absence of added amino acids(A) and in the presence of L-
glutamate lines with slight slopes are seen, this may indicate a postnatal change in
receptor affinity. In both other cases (B) and (C) the lines of best fit have slopes close to
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FIGURE 53: Alternative evaluation of the variance in postnatal Kd for pHldizocilpine
binding to synaptosomal membranes. 2
Plots of specific binding/Bmax (both calculated per mg protein) were constructed for
individual data points at each postnatal age. Straight lines were fitted using the method
of least squares to the equation: y=*mx+c. In the absence (A) and presence(B) of L-
glutamate lines with very slight gradients were found. This may indicate postnatal
change in Kd. Both other lines (C) and (D) have gradients close to zero indicating a lack
of postnatal change.
3-7-15 *w values under control conditions
3
Bmax values for [ HJdizocilpine binding in the absence of added L-glutamate
and glycine were calculated (Fig.54). Analysis of variance was applied to this data and
no significant differences between ages (PND5-PND90) were found, F(5) = 0.455.
This would suggest that adult levels of receptors are present from PND5-8 (mean age
6.0d; 0.89 ± 0.24 pmol/mg protein; n = 4). This is the age when corresponding
specific binding reached adult levels.
3.7.16 The effect of L-glutamate on B values
IllCtA
3
Corresponding Bwqv values for [ H]dizocilpine binding modulated by L-max
glutamate are shown in Fig.54. B values increase from 0.64 ± 0.08 pmol/mgmax
protein (n = 4) at PND5-8 (mean age 6.0d) to 1.71 ± 0.29 pmol/mg protein (n = 3) at
PND13-16 (mean age 14.3d), a value similar to that seen at PND90 (1.74± 0.25
pmol/mg protein; n = 3). Analysis of variance revealed a significant difference
between ages, F(6) = 3.393; p < 0.05. B_„ values at PND5-8 and PND9-12 weremax
significantly lower than at PND90 (p < 0.05). From PND13-16 B^^ was not
significantly different from that at PND90.
3.7.17 The effect of glycine on B^ values
3
The Bmax values for [ Hjdizocilpine binding in the presence of glycine are
shown in Fig.54. Analysis of variance revealed a significant difference between ages
F(5) = 3.010; p < 0.05. No Bmax is significantly different from that seen at PND90
(1.18 ± 0.26 pmol/mg protein). However,Bmax values between PND17 and PND24
are significantly higher than seen at PND5-8 and PND9-12 (p < 0.05).
3.7.18 The effect of L-glutamate and glycine on B valuesmax
3
Fig.54 shows the Bmax values for [ H]dizocilpine binding modulated by both
amino acids. B values are low at PNDO-4 (mean age 2.7d; 0.33 ± 0.12 pmol/mgmax
protein; n = 3) rising to a peak at PND13-16 (mean age 14.5d; 2.24 ± 0.44 pmol/mg
-81 -
FIGURE 54: Postnatal Rmax values calculated for fajdizocilpine binding in
synaptosomal membranes
B values were calculated as explained in the text from specific binding (SB), ligand
cJnc£ntration[L] and Kd. Values were fitted to the equation: Bmax = SB (Kd+ [L])/[L].
Bmax values were estimated under control conditions(CONTROL), in the presence of
L-glutamate (4GLU), glycine (+GLY) and both amino acids (-I-GLU/GLY). Statistical
analysis was performed using one-way analysis of variance followed by a t-test for each
set of data. A significant effect was seen when p < 0.05, see text for full details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
 
protein; n = 4), before reaching adult levels (PND90; 1.98 ± 0.3 mol/mg protein; n =
13). Analysis of variance revealed a significant difference between ages F(6) = 3.531;
p < 0.01. Only the Bmax at PNDO-4 is significantly different from that at PND90 (p <
0.05). The Bmax at PND13-16 is however significantly higher than those seen up to
PND12 and between PND17-20 (p < 0.05).
3.7.19 Comparison of values between control and modulatory conditions
Two-way analysis of variance was used to compare Bmax values at each age
range under all conditions with each other. This revealed that F(3) = 0.631. Therefore
3
Bmax values for [ H]dizocilpine binding to synaptosomal membranes are not
significantly altered from control conditions by the allosteric modulators L-glutamate
and glycine.
3
3.7.20 EC^-q values for L-glutamate and glycine modulation of \ Hldizocilpine binding
to washed synaptosomal membranes
Reproducible dose-dependent modulation was not observed at PNDO-4 therefore
no data is available for this age range. Maximum modulation was seen in the presence
of 10|iM L-glutamate and glycine both in adult (Fig. 17) and immature tissue (Fig.55).
EC50 values for L-glutamate modulation were calculated (Table 14A). Analysis of
variance revealed no significant differences between ages F(6) = 0.991.
Reproducible modulation was not easily measured at PNDO-4 for glycine.
EC^q values from PND5 onwards are displayed in Table 14B. Analysis of variance
revealed no significant differences between ages during postnatal development, F(6) =
2.168. This is an indication that the ability of L-glutamate and glycine to modulate
3
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FIGURE 55 : Modulation of foriHizncilpinp: hjnding to synaptosomal membranes at
two postnataj ages
Binding of [ H]dizocilpine was measured as previously described in Fig.44, but in the
presence of incresasing concentrations of L-glutamate(A) or glycine(B: 0.01-100pM).
Binding was expressed as a percentage of binding under control conditions.
A.ECso values of 0.19pM and 0.22pM were calculated for L-glutamate modulation at
PND5 andPND 14 respectively. !
B.ECso values of 0.1 lpM and 0.1OpM were calculated for glycine modulation at PND5
andPND 14 respectively.
TABLE 14 ECso VALUES FOR L-GLUTAMATE AND GLYCINE
MODULATION OF [TilDIZOCILPINE BINDING TO
SYNAPTOSOMAL MEMBRANES
Membranes were incubated with [^dizocilpine (InM) at 25°C for 45 min in the
presence of increasing concentrations of L-glutamate (A) or glycine (B) (0.01 -
lOOpM). Non-specific binding was measured with dizocilpine (30|iM). Data were
fitted to the logistic equation Y = MX /(X + ECso). Analysis of variance revealed no
significant differences between ages.
A: L-Glutamate
AGE RANGE ECso n MEAN AGE
(days) (M-M) (days)
0-4 NM
5-8 0.17 ±0.05 5 6.4
9-12 0.10 ±0.07 4 10.0
13-16 0.08 ± 0.06 4 14.5
17-20 0.08 ± 0.05 4 18.8
21-24 0.06 ± 0.01 3 23.3
25-28 0.06 ± 0.02 3 27.7
90 0.28 ±0.05 15 90
B: Glycine
AGE RANGE ECso n MEAN AGE
(days) (M-M) (days)
0-4 NM
5-8 0.09 ± 0.05 5 6.4
9-12 0.25 ± 0.09 4 10.0
13-16 0.07 ± 0.01 4 14.5
17-20 0.15 ±0.03 4 18.8
21-24 0.05 ± 0.01 3 23.3
25-28 0.14 ±0.07 3 27.7
90 0.11 ±0.01 13 90
Values represent mean ± s.e.m.
NM: not measured
3.7.21 Alternative evaluation ofEC-Q variation for L-glutamate and glycine
Plots of all EC^q values for L-glutamate and glycine were made with respect to
age and straight lines fitted as described previously (Fig.56). The line of best fit had a
positive gradient for L-glutamate data. This may indicate a postnatal change.
However the line of best fit for glycine data had a slope close to zero indicating a lack of
postnatal change. Inclusion of PND90 data did not influence either line.
3.8 I^ICPP BINDING TO SYNAPTOSOMAL MEMBRANES
THROUGHOUT POSTNATAL DEVELOPMENT
Synaptosomal membranes were prepared from pooled cerebral cortices and
3
hippocampi as previously described and as used for [ H]dizocilpine binding. This
3enables a direct comparison with [ H]dizocilpine binding data.
3.8.1 Specific binding of T^HICPP
Specific binding was measured throughout postnatal development and as for
3 3
[ H]dizocilpine binding was divided into age ranges (Fig.57). [ H]CPP binding was
low at PNDO-4 and increased gradually with age (Fig.57A). Binding at PNDO-4 (mean
age 3.6d; 9.88 ± 2.8 fmol/mg protein; n = 3) was not significantly different from that at
PND5-8 (mean age 7.3d; 7.34 ±1.8 fmol/mg protein; n = 3). It accounted for around
15% of the binding measured in adult rats (PND90; 49.5 ± 3.8 fmol/mg protein; n =
11). Binding increased from PND9-12 onwards, reaching around 50% of adult levels
by PND13-16 (mean age 13.4d; 25.94 ± 4.6 fmol/mg protein; n = 4). Maximum
f^HJCPP binding was measured at PND21-24 (mean age 21.8d; 52.9 ± 3.2 fmol/mg
protein; n = 3). This corresponds to 107% of the PND90 value. Analysis of variance
revealed a significant difference between binding at different ages (F(6) = 14.621; p <
0.01). Only binding at PND21-24 was not significantly different from that at PND90.



































FIGURE 56: Alternative evaluation of the ECso values for L-glutamate and glycine. 2
Individual ECso values for L-glutamate(A) and glycine(B), have been plotted against
postnatal age and fitted using the method of least squares with a straight line, using the
equation; y=mx+c, to estimate the variance. L-Glutamate(A) modulation reveals a line
with a positive gradient. This may indicate a postnatal change in the ability of L-
glutamate to modulate binding. The line of best fit for glycine modulation has a gradient
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FIGURE 57: Postnatal binding of [%UCPP to synaptosomal membranes
Membrane samples were incubated at 25°C for 25min with[3H]CPP (lOnM) in the
absence or presence of L-glutamate (ImM) to measure total and non-specific binding.
Specific binding was calculated at individual ages both per mg protein (A) and per mg
wet weight tissue (B). Values were grouped and meaned as explained in the text.
Statistical analysis was performed using one-way analysis of variance followed by a t-
test for each set of data. A significant effect was seen when p < 0.05, see text for full
details.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
3When [ H]CPP binding data was expressed per mg tissue a similar profile is
seen (Fig.57B). Binding was again low throughout the first postnatal week followed
by a gradual increase throughout postnatal development. At PNDO-4 and PND5-8 the
amount of binding is very low (0.193 ± 0.03 and 0.161 ± 0.05 fmol/mg tissue
respectively; n = 3) being around 5% of the adult level. Levels of binding reach
approximately 50% of the adult amount at PND17-20 (mean age 18d; 1.6 ± 0.13
fmol/mg tissue; n = 3) this is later than when expressed per mg protein. At PND21-24
(mean age 21.8d; 2.54 ± 0.07 fmol/mg tissue; n = 3) binding has reached just over 80%
of the adult level. Significant differences identical to those seen when expressed per
mg protein were found with analysis of variance, F(6) = 16.336; p < 0.05. Binding
between PND0 and PND20 is significantly lower than at PND90 (p < 0.05).
33.8.2 Binding parameters for f H1CPP binding during postnatal development
As for [ H]dizocilpine binding it is important to determine whether these
observed changes in the amount of specific binding throughout postnatal development
3
are due to changes in receptor affinity or to receptor density. Thus [ H]CPP binding
was inhibited with increasing concentrations of CPP over the range 0.03(iM to 100p.M.
K, and Bm values were calculated,d max
33.8.3 Kd for [ HICPP binding during postnatal development
values for [^H]CPP binding are displayed in Table 15. Between PND0 and
3
PND8 specific [ H]CPP binding was too low to give reproducible inhibition, therefore
these values could not be calculated. A value of 0.39p.M was however
calculated in one instance at PND8. This value is similar to the adult value (PND90;
0.37 ± 0.06|i.M; n = 11). The value for [^H]CPP binding does not change
throughout postnatal development. Thus, analysis of variance revealed no significant
differences between values calculated at different ages postnatally, F(4) = 0.072.
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TABLE 15 Kd VALUES FOR T%1CPP BINDING
Membranes were incubated with [%I]CPP (lOnM) at 25°C for 25 min in the presence
of increasing concentrations of CPP (0.03 - lOOjiM). Non-specific binding was
measured with L-glutamate (ImM). ICso values were estimated graphically and Kd
values calculated using Equation 2 (Section 2.7). No significant differences between
ages were revealed with analysis of variance.
AGE RANGE Kd n MEAN AGE
(days) OiM) (days)
0-4 NM
00I 0.39 1 8.0
9-12 0.31 ±0.13 3 10.7
13-16 0.48 ±0.16 4 13.4
17-20 0.33 ±0.10 3 18.0
21-24 0.36 ±0.11 3 21.8
90 0.37 ± 0.06 11 90
Values represent mean ± s.e.m.
NM: not measured
Alternative evaluations of the variance in are shown in Fig.58. Both plots
(SB/Bmax and all values) have lines of best fit with gradients close to zero. This
supports the findings of the analysis of variance.
3.8.4 values for f3HlCPP binding during postnatal development
Corresponding B values were calculated (Fig.59). The lowest B„,0„ valuemax max
was found at PND5-8 (PND8; 0.323pmol/mg protein; n = 1). The Bmax values
increased gradually from this age reaching a maximum value at PND90 (2.57 ±
0.49pmol/mg protein; n = 11). Analysis of variance revealed a significant difference
between ages, F(4) = 5.769; p < 0.05. Further analysis revealed that Bmax values
between PND9 and PND16 were significantly lower than at PND90 (p < 0.05).
3 33.8.5 Comparison ofB^ values for f H1CPP binding and r Hldizocilpine binding
3 3
[ H]CPP Bmax values were compared with those for [ H]dizocilpine binding in
the presence of L-glutamate and glycine to synaptosomal membranes. No differences
were seen between the two ligands when corresponding ages were compared (F(4) =
0.874.
3.9 THE EFFECT OF AN ACUTE HYPOXIC INSULT ON THE BINDING
OF I3H1D1Z0CILPINE TO PNDO CENTRAL TISSUE : PRELIMINARY
DATA
The perinatal brain is particularly susceptible to neuronal damage via activation
of the NMDA receptor following an hypoxic-ischaemic insult (Andine et al, 1988;
McDonald et al, 1989). Having established the existence of the NMDA receptor from
birth (PNDO) onwards, a preliminary study was undertaken on PNDO Lister Hooded rat
pups which had been subjected to an acute hypoxic insult in utero (Kendall et al, 1991).
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FIGURE 58: Alternative evaluation of the postnatal variance in the Kd for f%ICPP
binding to synaptosomal membranes
Each measurement of Kd, Bmax, and specific binding (calculated per mg protein) has
been used to estimate the postnatal variance in receptor affinity for [3H]CPP binding.
Straight lines(y=mx+c) have been fitted using the least squares method to plots of
individual determinations of specific binding/Bmax (A) and Kd(B). The gradients of




























FIGURE 59: Postnatal Bmax values for |~H1CPP binding
Bmax values were calculated as explained in Fig.54. Statistical analysis was
performed using one-way analysis of variance followed by a t-test. A significant effect
was seen when p < 0.05, see text for full details. Due to low specific binding, Kd and
hence Bmax values could not be measured at PNDO-4.
*, P < 0.05 when compared to PND90 value. Number of observations are indicated
above each column.
procedure described in Appendix 1. A high mortality rate is the biggest problem
associated with this procedure, consequently lack of viable tissue restricted these
studies.
3
The first study compared [ Hjdizocilpine binding between control and hypoxic
tissue with a comparison of the levels of binding in a cortical/hippocampal preparation
and a cerebellar preparation. Whole membranes were used (Table 16). Binding,
regardless of the method of expression was always greater in the cerebellum than the
cortex/hippocampus. [ H]Dizocilpine binding to cortical/hippocampal membranes
from hypoxic pups could be modulated to a greater extent than the control membranes.
However, lack of tissue precluded further studies to find out whether this is a significant
effect. An interesting observation is that in both control and hypoxic tissue no increase
in binding was observed in cerebellar membranes with L-glutamate and glycine. In
each case a decrease in the amount of specific binding was observed. The percentage
increase seen in membranes prepared from cortical/hippocampal tissue is very similar
to that already described for whole membranes (Fig.36).
3
The data in Table 17 are for [ H]dizocilpine binding to synaptosomal
membranes prepared from control and hypoxic tissue. It appears that there is no
change in the specific binding detected between control and hypoxic tissue, whether
expressed per mg protein or mg tissue, with these values being very similar to those in
Fig.44. Binding of [Hjdizocilpine to both control and hypoxic tissue was modulated
by both L-glutamate and glycine (10(iM) as measured by an increase in specific
binding. The major difference between hypoxic and control binding is that the
percentage increase in binding due to L-glutamate/glycine modulation is less in the
tissue from the hypoxic pups. However, further studies should be carried out to
indicate whether this effect is significant. This may be an initial indication of an
alteration in NMDA receptor function.
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TABLE16BINDINGOF^HIDIZOCI PINETOCONTROLA DHYPOXICTISSUE1.WH LEMEMBRAN S Membranesprepar dfromeith rpooledc rticalhi pocampalis uerc rebellartissuew rin ub t di h(^dizoci pineInM)t25°Cfor45minintheabse cendpresence( odulated)fL-glutamateang ycin(bothlOpM).No -specifici d ngwassuredwithdizocilpine(30| M).Spec ficbind ngwascalculateddexpressedpe entageofco trolb ding. BINDINGCO ITIONSSPECIFICBINDI G%CO TROLSPECIFICB DINGTROLfmol/mgproteinBINDINGfmol/mgtissue%BINDING HYPOXIC
1.Cortex/hippocampus control25.69-0.76 modulated56.732211.67220 2.Cerebellum control87.77-2.22 modulated46.76-471.18-47 CONTROL
1.Cortex/hippocampus control30.33-84 modulated47.50157321 7 2.Cerebellum control127.669 modulated76.01-391.77- Valuesrmeansoftwoindep ndentobservatio s.


























The pharmacology of the NMDA receptor has been extensively investigated.
This is not only for experimental reasons but also because compounds acting as
antagonists at this site have great potential as therapeutic compounds (Herrling, 1989).
A great deal of research has been directed towards finding compounds active as
antagonists at specific sites on the NMDA receptor and which cross the BBB easily
while having minimum side effects. To date, the compounds described, are dizocilpine
which binds to a site within the channel, competitive antagonists of the neurotransmitter
site, antagonists of the strychinine insensitive glycine site and compounds acting at the
polyamine site (Williams et al, 1991; Collingridge and Lester, 1989). The technique
of radioligand binding has become an important tool in the study of drug/hormone
receptor interactions. This is largely due to the increased availability of biologically
active compounds radiolabeled to a high specific activity. The present study has
investigated the NMDA receptor complex using this technique in both immature and
mature brain tissue. Radioligands with high affinities for their binding sites were used.
Generally, the higher the affinity of a radioligand the lower the associated non-specific
binding, since lower ligand concentrations can be used. By referring to the criteria of
Bylund and Yamamura (1990) the proportion of specific binding detected with
[^H]CPP and [^H]D-AP5 (i.e. < 50%) is "barely adequate" while that seen with
3
[ H]dizocilpine (> 90%) is "excellent". Thus, the greater the proportion of specific
binding, the greater the quality of the assay. This emphasises why it is important to
establish optimal experimental conditions.
The reason for using the "barely adequate" ligands ([^H]CPP and [^H]D-AP5) is
that they are very selective for their binding site on the NMDA receptor. Foster and
Fagg (1987) compared and contrasted radioligands which bind to the NMDA
3
neurotransmitter recognition site. They concluded that [ H]L-glutamate was the best
ligand since it had the highest proportion of specific binding associated with its binding.
However since D-AP5 and NMDA could only inhibit 70-80% of binding, it was not
-88-
binding exclusively to the NMDA receptor. [^H]NMDA and [%i]D-AP5 although
very selective were found to be least suitable since they were associated with very low
specific binding (30-40%).
Only radiolabelled antagonists have been used in the current study.
Radiolabeled agonists may label only a proportion of the tote population of receptors
(Thedinga et al, 1989). Radiolabelled antagonists on the other hand genereiy label the
tote receptor population (Bylund and Yamamura, 1990). The binding of radiolabelled
agonists may however be a more accurate reflection of the physiologically relevant
receptor population. This situation is particularly relevant to studies of the NMDA
receptor where agonist (labelled by [ H]L-glutamate) and antagonist (labelled by
3
[ H]CPP) states are proposed to exist (Monaghan et al, 1988). In this study evidence
for heterogenous antagonist receptor states is suggested by the differential modulation
of ligands binding to the neurotransmitter recognition site via the allosteric glycine
3
modulatory site. Monaghan (1991) has provided evidence that [ H]dizocilpine binding
sites are also heterogeneous.
4.2 r%lCPP. A COMPETITIVE NMDA ANTAGONIST
CPP has been shown to be highly specific for the NMDA receptor by having no
significant effects in around twenty other neurotransmitter binding assays (Lehmann et
al, 1987) as well as other functional assays (Childs et al, 1988). However, a report
3
appeared claiming that CPP inhibited the binding of [ Hjflunitrazepam having a K-
value of 430pM, making it 250 times more potent at the benzodiazepine site than at the
NMDA receptor (White et al, 1988). This was later disproved by Williams et al (1988)
who demonstrated reciprocally that neither CPP nor CGS19755 had any ability to
3
displace [ HJflunitrazepam binding to central membranes.
3
The optimal experimental conditions found for [ H]CPP binding are in general
agreement with those used by other research groups (Murphy et al, 1987; Pullan et al,
2+
1990). Inclusion of Ca (> ImM) in the incubation buffer of radioligand binding
assays has been reported to reduce the proportion of non-specific binding (Olverman et
-89-
al, 1988). However this was not found in the current study. The concentration of
assay buffer can readily influence binding of radioligands (Wilkin et al, 1981; Scott et
3
al, 1992). In the current study [ HJdizocilpine binding was more easily measured
using 5mM Tris-HCl than 50mM Tris-HCl. 5mM buffer proved unsuitable for
3
measuring [ H]CPP binding. This is most likely a membrane interaction rather than a
3
receptor interaction since L-glutamate modulation of [ H]dizocilpine binding can be
measured with 5mM and 50mM buffer. This effect is mediated via the same site as
3
[ H]CPP is binding to. To eliminate any effects chloride ions (Tris-HCl) might be
having on binding, Tris-acetate was substituted as assay buffer. No differences were
observed, thus chloride ions were probably not influencing binding. Binding was
highest at pH 7.75, this is in agreement with the findings of Murphy et al (1987) who
3
demonstrated maximal [ H]CPP binding at pH 7.6-7.8. Reduction of endogenous
EAA's was attempted by extra washing of the membranes preparation. No
improvements on binding were measured. This may reflect a low concentration of
residual EAA's in the synaptosomal membrane preparation. This is further supported
by the fact that [ HJdizocilpine binding to an identical membrane preparation could be
extensively modulated by L-glutamate and/or glycine (see Section 3.3). Under the
conditions used in the present study [ H]CPP bound with a high affinity to a single
population of receptors which display similar affinities for the antagonist CPP and the
agonist L-glutamate as previously reported (Watkins and Olverman, 1988; Murphy et
al, 1987).
3
Like the present study, most other studies have restricted [ HJCPP binding to
synaptosomal preparations. Freshly prepared whole membranes were found to be
unsuitable in this study due to low specific binding. However a couple of studies have
successfully measured [ H]CPP binding to whole membranes using a filtration method
to terminate binding (Erdo and Wolff, 1990; Ogita and Yoneda, 1990b).
Centrifugation is the preferred method of assay termination due to the rapid dissociation
of [^H]CPP from its binding site (Watkins and Olverman, 1988; Pullan et al, 1990;
3
Murphy et al, 1987). Evidence that the use of a filtration assay for [ HJCPP binding
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may not result in the same population of sites being labelled as those in a centrifugation
assay comes from the findings of Monaghan et al (1988). They described modulation
3of [ HJCPP binding by glycine which was different to that seen in the present study and
3
others (see Section 4.4; Olverman and Watkins, 1989). Termination of [ H]CPP
binding by filtration in this study resulted in very similar findings to that of Murphy et
al (1987), i.e. very little specific binding was detected.
Ogita and Yoneda (1990b) not only used a filtration assay for termination of the
binding process they also used membranes which were detergent treated (0.08% Triton
3
X-100). They report that this increased the affinity of [ HJCPP for its binding site
three times to 0.08 luM with no alteration in B value. This is the lowest K, value^ max a
3
reported for [ HJCPP binding, and helps to explain why they could successfully use a
filtration assay. Other studies employing detergent treated membranes do not report
such high affinity values. Murphy et al (1987) do report an enhancement of specific
binding in the presence of Triton compared with untreated membrane preparations.
While the use of detergents in preparing membranes for use in ligand binding studies
may be beneficial, problems do exist (Helenius and Simons, 1975).
4.3 r3HlDIZOClLPINE. A NON-COMPETITIVE NMDA ANTAGONIST
Binding of [ HJdizocilpine was measured in both whole and synaptosomal
membrane preparations prepared from rat brain tissue. This ligand bound to a single
population of binding sites in both membrane preparations. Binding could be inhibited
by unlabelled dizocilpine and increased by the addition of L-glutamate and/or glycine.
The extent of this modulation was clearly dependent on the concentration of these
amino acids available at the receptor. This is consistent with the established use
dependency of this compound (Davies et al, 1988).
The binding data presented here were best fitted to a single site for binding to
both membrane preparations in agreement with other studies (Foster and Wong, 1987;
Wong et al, 1986, 1988). Morin et al (1989) detected two [^H]dizocilpine binding
sites, a high affinity (K^ = 4nM) site and a low affinity (K^ = 1 lOnM) site, in the rat
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3
cortex. Other studies, have also detected two similar binding sites for [ HJdizocilpine
binding, however not after 45 min incubation as used in the current study and by Morin
et al (1989). High and low affinity sites are detected after much longer incubation
periods when binding has reached "true" equilibrium and modulation by L-glutamate
and glycine cannot be detected (Javitt and Zukin, 1989). Javitt and Zukin (1989)
3
propose that [ HJdizocilpine binding reaches "true" equilibrium after four hours of
incubation with membranes. After this time modulation by L-glutamate and glycine
cannot be detected. They suggest that NMDA agonists act to increase the association
rate but not the affinity of [ H]dizocilpine binding. They propose a complex model of
ligand, receptor interaction whereby dizocilpine can bind to both open and closed
conformations of the NMDA receptor. Morin et al (1989) proposed that their high
affinity site may represent the true NMDA receptor binding site while the low affinity
site may be the PCP or a site.
3
The binding of [ H]dizocilpine to whole and synaptosomal membrane
preparations, was variable under different experimental conditions. Buffer
concentration may influence binding. Binding was more easily measured using 5mM
Tris-HCl (pH 7.4) compared with 50mM Tris-HCl (pH 7.4). A similar effect of buffer
on [^HJdizocilpine binding has recently been reported (Scott et al, 1992). Buffer
concentration has previously been demonstrated to influence specific binding of
radioligands to identified neurotransmitter receptors (Wilkin et al, 1981). This is likely
to be a non-specific membrane effect and not a receptor mediated phenomena. Tris
buffer has been reported to have toxic metabolic effects on cells (Gillespie and
3
McKnight, 1976). Bowery et al (1988) measured [ H]dizocilpine binding
autoradiographically using 5mM and 50mM Tris-HCl at physiological pH. They found
no differences in binding. In the present study however it was decided that the lower
buffer concentration provided optimal conditions for binding and that it would enable
comparisons with other studies to be made more easily (Foster and Wong, 1987; Wong
et al, 1988; Ransom and Stec, 1988).
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The concentration of EAA agonists available at the NMDA receptor is an
important consideration not only in functional but in radioligand binding studies. Most
studies aim to reduce the endogenous EAA content of their membrane preparation such
3that exogenous modulation of [ H]dizocilpine binding can be measured. In the present
study this was done by extra washing and freeze/thawing of the membranes. The
3reduction in endogenous EAA's is reflected by the reduced affinity of [ HJdizocilpine
for its binding site. Extra washing led to an increase in Bmax, the reason for this is
unclear but extra preparation time may have lead to changes in the membranes such that
important intracellular constituents were lost or adversely affected. Scott et al (1992)
have reported that extensive washing and freezing of membrane preparations was
3deleterious to [ HJdizocilpine binding. However in this study only extensive washing
appeared to be deleterious to binding. An alternative method employed to reduce
endogenous EAA's is to treat membranes with detergent (Ogita and Yoneda, 1989).
Pharmacologically the [ HJdizocilpine binding site in Triton treated membranes
resembled the site described in the current study. The extent of modulation was not
greatly different from that reported here and elsewhere (Foster and Wong, 1987). It
can be assumed that such treatment provides no greater benefits than the methods used
here to reduce endogenous EAA's.
3Both L-glutamate and glycine enhanced [ HJdizocilpine binding as described
previously (Loo et al, 1986; Reynolds et al, 1987; Wong et al, 1988; Foster and
Wong, 1987; Ogita and Yoneda, 1990a). The extent varied between membrane
preparations, reflecting the endogenous EAA content. Least modulation was detected
with fresh (normal washed) whole membranes, greatest modulation was seen with
previously frozen synaptosomal membranes. These two preparations are assumed to
have the highest and lowest endogenous EAA content. However, one notable effect
was that glycine always modulated [ HJdizocilpine binding to a lesser extent than L-
glutamate. L-glutamate and glycine when used in combination increased binding to a
greater extent than L-glutamate alone. This is consistent with other reports (Tremblay
et al, 1990). To obtain a functional response to glycine an NMDA agonist must be
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present (Johnston and Ascher, 1987). Since glycine alone has no effect (but see
Meguro et al, 1992), it is proposed that the response to glycine is due to residual EAA's
in the membrane preparations. The activation state of the NMDA receptor in a
membrane preparation is therefore uncertain unless the concentration of EAA's is
known. For this reason some [ H]dizocilpine binding studies have used very crude
unwashed membranes since the endogenous EAA concentration is assumed to be high
enough to maximally activate all available NMDA receptors (Paleos et al, 1990;
Majeswka et al, 1989). There are however many other endogenous factors which may
2+ 2+be influencing the binding of dizocilpine including polyamines, Mg and Zn (Wong
et al, 1988; Tremblay et al, 1990; Williams et al, 1991). It will prove difficult to
regulate all of these factors experimentally. Consequently washing or freeze/thawing
membranes will also alter the concentrations of these modulators, which may in turn
influence the binding of site specific radioligands to the NMDA receptor.
Specific binding is higher in whole membrane preparations in the absence of
added modulating amino acids than in synaptosomal membrane preparations. This is
probably due to the higher endogenous EAA levels in whole membrane preparations
which would explain the higher affinity of [ H]dizocilpine for its binding site under
control conditions (see Section 3.3.3). The increased binding in whole membranes is
not due to an increased receptor density since the Bmw for [ H]dizocilpine binding is
greater in synaptosomal membranes. Whole membrane preparations differ from
synaptosomal preparations in that they contain membrane fragments from all the cell
whereas synaptosomal membranes contain material concentrated from the neuronal
synapse. Binding to receptor sites in synaptosomal membrane preparations is likely to
represent physiologically relevant synaptic receptors. Binding to whole membrane
preparations may include extra-synaptic receptors though in the case of the NMDA
receptor no evidence for their existence is currently available (Erdo and Wolff, 1989).
Usowicz et al (1989) have provided evidence for the existence of L-glutamate receptors
on glia. However, on the particular astrocytes studied only non-NMDA responses
could be detected. The magnitude of the response to L-glutamate was however
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equivalent to that of NMDA in neuronal cells. The role of such EAA receptors is
unclear (Gallo et al, 1989; Usowicz et al, 1989). It is possible that NMDA receptors
may exist on glia. Both membrane preparations contain glia, and may therefore both
allow binding to more than just the synaptically located, NMDA receptor.
The rank order of potency displayed by the stereoisomers and racemic mixture
of dizocilpine differed between the two membrane preparations. This was maintained
in the presence of L-glutamate. Monaghan (1991) proposed heterogeneous
3 3
[ H]dizocilpine sites. This may explain the current finding in that [ H]dizocilpine is
binding to a slightly different population of receptors in each membrane preparation.
This however remains to be demonstrated.
Although dizocilpine has been demonstrated to block the NMDA associated ion
channel, the physiological relevance of this binding site remains unclear. One
possibility is the existence of an endogenous substance which acts to modulate NMDA
receptor activity via the dizocilpine binding site. Zukin et al (1987) have presented
evidence that such a substance exists in extracts of brain tissue. However it may be
more specific for the PCP/a site than the NMDA dizocilpine/PCP site. This would
seem to warrant further research since the existence of such a substance may have
clinical relevance.
4.4 INTERACTIONS BETWEEN THE NMDA NEUROTRANSMITTER SITE
AND GLYCINE MODULATORY SITE
Glycine has been demonstrated here and elsewhere (Wong et al, 1988; Loo et
3 3
al, 1986) to modulate the binding of [ Hjdizocilpine and [ H]TCP to membrane
preparations. The increase in specific binding measured here in the presence of glycine
is due to an increase in dizocilpine binding site affinity. Functionally, glycine alone is
inactive at the NMDA receptor (Nowak et al, 1984). The modulatory effect of glycine
in [ H]dizocilpine binding studies may be due to endogenous EAA agonists in the
membrane preparation. This infers that a modulatory interaction takes place between
the neurotransmitter site and the allosteric glycine on the NMDA receptor complex.
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3 3This interaction was investigated using [ H]CPP and [ HJD-AP5 binding and the
results obtained provide further evidence for the differential modulation of the
neurotransmitter recognition site via the glycine site, as originally demonstrated by
Monaghan et al (1988). Alternatively the results may provide evidence for distinct
isoforms of the NMDA receptor (Monaghan, 1991).
4.4.1 Glycine
Although endogenous glycine concentrations in the synaptosomal membrane
preparations were not measured, using an identical membrane preparation to that used
3 3 3in [ H]CPP and [ H]D-AP5 binding studies, modulation of [ H]dizocilpine binding by
exogenously applied glycine could be measured. It is proposed that the glycine site is
not fully activated under the experimental conditions employed in this study although it
is likely to be partially activated due to residual endogenous glycine.
Glycine was demonstrated to modulate the binding of [^H]CPP and [^H]D-AP5.
Assuming that it is acting through the same site, this is a further indication that the
NMDA associated glycine site is not saturated in this membrane preparation. Dose-
dependent enhancement and inhibition (± 20%) were seen for [ H]CPP binding with
maximal binding measured in the presence of 3|iM glycine. Only a substantial dose-
3
dependent inhibition (50%) was seen for [ H]D-AP5 binding, with maximum
inhibition measured in the presence of 3jiM glycine. This suggests that a differential
modulation of non-competitive antagonist binding by glycine exists. These two
competitive antagonists were previously thought to bind to the same receptor site in a
similar fashion (Watkins and Olverman, 1988). Thus two possibilities exist, binding
may be to one site but in a different manner or else to two separate sites with which
glycine interacts differently.
3
Olverman and Watkins (1989) have reported similar findings for [ H]D-AP5
3
and [ H]CPP binding, modulated with either D-serine or glycine. Fagg & Baud (1988)
however reported that glycine at concentrations up to lOOpM did not influence the
binding of [^H]CPP. These differential effects of glycine on [^H]CPP binding may be
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due to different concentrations of endogenous glycine in the membrane preparations.
3
Monaghan et al (1988) conversely report an effect of glycine on [ H]CPP binding that
3is identical to that seen on [ H]D-AP5 binding in the present study (i.e. 50% inhibition).
3
Danysz et al (1989) also demonstrated only inhibition (20%) of [ H]CPP binding with
increasing concentrations of glycine. These studies differ from the present one in that
the binding assays were terminated using the filtration method. Filtration may result in
3
a different population of NMDA receptors being labelled with [ H]CPP to that labelled
3
ina centrifugation assay. [ H]CPP binding in a filtration assay may be to the same
3
population or state of NMDA receptors as detected by [ H]D-AP5 in a centrifugation
assay. In a centrifugation assay [%I]CPP is thought to bind to the agonist as well as the
antagonist state of the receptor (Olverman and Watkins, 1989). Monaghan et al (1988)
3
also reported an effect of glycine on NMDA sensitive [ H]glutamate binding which
3
resembled that of glycine on [ H]CPP binding in the present study. This may support
3
the theory that [ H]CPP binds to both agonist and antagonist states of the receptor
(Olverman and Watkins, 1989).
3The main reason for the differences in binding between [ HJD-AP5 and
3
[ H]CPP in the presence of glycine is thought to be their different structures. It is
possible that the two compounds, CPP which contains 7 carbon atoms (C-7) and is
conformationally fixed and, D-AP5 which contains 5 carbon atoms (C-5) and is
conformationally flexible, are able to induce different conformational states of the
receptor by binding in a differential manner. This may therefore allow glycine to
differentially modulate the neurotransmitter binding site depending on the
conformational state induced. Table 18 summarises the reported interactions between
the glycine site and the neurotransmitter site.
3
[ H]CGP 39653 is the most potent competitive NMDA antagonist yet
3
synthesised (K^ = 6nM). The effect of glycine has now been investigated on [ H]CGP
39653 (C-7) binding (Sills et al, 1991). Glycine inhibited 63% of the binding in a
biphasic manner resulting in IC^q values of 0.54pM and 0.87)iM. This is proposed to
be allosteric modulation and not competitive inhibition (Sills et al, 1991). This is quite
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TABLE 18 REPORTED INTERACTIONS BETWEEN THE NMDA
NEUROTRANSMITTER SITE AND THE ASSOCIATED GLYCINE
SITE
RADIOLIGAND GLYCINE HA-966 7-Clkyn
[3FI]CPP t^0.2) t(l, 3, 9) 4.0,3)
4-(3,5)
«*(4)
[3H]D-AP5 4.0,2) 4»0) 4.0)
[3H]L-Glutamate t*(5) 4^(10) 4,(11)
[3H]CGP 39653 4,(6) ed2)
CPP HA-966 D-AP5 NMDA L-GLUTAMATE
[3H]Glycine ^(7) 4,(10) 4^(7,8)^(7) «*(7)
/—soo
[3H]L-689,560 4.(7) 4.(7) t (7) 0(7)
Abbreviations:
t Enhancement of binding
4. Inhibition of binding
't\^Enhancement and inhibition of bindng
No effect on binding














Olverman and Watkins (1989)
Danysz et al (1989)
Baud and Fagg (1988)
Monaghan et al (1988)
Sills et al (1991)
Grimwood et al (1991)
Monahan et al (1989)
Pullan et al (1990)
Foster and Kemp (1989)
Kemp etal (1988)
Pingping et al (1991)
3
different to the effect of glycine on [ H]CPP binding (C-7). It would seem therefore
that the differences in binding may be more subtle than just assuming the basic C-5, C-7
structural differences. Perhaps each of these different structures allows the NMDA
receptor to adapt differing conformational states in the presence of glycine, and thus
multiple states of the receptor can exist, or else multiple receptor subtypes exist each
having differing sensitivities to competitive antagonists at the neurotransmitter binding
site.
Reciprocal investigations of the effects of these competitive antagonists on
3
[ H]glycine binding have also been reported (Table 18). C-5 compounds (D-AP5,
CGS-19755, CGP 37849) all decreased binding of [^H]glycine by around 50%. C-7
3
compounds on the other hand had no effect or caused slight inhibition of [ H]glycine
binding (Monahan et al, 1990; Grimwood et al, 1991b). These findings would appear
to agree with the effects of C-5 and C-7 compounds which would be predicted by the
present study, although strictly speaking C-7 compounds may have been predicted to
enhance [ H]glycine binding. Endogenous glycine levels may have influenced the
results.
3
Having demonstrated that glycine (3|iM) maximally enhanced [ HjCPP-
3
binding, this concentration of glycine was investigated on the inhibition of [ HJCPP
binding and compared with inhibition under control conditions. Inhibition by CPP (C-
7), L-glutamate (agonist) and 7-Clkyn (proposed to be an antagonist at the glycine site)
was unaffected. Glycine is suggested to promote the agonist state of the receptor
3
(Monaghan et al, 1988) [ HjCPP is though to bind to both the agonist and antagonist
states of the receptor (Olverman and Watkins, 1989). This may lead to the prediction
that the effect of glycine would be to increase the affinity of L-glutamate and CPP for
3
the [ H]CPP binding site due to an increased proportion of agonist sites. This was not
detected. The affinity of D-AP5 was however significantly decreased in the presence
of glycine compared to control conditions, further confirming differential regulation of
C-5 and C-7 antagonist binding by glycine. This does support the proposal that D-AP5
binds mainly to the antagonist state of the receptor. Glycine may therefore be
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promoting a state of the receptor (agonist state) which is unfavourable to C-5
antagonists but favourable to C-7 antagonists (which may bind to both states). These
findings support the proposal of Monahan et al (1990) who suggest a close functional
relationship between the C-5 antagonist site and the glycine site on the NMDA receptor
3
complex. 7-Clkyn inhibition of [ H]CPP binding was also unaffected in the presence
of glycine, it may directly interact preferentially with the agonist state of the receptor
(see Section 4.4.3).
4.4.2 HA-966
HA-966 has been proposed to be either an antagonist or a partial agonist at the
NMDA receptor glycine site (Fletcher and Lodge, 1988; Foster and Kemp, 1989). A
functional characterisation cannot be made from the current binding studies, but two
different effects of HA-966 were seen on [^H]D-AP5 and [^H]CPP binding. [^H]D-
AP5 binding was partially inhibited by increasing concentrations of HA-966 while
3
[ H]CPP binding was greatly enhanced in dose-dependent manner. The effect on
3
[ H]CPP binding has been demonstrated elsewhere using both centrifugation and
filtration assays (Pullan et al, 1990; Danysz et al, 1989). HA-966 appears to promote
3
a state of the receptor which is favourable to [ H]CPP binding.
3
HA-966 was also investigated on the inhibition of [ H]CPP binding. Different
results were also found from those for glycine modulation. The affinities of CPP and
7-Clkyn were increased in the presence of HA-966 with that of D-AP5 being unaltered.
The affinity of L-glutamate was reduced in the presence of HA-966. This provides
further evidence that glycine and HA-966 are interacting with the proposed C-7 and C-5
states of the NMDA receptor differently. These findings may be accounted for by HA-
966 reducing the ability of glycine to confer the agonist preferring state of the receptor,
thus the affinity for L-glutamate is reduced while that for CPP is increased since it also
binds to the antagonist state of the receptor. However, in these studies glycine itself did
3
not increase the affinity of L-glutamate for the [ H]CPP site and HA-966 did not
increase the affinity of D-AP5. HA-966 may be relieving the effect of endogenous
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3
glycine on [ HJCPP binding thus promoting an antagonist state of the receptor. Kemp
and Priestley (1991) in agreement, propose from electrophysiological studies, that HA-
966 has a higher affinity for the antagonist state of the receptor. Since the affinity ofD-
3AP5 was not increased in the presence of HA-966 and HA-966 inhibited [ HJD-AP5
binding it seems that this C-5 antagonist may be binding to a different site or receptor
3
state from [ H]CPP (C-7) such that a number of antagonist states may exist.
HA-966 enhances the binding of a C-7 antagonist to the NMDA receptor.
However, it reduces the binding of a C-5 antagonist in a similar way to glycine. This
3effect on [ H]D-AP5 binding may suggest that HA-966 has agonist properties at the
3
glycine site. HA-966 also increased the affinity of 7-Clkyn for the [ H]CPP binding
site. These two compounds are proposed to be acting at the same site. In the present
study only high concentrations of 7-Clkyn (ImM) influenced [^H]CPP and [^H]D-AP5
binding (see Section 3.4.6). This is probably a direct interaction with the
neurotransmitter site since lower concentrations (30pM) are effective at the NMDA
associated glycine site (Kemp et al, 1988). In the presence of HA-966, 7-Clkyn binds
preferentially to the same site as CPP as reflected by the increase in their respective
affinities. Pullan et al (1990) and Danysz et al (1989) have demonstrated that the
enhancement of [ H]CPP binding by HA-966 can be competitively inhibited by both 7-
Clkyn and glycine. This is an indication that all three compounds are acting at the same
site. This is supported by the present study which demonstrated that increasing
i 3
concentrations of glycine can inhibit the HA-966 enhanced component of [ H]CPP
binding with an IC^q of around 6(iM.
Electrophysiologically HA-966 decreased the component of NMDA-mediated
responses enhanced by glycine (Foster and Kemp, 1989) and reduced NMDA-mediated
responses which could not be enhanced by glycine, in both cultured cells and more
intact preparations (Fletcher and Lodge, 1989). This suggests that HA-966 is an
antagonist of glycine responses. HA-966 however also displayed agonist activity by
increasing NMDA-mediated responses when glycine concentrations were low (Foster
and Kemp, 1989; Huettner, 1990; Henderson, et al, 1990). [^H]Glycine binding is
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inhibited by HA-966 in a competitive manner with variable IC^q values (Pullan et al,
1991; Foster and Kemp, 1989). Spermine increased the affinity of glycine agonists but
3
not antagonists in [ H]glycine binding studies (Pullan et al, 1991). Thus the affinity of
HA-966 like that of glycine was increased while the affinities of 7-Clkyn and DNQX,
antagonists at the same site, were unaffected. It is also possible that the glycine site
itself exists in different conformational states perhaps conferred by different
compounds leading to differential interactions with the different states of the
neurotransmitter site. HA-966 also competitively antagonised the modulatory effect of
glycine but not L-glutamate on [ H]dizocilpine binding, resulting in displacement of
the dose response curve to thejight (Kloog et al, 1990). All these effects are overcome
by increasing glycine concentrations. These properties have lead to the suggestion that
HA-966 is most likely a partial agonist possessing a low intrinsic activity (Foster and
Kemp, 1989).
3HA-966 does not however display the same effects as glycine on [ H]CPP
binding, although a similar effect is seen on [ H]D-AP5 binding. A possible
explanation for this is that the conformational states induced by the different structures
of CPP and D-AP5 are differentially modulated not only by glycine but also by HA-
966, which is not chemically similar to glycine and may therefore interact with the
glycine site in a different way. The differences seen in the present study, between the
effects of HA-966 on C-5 and C-7 antagonist binding are, like the differential effects of
glycine, further complicated by the effect of HA-966 on the binding of [^H]CGP 39653
(C-7). Pingping et al (1991) report that HA-966 is without effect on the binding of this
3
C-7 antagonist, but report a similar enhancement of [ H]CPP binding as described here.
They propose multiple NMDA neurotransmitter sites in the rat brain.
4.4.3 7-Chlorokynurenic Acid
7-Clkyn, has been demonstrated to have increased NMDA antagonist activity
compared to kynurenate (a broad spectrum EAA antagonist) by selectively
antagonising the effects of glycine at the strychnine insensitive glycine site (Kemp et al,
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1988). However, 7-Clkyn has also been proposed as an inverse agonist at the glycine
site (Kemp et al, 1988; Foster and Kemp, 1989). This study has demonstrated that 7-
3
Clkyn has a different effect on [ HJCPP binding from HA-966 and glycine. 7-Clkyn
3
inhibited the binding of [ H]CPP, in a dose-dependent manner, though inhibition was
incomplete. [^H]D-AP5 binding was also inhibited in an identical manner. The
3 3
inhibition of [ H]CPP and [ HJD-AP5 may be due to a direct interaction with the
neurotransmitter binding site, as already mentioned, since inhibition is only seen at high
concentrations (K. ~ 100|iM). This is similar to the effect of 7-Clkyn on NMDA-
sensitive [ H]L-glutamate binding (Kemp et al, 1988). Lower concentrations of 7-
Clkyn (30jiM) are effective at blocking glycine responses mediated via the NMDA-
associated glycine site (Kemp et al, 1988). In the two binding assays in the present
study no effect of 7-Clkyn at 30pM was seen. These findings suggest that 7-Clkyn
does not distinguish between C-5 and C-7 antagonist binding and since it also has a
3
similar effect on [ H]L-glutamate binding it may not preferentially bind to the agonist
or antagonist state of the receptor.
In the presence of increasing glycine concentrations 7-Clkyn inhibited binding
3
of [ H]CPP to around 20% of maximal binding, as seen in the presence of 7-Clkyn
(ImM) alone. This component of binding is therefore 7-Clkyn and glycine insensitive.
This suggests that 7-Clkyn is not interacting with the glycine site in a competitive
manner and thus a direct interaction with the [^H]CPP site was occurring. In the
presence of increasing concentrations of HA-966 however this component of binding
remaining in the presence of 7-Clkyn (ImM) could be inhibited completely. HA-966
3
also increased the affinity of 7-Clkyn for the [ HJCPP site. These findings may reveal
3
a close interaction between the state of the [ HJCPP site conferred by HA-966, and the
favoured binding site of 7-Clkyn. Under control conditions (in the absence of




7-Clkyn inhibited [ H]glycine binding dose-dependently (K. = 0.56pM), being
around eighty times more potent than kynurenate and having a greater affinity for the
site than HA-966 (K. = 14|jM) (Kemp et al, 1988; Kloog et al, 1990). Since 7-Clkyn
3 3
at low micromolar concentrations had no effect on either [ HJCPP or [ H]D-AP5
binding a direct interaction with the neurotransmitter site has almost certainly been
3
studied here. [ H]TCP binding enhanced by glycine, was competitively antagonised
by both 7-Clkyn (10pM) and HA-966 acting at the NMDA-associated glycine site
(Kloog et al, 1990). However 7-Clkyn also had a similar effect on L-glutamate
3
enhanced [ H]TCP binding. This effect is due to an action at the neurotransmitter site.
This demonstrates the lack of specificity of 7-Clkyn and indicates mixed sites of
actions.
Two glycine site antagonists have been described and radiolabelled. L-689,560
and 5,7-dichlorokynurenate (5,7-DCKA) are both specific for the NMDA glycine site
(Grimwood et al, 1991b; Baron et al, 1991). Grimwood et al (1991b) have
investigated the effects of C-5 and C-7 competitive antagonists in addition to NMDA
and L-glutamate on the binding of [^H]L-689,560 (Table 18). The C-5 antagonists
inhibited binding by around 30% while C-7 antagonists inhibited binding to 50% of
control levels. L-glutamate had no effect on binding while NMDA decreased it by
30%. From the current study it may have been predicted that C-5 and C-7 competitive
antagonists would have a similar effect on [ H]L-689,560 binding since 7-Clkyn does
not distinguish between [^H]CPP and [^H]D-AP5 binding. Grimwood et al (1991b)
suggested that C-5 and C-7 competitive antagonists may confer differential
conformational states on the NMDA receptor which influence the binding of glycine
site agonists and antagonists. However, it may be that the converse is also true.
If HA-966 and 7-ClKyn are both acting at the glycine site, as a partial agonist
and an antagonist respectively, it should be possible to block the agonist activity of HA-
966 with 7-Clkyn. Conversely it should be possible to overcome the block of NMDA
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responses by 7-Clkyn with HA-966. This would not only prove that these two
compounds are acting at the same receptor site but that they are classified correctly.
This remains to be demonstrated.
Kemp and Priestley (1991) propose that since 7-Clkyn has little effect on the
kinetics of L-glutamate-mediated responses, that it is a "neutral" antagonist at the
glycine site. The data presented in this study would suggest that it is also an inhibitor
of C-7 and C-5 radioligand binding at the neurotransmitter site. However, modulation
may suggest that it acts preferentially at the antagonist state, if that is the state of the
receptor conferred by HA-966.
4.4.4 Physiological relevance
3
If [ H]CPP does bind to agonist preferring states of the NMDA receptor, as well
as to antagonist preferring states, then the findings of this study would appear to support
the existence of these two states. Glycine promotes the agonist state while HA-966
promotes the antagonist state. The findings however are also in support of the theory
that C-5 and C-7 competitive antagonists at the NMDA receptor promote different
conformational states of the receptor leading to differential modulation via the allosteric
glycine site. 7-Clkyn in agreement with other studies, is interacting directly with the
neurotransmitter site at high concentrations, and is not causing its effect via the glycine
site.
3
Recent evidence, obtained with the C-7 antagonist [ H]CGP 39653, lead us to
believe that the actual situation is not as clear cut as either of these theories might
3
suggest. The binding of this compound is modulated differently to that of [ H]CPP
and [^H]D-AP5 by glycine and HA-966 (Sills et al, 1991; Pingping et al, 1991). This
therefore leads to the possibility of the existence of multiple NMDA neurotransmitter
sites. Each may have differing sensitivities to agonists and antagonists, and be
modulated differently via the glycine site. It has recently been proposed that the
NMDA glycine site may also be heterogeneous (Yoneda et al, 1991). This theory, like
the others remains to be demonstrated, but may be resolved by receptor cloning studies
-104-
which are undoubtedly underway. They may lead to the discovery of multiple NMDA
receptor subtypes as has already been demonstrated for other EAA receptors (Tanabe et
al, 1992; Keinanen et al, 1990).
3
Monaghan (1991) has demonstrated differential modulation of [ H]dizocilpine
binding in the presence of saturating concentrations of spermine and glycine. The
3anatomical profile of [ H]dizocilpine binding in the presence of low concentrations of
3
L-glutamate (0.3|iM) resembled the profile of [ H]L-glutamate binding. In the
presence of high concentrations of L-glutamate (10|iM) the profile resembled that of
3
[ H]CPP binding. He proposed the existence of distinct isoforms of the NMDA
receptor as opposed to differential states regulated by glycine. The cerebellar NMDA
receptor has also been proposed to be different from other characterised NMDA
receptors due to its different pharmacological profile (Monaghan, 1991).
The physiological significance of these findings is still unclear. These effects
are all manifest by exogenous compounds (apart from glycine). It is unknown whether
under normal physiological conditions, the NMDA receptor, and glycine site are going
to exist in antagonist states, unless there is an endogenous substance to act on the site.
However, it is likely that in pathological conditions, in which the NMDA receptor is
implicated, that the interactions between the glycine site and the neurotransmitter site
are altered in some way resulting in different proportions of receptor states. The
existence of isoforms of the NMDA receptor with differential sensitivities to
endogenous agonists and exogenous antagonists does seem a more likely proposal.
Connick and Stone (1983) suggested that quinolinate may act a subpopulation of
NMDA receptors. It is possible that the other proposed EAA neurotransmitters (see
Section 1.2) may also act preferentially at different states or populations of NMDA
receptors with different physiological consequences. In the future therefore it may be
possible to target one population of NMDA receptors which are specifically responsible
for certain physiological or pathological phenomenon.
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As yet the role of glycine in higher brain regions is not as clearly defined as
lower regions. Some studies have demonstrated modulation of NMDA responses by
glycine while others demonstrate that glycine has no effect (Fletcher and Lodge, 1988;
Kemp et al, 1989; Ascher and Johnston, 1989; Thomson et al, 1989; Salt, 1989).
This may be due to different regional or synaptic levels of glycine. Likewise the
mechanism responsible for controlling release of glycine, and the source of the glycine
is still unknown. To further our understanding of NMDA receptor actions, the
neurotransmitter role of glycine in higher brain structures needs to be further
investigated.
4.5 ONTOGENY OF THE NMDA RECEPTOR IN RAT CNS
4.5.1 Introduction
The choice of a synaptosomal preparation for an ontogeny study may not be
completely appropriate. This is because the density of synaptic junctions is low at
early postnatal ages in rat CNS. However, such a preparation has been used
successfully in other developmental studies (Tremblay et al, 1990; Dudek et al, 1989).
Measurements of [ H]CPP binding to whole membrane preparations, as commonly
used in receptor ontogeny studies (Erdo and Wolff, 1990; Majewska et al, 1989;
Paleos et al, 1990), was not possible therefore a synaptosomal preparation was used at
3
all postnatal ages. This preparation also proved suitable for measuring [ Hjdizocilpine
3
binding during postnatal development. Binding of [ Hjdizocilpine was also measured
to whole membranes during postnatal development as a comparison.
3
Binding of both ligands to synaptosomal membranes and [ Hjdizocilpine to
whole membranes suggests that the ion channel and neurotransmitter site are both
present from an early stage of development. Binding of each ligand during postnatal
3
development, was to the same population of binding sites labelled by [ Hjdizocilpine
3
and [ H]CPP in synaptic and whole membranes prepared from mature tissue. Binding
3of [ HJdizocilpine to both membrane preparations could be modulated throughout
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postnatal development by the amino acids L-glutamate and glycine. This modulation
3 3
was as reported previously for binding of [ H]dizocilpine and [ H]TCP to adult tissue
(Loo, 1986; Reynolds et al, 1987; Foster and Wong, 1987; Morin,1989).
4.5.2 Postnatal development of the [%T]dizocilpine binding site
3
Binding of [ H]dizocilpine to synaptosomal and whole membranes was
measured throughout postnatal development. This ligand bound to a single high
affinity binding site corresponding to that previously characterised (Wong et al, 1986;
1988). Although it has around a 30-fold higher affinity for its binding site than
3
[ H]CPP for its binding site measurements of specific binding were still difficult to
obtain from very young rats (PNDO-4). This may be a reflection of the low density of
3
binding sites at such an age. [ H]CPP binding sites are also present in low numbers at
3this age. Since binding of [ H]dizocilpine requires the presence of agonist, either
residual endogenous EAA's or exogenously applied, it may be that reduced agonist
binding site density reduces the probability of NMDA receptor activation to allow
[^HJdizocilpine access to its binding site. Binding of [^H]dizocilpine to both
membrane preparations was measured in the absence and presence of added L-
glutamate and glycine. In the absence of added amino acids binding was probably due
to activation of the NMDA receptor by residual amounts of endogenous EAA's.
Nevertheless binding in the absence of added amino acids was very low, especially in
the synaptosomal preparation. This may be a reflection of the lower levels of
endogenous amino acids in the synaptosomal preparation and thus why a greater degree
of modulation was seen upon addition of exogenous amino acids. Addition of L-
3
glutamate (lOpM) and glycine (10|iM) maximally enhanced binding of [ HJdizocilpine
throughout postnatal development in agreement with other studies (Morin et al, 1989;
Boje and Skolnick, 1992).
In the absence of added amino acids adult levels of binding to the whole and the
synaptosomal membrane preparations were not reached at the same age range
regardless of whether data were expressed per mg protein or per mg tissue. Adult
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levels of binding are defined as the first age range when binding does not differ
significantly from that at PND90. Binding reached adult levels at PND5-8 in
synaptosomal membranes and PND13-16 in whole membranes when expressed per mg
protein and at PND9-12 and PND13-16 respectively when expressed per mg tissue
(Table 19). Levels of binding tend to rise to levels above that seen at PND90 before
falling to the adult level. Binding profiles in the presence of L-glutamate or glycine
largely mirror those of control binding in each membrane preparation. This suggests
that no underlying modulatory mechanism is changing postnatally. Likewise the ages
when adult levels of binding were reached mirror the control situation apart from
binding to synaptosomal membranes in the presence of both amino acids, when binding
reaches adult levels at a later age (PND9-12). This may be a reflection of the varying
extent of modulation measured in the presence of both L-glutamate and glycine in this
preparation throughout postnatal development. The reason for this is unclear since the
extent of modulation by individual amino acids did not vary postnatally. This may be a
reflection of an alteration in neurotransmitter site/allosteric glycine site coupling during
postnatal development. Similar alterations in extent of modulation of [ H]dizocilpine
binding were detected with whole membranes. When expressed per mg protein
specific binding reached adult levels at the same age as in the presence of the individual
amino acids. Specific binding expressed per mg tissue reaches adult levels at later ages
than when expressed per mg protein. The pattern of ages when adult levels are reached
under each modulatory condition is the same for whole and synaptosomal membranes
although the actual ages differ between preparations. The differences between data
expressed per mg protein and per mg tissue are not uncommon in receptor ontogeny
studies (Baudry et al, 1981; Sanderson et al, 1982), and serves to illustrate the
importance of expressing binding data using both methods.
Adult binding is therefore consistently reached at a later age in whole
membranes. These differences may be due to differences between the constituents of
the membrane preparations. Whole membrane preparations will contain both synaptic
and non synaptic material. The differences in the development profiles may be due to
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PNP9Q
EXPERIMENTAL CONDITION SPECIFIC BINDING B
1




+ L-Glutamate (IOjiM) 13 - 16
+ Glycine (IO^iM) 13 - 16




+ L-Glutamate (IOjiM) 5-8
+ Glycine (lOpM) 5-8
+ L-Glutamate and 9-12
glycine (both lOpM)
B. ['iflCPP
normal conditions 21 - 24 21 - 24 17 - 20
Values represent age ranges as used previously in PND. Age ranges were determined
by applying one-way analysis of variance followed by a t-test. They represent the age
range when specific binding or B first reach a level not significantly different frommax

















the incorporation in the whole membrane profile of binding to extra-junctional NMDA
receptors. It is possible that if extra-junctional receptors exist they may follow a
slightly different postnatal developmental profile from the receptor located in the
synaptic cleft. The protein content of the different membrane preparations may be
influencing the data since synaptosomal protein will be a subcomponent of that
measured with whole membranes.
Binding expressed per mg protein and per mg tissue have distinct profiles
presumably due to the postnatal alteration in protein content. If receptor number
increases at the same rate as total protein content, no increase in binding would be seen
postnatally. Since an increase in binding is seen postnatally, binding sites must be
synthesised at a faster rate relative to total protein production. The rate of binding site
synthesis must be maximal at the ages when transient peaks in binding the observed. In
the current study transient peaks in [ Hjdizocilpine binding are seen from the third
postnatal week. The subsequent decrease in binding to adult levels may represent a
time when the rate of receptor synthesis relative to total protein synthesis is slowing
down, thus the ratio of receptors to amount of protein will decrease. It has been
suggested that the gradual reduction in the ratio of binding sites to total protein
concentration partly reflects glial cell maturation which begins during the second
postnatal week (Baudry et al, 1981).
The reason for the overshoot of adult levels of binding, which is quite common
in receptor ontogeny is not fully understood. Baudry and Lynch (1982) and Tremblay
et al (1988) suggest that it may be during a period when increased synaptogenesis is
taking place. This may be particularly relevant since the NMDA receptor is implicated
in CNS neuronal development (see Section 4.5.6; Hunt and Patel, 1990).
3
Changes in postnatal [ Hjdizocilpine binding would appear to be due to
increased receptor density, rather than to increased receptor affinity. The postnatal
increase in receptor density under each modulatory condition follows a similar profile
to that seen for specific binding under the same condition. Bmax is consistently higher
at all ages in a synaptosomal preparation as would be predicted. Bmax values reach
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levels not significantly different from that seen at PND90, at the same age or earlier
than levels of binding reach PND90 levels. The similar profiles for specific binding
and Bmax supports the finding that is not altering postnatally.
L-Glutamate and glycine, separately or in combination increase specific binding
as a result of an increase in receptor affinity. The rank order of potency is the same in
immature and adult preparations. Throughout postnatal development the following
order is seen, L-glutamate and glycine > L-glutamate > glycine. This is in agreement
with previous reports (Tremblay et al, 1991; Foster and Wong, 1987). The extent of
modulation by these amino acids is different in the two membrane preparations
probably, as discussed earlier, reflecting the different endogenous EAA content.
Generally, for each condition the extent of this modulation was similar at all ages to that
seen at PND90. There were a couple of exceptions. L-Glutamate did not increase
specific binding of [ H]dizocilpine to whole membranes at PNDO-4 compared to
control binding. The corresponding for binding at this age was higher than at all
others. Therefore it may be that L-glutamate has a reduced ability to modulate
3
[ H]dizocilpine binding at this age. However, a combination of L-glutamate and
glycine did increase specific binding. This finding at PNDO-4 may well be due to the
unreliability of the assay on membranes prepared from very young animals due to the
low density of binding sites. The other differences were seen for binding in the
presence of both amino acids to whole and synaptosomal membranes, when modulation
at certain ages was significantly less than at PND90. Since modulation by individual
amino acids was constant postnatally, and the postnatal EC^q values did vary
significantly from that at PND90 this is an unusual finding. It may reflect postnatal
alterations in the coupling between the neurotransmitter site and the allosteric glycine
site.
Up to four hypotheses have been proposed as to why NMDA agonists increase
3 3
the binding of [ H]dizocilpine and [ HjTCP. The first theory is that the increase in
binding of these radioligands is due to an increase in receptor density with no alteration
in receptor affinity (Javitt and Zukin, 1989). The developmental study of Tremblay et
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al (1990) presented further evidence in support of this (see Section: Ontogeny of
[^H]TCP binding). They also demonstrated that Bmax for [^H]TCP binding increased
in the presence of NMDA compared with binding in the absence of NMDA at PND9
with no alteration in compared with control conditions suggesting that this
mechanism is present postnatally. However, the findings of the present study suggest
3that at a given age the alteration in [ H]dizocilpine binding in the presence of NMDA
agonists is due to a change in affinity with no change in receptor density. This is in
agreement with a number of other studies (Foster and Wong, 1987; Morin et al, 1989;
Ransom and Stec, 1988; Reynolds et al, 1987). This is true at all postnatal ages, no
matter the modulatory condition. Javitt and Zukin (1989), however go on to further
their hypothesis by proposing that [ H]dizocilpine interacts with multiple states of the
NMDA receptor complex. The Bmax is thought to increase because dizocilpine
becomes trapped in the channel due to the presence of agonist. The final theory is that
NMDA agonists increase the association and dissociation rates of the binding of
3 3
[ H]TCP again with no alteration in K^. These increases in [ H]TCP binding can only
be measured in non-equilibrium conditions (Jaritt and Zukin, 1989; Bonhaus et al,
1989). They therefore suggest that at "true" equilibrium (4 hours of incubation) the
cannot be altered. This would therefore suggest that binding in the present study has
not been performed at true equilibrium, although it has the advantage of being able to
measure modulation of [ H]dizocilpine binding. These conditions have been
employed elsewhere for this reason (Boje and Skolnick, 1992). It must be concluded
from these multiple findings and theories that the exact mechanism by which NMDA
agonists modulate the binding of the non-competitive antagonists is still not fully
understood.
3
Morin et al (1989) used [ H]dizocilpine to study the development of the NMDA
associated ion channel and present similar findings to those reported here. Using a
well-washed (eight times after freeze/thawing) whole membrane preparation they
measured [ H]dizocilpine binding to three brain areas, the cortex, hippocampus and
brainstem. The hippocampus showed highest levels of binding at all ages tested. In
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3
both cortex and hippocampus [ HJdizocilpine binding increased with increasing
postnatal age. Interestingly binding to the cerebellum was relatively high at PND3
(twice the adult value) peaking at four times the adult value at PND15. This high
binding may explain why in the present study binding to the cerebellum at PNDO was
much higher than in the hippocampal/cortical preparation (Table 16). The cerebellar
NMDA receptor is reported to be a different isoform to that found in higher CNS
regions (Monaghan et al, 1991). This may explain these findings, in that it may have a
developmental profile distinct from NMDA receptor(s) in higher CNS regions. A
postnatal autoradiographical study of [HJdizocilpine binding would provide
information about regional variations in the development, of [ HJdizocilpine binding
sites and would complement membrane binding studies. Unfortunately Morin et al
(1989) do not study any ages after PND20 when it is possible that levels of binding
overshooting the adult levels may have been detected thus corresponding with the data
3
presented here. They do report that changes in [ H]dizocilpine binding postnatally are
due to alterations in receptor number and not affinity. Morin et al (1989) also
3
measured the extent of the modulation of [ HJdizocilpine binding in the presence of
exogenous amino acids. In agreement with the present study they find no significant
differences between modulation at PND7 and adult. Overall their extent of modulation
\
is similar to that found here in whole membranes. Since they use a well washed (8 x)
preparation it may have been expected that they would obtain a far greater degree of
modulation due to negligible endogenous ligands (Foster and Wong, 1987). Morin et
al (1989) do not quote the levels of endogenous neurotransmitter in their preparation,
but they do find values very similar to those found in this study.
Boje and Skolnick (1992) have investigated the effect of glycine on
3
[ HJdizocilpine binding during postnatal development to a whole membrane
preparation. They too present similar findings to those found here in that the EC^q for
glycine does not alter postnatally and that the alteration in postnatal specific binding is
due to an alteration in receptor density rather than to an alteration in receptor affinity.
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They report that adult levels of binding are reached at PND12. This age corresponds to
that found in the present study. In addition they report that association and dissociation
3
rates of [ H]dizocilpine for its binding site do not alter postnatally.
Ontogeny of T^HITCP binding
3Other studies relevant to this [ Hjdizocilpirie ontogeny study are studies of the
3 3
ontogeny of the [ H]TCP binding site. [ H]TCP binds to the dizocilpine site (Maragos
et al, 1988; Wong et al, 1988). However, 60 - 8p% of [^H]TCP binding can be
displaced by dizocilpine. The remaining 20% - 40% is almost certainly bound to
another site, the a site being the main candidate (Sonders et al, 1988). Therefore
3
[ H]TCP binding as a measure of the ontogeny of the dizocilpine binding site may not
3be equivalent to [ Hjdizocilpine binding, but may in fact incorporate binding to another
site.
3
Two developmental studies have used [ H]TCP to measure NMDA receptor
binding to whole membranes (Paleos et al, 1990; Majewska et al, 1989) containing
high concentrations of endogenous amino acids to allow maximal modulation. A
further study has used well washed synaptic membranes (Tremblay et al, 1990). All
three studies found an increase in the amount of specific binding with increasing age.
\
Majewska et al (1989) present a very similar developmental profile to that presented
here for [ H]dizocilpine binding to whole membranes. Adult levels of binding were
reached at PND14. They also demonstrate that binding gradually declines between
PND90 to PND360. Paleos et al (1990) present a binding profile where adult values
are reached at PND21, later than found by Majewska et al (1989). Both studies also
characterise the ontogeny of the a receptor using different ligands, showing that it has a
postnatal developmental profile distinct from the NMDA ion-channel site.
Tremblay et al (1990) using synaptosomal membranes found adult levels of
3
[ H]TCP binding at around the third postnatal week (PND15-21) under control and
modulated binding conditions. This is later than reported in the present study for
3
[ Hjdizocilpine binding. Unlike this study postnatal binding never rose above adult
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2+
levels. They also examined the effects of NMDA and/or glycine as well as Mg on
3
[ H]TCP binding throughout development. In agreement with this study they found
modulation to be apparent at all ages tested. The extent of modulation also did not alter
2+ 3
postnatally. Interestingly Mg decreased [ H]TCP binding from PND6 onwards.
2+
At this age endogenous Mg block of NMDA mediated responses is not apparent
(Bowe and Nadler, 1991). Tremblay et al (1990) also conclude that the changes seen
in postnatal binding of [%I]TCP are due to alterations in Bwov but not to K,1X1cLX u
throughout postnatal development. However, they demonstrate that NMDA agonists
3
increase [ H]TCP binding by increasing B„ . with no alteration in K. duringmax ci
postnatal development. Their study also incorporated autoradiographical measures of
3
[ H]TCP binding, in the developing hippocampus showing similar profiles for the CA1
and CA3 regions. The CA1 region had consistently higher binding postnatally.
3
[ HJDizocilpine has been successfully used previously in autoradiographical studies
with mature tissue to examine regional binding (Bowery et al, 1987; Monaghan, 1991).
3
As already mentioned an autoradiographical study using [ H]dizocilpine in immature
tissue has as yet not been reported. A study of this type would complement membrane
binding studies. NMDA receptor isoforms have been proposed on the basis of
differential [ HJdizocilpine binding (Monaghan et al, 1991). A postnatal
autoradiographical study, apart from providing information on sites in distinct and
specific CNS regions, may provide information on the postnatal development of distinct
receptor subtypes.
Ontogeny of the NMDA-associated glycine site
The developmental profile of the NMDA associated glycine site has been
studied. Tremblay et al (1990) have characterised the site in the hippocampus using
3
strychnine insensitive [ H]glycine autoradiography. They showed that binding
increased postnatally in all areas reaching adult levels by PND10. The postnatal
distribution of binding was almost identical to that seen in adult tissue (Bristow et al,
3
1986), and also corresponded well with the distribution of [ H]TCP binding sites
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3
(Tremblay et al, 1990). Shinohara et al (1990) measured [ H]glycine binding. They
found a very similar development profile in rat forebrain membranes and in agreement
with Tremblay et al (1990) demonstrated that this was due to an increase in receptor
number and not to a change in receptor affinity. This supports the finding of the
present study in that the EC^q for glycine did not alter postnatally, since these effects
are manifest via the same site on the NDMA receptor complex.
4.5.3 Postnatal development of the I^HICPP binding site
3
[ H]CPP binding during postnatal development increased gradually from low
levels at PNDO-4 with adult levels reached during the fourth postnatal week (PND21-
24). The changes in the amount of specific binding were due to an increase in receptor
3
density with increasing age. The affinity of the receptor for [ H]CPP, did not alter
postnatally, thereby suggesting that this is fixed during development. Kj values for
3
[ HjCPP binding measured postnatally, correspond to those previously reported for
3
[ H]CPP binding measured in adult tissue using a centrifugation assay (Watkins and
Olverman, 1988; Lehmann et al, 1987). A similar developmental profile was found
regardless of whether data was expressed per mg protein or per mg tissue. The
3
[ H]CPP binding site was expressed in neuronal membranes at a faster rate than total
protein synthesis, since an increase in binding was seen with age. This profile, i.e. low
binding at birth, reaching adult levels during PNW4, corresponds to the developmental
profile of synaptic junction density as well as to the L-glutamate/aspartate and
quinolinate concentration profiles in rat CNS (Erdo and Wolff, 1990b; Aghajanian and
Bloom, 1967; Moroni et al, 1984b).
3
There has only been one other report in which [ HjCPP has been used to study
the ontogeny of the NMDA receptor. Binding of ["^HjCPP was measured to whole
membranes prepared from rat visual cortex using a filtration assay (Erdo and Wolff,
1990a). They produced a binding profile almost identical to that produced in the
present study, whereby binding was initially very low increased rapidly during the
second post-natal week before reaching maximum binding levels around the fourth
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postnatal week, before declining gradually until PND360. They likewise found the
differences in the amount of binding between ages to be due to a change in receptor
density rather than to a change in receptor affinity in agreement with the present study.
However, the affinity value measured in the study of Erdo and Wolff (1990) was
considerably higher than that measured here, and in other studies using a centrifugation
assay (Olverman et al, 1986; Lehmann et al, 1987; Watkins and Qlverman, 1988). It
is possible that Erdo and Wolff are therefore not measuring the same state of the
receptor as measured here using a centrifugation assay (Olverman and Watkins, 1989).
No ontogenic studies have yet been reported using radiolabelled competitive NMDA
3
antagonists which have a greater affinity for the binding site than [ H]CPP, e.g. CPP-
ene or CGS 39653 (Aebisher et al, 1989; Sills et al, 1991). Therefore the other studies
with which this work must be compared are those using the less specific ligand
3 3 3
[ H]glutamate. However [ H]CPP and [ H]glutamate may be labelling different sites
or different conformations of the NMDA site, the so called antagonist and agonist
preferring sites respectively (Monaghan et al, 1988) or different receptor isoforms




Postnatal binding of rHIL-glutamate
3
Early studies of the ontogeny of EAA receptors using [ H]glutamate binding did
not account for the existence of EAA receptor subtypes. This therefore makes it very
difficult to compare the data presented in the current study with that previously
reported. Baudry et al (1981) and Sanderson and Murphy (1982) showed two different
3
[ H]glutamate binding profiles in the hippocampus and cortex respectively, during
postnatal development. Both studies observed transient peaks in binding during
postnatal development at PND9. These studies conclude that adult levels of binding
are reached at PND23 in the rat hippocampus and at PND50 in the cortex. Adult
3
binding at PND23 is in agreement with that found here for [ H]CPP binding, although
3PND50 is considerably later. Likewise [ H]glutamate binding to cerebellar tissue
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showed a transient peak in the amount of specific binding, but at PND21 (de Barry et al,
1980). The data presented in the present study reveal no such pronounced transient
peaks in binding regardless of the method of data expression, this may be because the
membranes incorporate both cortices and hippocampi and thus transient binding, if site
specific, is masked. Perhaps more likely it is because these early studies are measuring
binding to multiple glutamate receptor subtypes. Erdo and Wolff (1990) also did not
3
detect any postnatal transient peaks in binding with [ H]CPP but did find them for both
3 3
[ H]KA and [ H]AMPA binding during postnatal binding.
It is very difficult to adequately compare these three early reports since they all
report different values for L-glutamate and use different membrane preparations
and assay conditions. Since a proportion of the Cl"/Ca^+ independent [^HJglutamate
binding sites have been classed as potentially representing the NMDA receptor (Foster
and Fagg, 1984) only the study of Sanderson and Murphy (1982) may be relevant to
NMDA receptor ontogeny. However, their profiles bear least resemblance to those
presented here or to that of Erdo and Wolff (1990).
3NMDA sensitive [ H]glutamate binding during postnatal development has smce
been measured. The results presented here are however not all in agreement with either
of these studies (Tremblay et al, 1988; Represa et al, 1989). They reveal a transient
increase in NMDA sensitive [ H]glutamate binding sites during development, of the
human and rat hippocampus using both radioligand binding and autoradiography.
Transient peaks were detected at PND8 and foetal weeks 23-27 in rat and human tissue
respectively. This transient peak in binding in the rat hippocampus would appear to
occur at the same age as that found by Baudry et al (1982). In fact Tremblay et al
(1988) make such a comparison but this is not an entirely valid comparison since
Baudry et al (1982) only see their transient peak when expressing their data per mg
protein and not when expressing their data per mg tissue. Tremblay et al (1988) do
3
however find that adult levels of NMDA sensitive [ H]glutamate binding are seen at
PND22. This is in agreement with the data presented in this study and also that of Erdo
and Wolff (1990). One finding which seems to be constant throughout all these studies
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and in agreement with the present one is that the changes in postnatal binding are due to
changes in Bmax and not to alterations in K^. This lack of change in affinity for
3
[ H]L-glutamate binding postnatally would agree with the lack of change in the EC^q
3for L-glutamate modulation of [ H]dizocilpine binding as demonstrated here, since
these effects are mediated via the same site on the NMDA receptor.
In contrast to the evidence for an increase in binding to NMDA sites being due to
an increase in Bmax, Garcia-Ladona et al (1990) present data which may suggest that in
mouse deep cerebellar nuclei binding to EAA receptors remains constant postnatally.
They tentatively suggest that their [^H]glutamate binding paradigm may be labelling
NMDA receptors, and that the Bmov remains constant throughout postnatalmaX
development. This may be further evidence that the cerebellar binding site is different
to that in higher brain regions, and as such has a different developmental profile.
One factor which seems to be constant throughout most of these studies and is
also apparent from the data presented here, is that the NMDA binding site appears very
early in development. Since it is present at PNDO it is almost certainly present
prenatally. Represa et al (1989) provides evidence for this using human foetal tissue.
They measured NMDA binding sites at 18 weeks of gestation. Binding at earlier ages
have not been reported. In order to ascertain the significance of these binding sites at
such an early stage of development, functional studies should be performed if at all
possible to investigate the actions of the receptor at such an early stage of development.
Such studies should also determine whether the characteristics of this prenatally
expressed receptor are equivalent to those of the mature form of the NMDA receptor.
Insel et al (1990) using autoradiography performed the first detailed study of
NMDA receptor ontogeny in the rat forebrain. NMDA sensitive [^H]glutamate
binding sites were measured. Highest levels of binding were seen in the CA1 region of
the hippocampus, the dentate gyrus and the striatum at all ages studied (PND0-PND60),
in agreement with a previous study using adult tissue (Monaghan et al, 1983). In all
areas of the cortex and hippocampus binding increased postnatally to levels
significantly higher than adult between PND14 and PND28 before decreasing to
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PND60 levels. Interestingly at PND1 levels in the cortex and hippocampus ranged
from 50% to 125% of adult levels. This is far higher than that seen with any
radioligand binding study, including the present one. Insel et al (1990) report that a
pattern of binding consistent with that seen in the adult becomes apparent from PND14.
This study will be measuring the "agonist-preferring" state of the receptor as opposed to
the "antagonist" state as measured here. This may therefore account for the different
3
profiles and levels of binding. Miyoshi et al (1991) have performed [ H]CPP
autoradiography in the aged rat brain from two months to twenty one months of age.
They find that binding decreases with increasing age to levels significantly lower than
at two months of age in the cortex, caudate putamen and nucleus accumbens but not in
the hippocampus (Miyoshi et al, 1990). This provides further evidence for site-specific
alterations in NMDA binding sites during development.
A drawback of the data presented in the present developmental study therefore is
that the membrane preparation consisted of two brain structures which may have
different postnatal binding profiles. This preparation was used in an effort to try and
3
facilitate the [ H]CPP assay since binding is not particularly easy to perform, even
3
using mature tissue. With the advent of the new radioligand [ H]CGP 39653 (Sills et
al, 1991) it should now prove easier to carry out such a study since the for this
compound is 6nM and the assay has the added benefit of using the filtration technique,
thus making it easier to perform. This assay may measure the "antagonist preferring"
state of the NMDA binding site and may be an interesting comparison to that of Insel et
al (1990) who have measured the agonist state of the receptor. However, as already
3
discussed [ H]CGP 39653 may not be binding to the same receptor subtype or state as
3
[ H]CPP (see Section 4..4; Pingping etal, 1991). A different postnatal binding profile
3
to that seen with [ H]CPP may be found.
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3 34.5.4 Comparison Of \ Hldizocilpine and \ H1CPP postnatal binding
Adult levels of [^Hjdizocilpine binding (expressed per mg protein) regardless of
the membrane preparation used and the modulatory condition employed, are reached at
an earlier age than adult levels of [^H]CPP binding in the current study. This is in
agreement with many of the comparative studies (Tremblay et al, 1990; Erdo and
Wolff, 1990a; Morin et al, 1989; Paleos et al, 1990). All the studies are in agreement
that the postnatal changes in binding are due to an increase in receptor density with no
corresponding changes in receptor affinity. The developmental profile of the NMDA
glycine site most closely parallels that of the [ HJdizocilpine site in the present study.
This suggests that the rate limiting factor in NMDA receptor complex development
may be the postnatal appearance of the neurotransmitter. The NMDA neurotransmitter
site therefore develops at a slower rate than the ion channel site. One reason may be to
limit the number of binding sites and hence to limit overactivation during early
postnatal development when the immature CNS is susceptible to excitotoxic damage
(McDonald et al, 1988)). Another possibility is to reduce the rate of synaptogenesis
thus limiting the rate of programmed cell-death early in life.
3 3
The ratio of [ H]CPP binding sites to [ H]dizocilpine sites in synaptosomal
membranes prepared from adult tissue is approximately 1:1 in the present study. This
is in agreement with the findings of Thedinga et al (1989). Thedinga et al (1989) go on
to suggest that the real ratio of NMDA neurotransmitter sites to ion channels is 2:1.
3
This is because [ H]CPP is only labelling one population of sites, the "antagonist-
3
preferring" site and the density of NMDA-sensitive [ H]glutamate sites must be taken
into account. The differential rate of development of the two binding sites means that
this ratio is going to alter during postnatal development probably with regional
differences. An interesting reciprocal study which may provide a link between
3 3
postnatal [ H]CPP and [ HJdizocilpine binding would be to investigate the effects of
3
CPP, on [ H]dizocilpine binding in the presence and absence of L-glutamate. The
3
effects found should correlate well with the binding of [ H]CPP to the same membrane
preparation.
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Since both L-glutamate and glycine, both separately and together, can modulate
3the binding of [ H]dizocilpine to membrane preparations from very young animals
these three sites must be functionally coupled from a very early stage of development,
thus promoting NMDA receptor activation.
4.5.5 The postnatal development of non-NMDA receptors
The ontogeny of other EAA receptors has been studied. Two studies have
examined the ontogeny of the metabotropic receptor (Palmer et al, 1988; Dudek et al,
1989). Metabotropic receptor linked IP metabolism was investigated postnatally in
various brain regions. Different profiles were seen in the areas studied but generally in
all areas IP stimulation was highest in the first postnatal week, decreasing with
increasing age apart from in the olfactory bulb when a transient peak was seen at PND6
after which levels remained low until adulthood. Other notable transient peaks were
observed in the hippocampus at PND9 and the cerebellum at PND6 (Palmer et al,
1988). During these transient peaks QA stimulation was also sensitive to modulation
by NMDA indicating a mixed receptor population. This may correlate with the early
peaks in NMDA sensitive [ H]L-glutamate binding shown by Tremblay et al (1988)
but it in no way reflects the data presented here for postnatal binding to the NMDA
receptor. The findings may be an indication of the involvement of both the
metabotropic and the NMDA receptor in synaptic development and maintaining
synaptic plasticity in the developing CNS (Dudek et al, 1988; Nicoletd et al, 1986;
Bear et al, 1987). The metabotropic receptor may have an important role to play in
synapse development in the neonate, while NMDA receptor number is still low.
The KA receptor is the best studied non-NMDA receptor in the immature CNS.
This receptor has been reported to increase in number with no apparent change in
affinity, during postnatal development, in the cerebellum and hippocampus with peak
levels reached during adulthood in rats and at birth in humans (Campochiaro and Coyle,
1978; Ben-Ari et al, 1984; Represa et al, 1986). Erdo and Wolff (1990a) found a very
different pattern for both KA and AMPA receptor ontogeny. The density of both non-
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NMDA binding sites in rat cortex peaked transiently at very high levels during the first
few days of life, declining to adult levels, which were significantly lower than at birth,
during PNW3-4. These transient peaks were reached at an even earlier age than those
3
previously seen for NMDA-sensitive [ HJglutamate binding (Tremblay et al, 1988).
3 3Postnatal autoradiography studies of [ H]KA and [ H]AMPA binding (Miller et al,
1990; Insel et al, 1990) do not agree with the findings of Erdo and Wolff (1990).
These studies indicate an increase in binding to both KA and AMPA sites with
3 3
increasing age. Peak levels of [ H]KA and [ H]AMPA binding, higher than adult
levels, were seen during PNW3-4. Another anomaly between these two sets of data
3
concerns [ H]AMPA binding. Erdo and Wolff (1990a) found the alteration in binding
to be due to a change in receptor affinity with age whereas Insel et al (1990) proposed
that their changes were due solely to an increase in receptor density. This is the only
study of the postnatal development of EAA receptors where the affinity is proposed to
3alter with age. L-AP4, quisqualate, AMPA and ibotenate sensitive [ HJglutamate sites
have been demonstrated to be present in high density in the deep cerebellar nuclei of
mice at PND10 decreasing in number by PND25 and remaining low in the adult
(Garcia-Ladona et al, 1990). This is similar to their findings for the NMDA receptor.
The significance of these results is unclear, although it may be an indication that
different brain areas have different non-NMDA receptor ontogeny profiles as well as
different NMDA receptor profiles (Insel et al, 1990; Miller et al, 1990).
From the diversity of studies on EAA receptor ontogeny it is difficult to
adequately compare studies between different research groups and present a definitive
picture of the postnatal development EAA receptors. Different ligands, membrane
preparations, assay procedures and data presentation make comparisons difficult. In
general a comparison of the present data for [ H]CPP binding with that for the
ontogeny of KA and AMPA receptors of Insel et al (1990) and Miller et al (1990)
3
suggests that these receptors may develop in parallel. Perinatally [ H]CPP binding
sites, KA and AMPA sites are low although not in the study of Erdo and Wolff. A
rapid increase in the number of binding sites seems to occur during the second postnatal
-122-
week, reaching or overshooting adult levels during postnatal weeks 3-4 before falling to
adult levels. The [ Hjdizocilpine site appears to have a distinct developmental profile
when compared to other EAA receptors. The postnatal profile of KA and AMPA
receptor development found by Erdo and Wolff (1990a) would tend to confound the
idea that these three receptor sites develop in parallel.
4.5.6 The relationship of postnatal binding to functional studies
Apart from the good correlation of NMDA receptor development with
synaptogenesis and brain excitatory amino acid content, these data can be compared
with findings from postnatal investigations of EAA receptors acquired using different
techniques. The data from the present study shall be discussed in the context of
electrophysiological studies, neurotrophic studies, neurotoxicity studies and concluding
with a discussion on the role of NMDA antagonists.
(i) Electrophysiological studies
Murphy and Baraban (1990) have demonstrated in cultured ED 17
(embryonicday) cortical cells that NMDA induced currents are very small until after
14-15 days in culture (suggested to correlate to PND8-9). A reason for small currents
at these ages may be that there are few NMDA binding sites present and available to be
3
activated. This would agree with the current findings for [ H]CPP binding which is
very low up to PND8. Of course there is the anomaly of culturing to be taken into
account since there is no reason to believe that cultured cells behave as cells developing
in vivo would.
The AP5-blockable component of L-glutamate induced currents has been
examined in the rat visual cortex during postnatal development until PND21 (Stern and
Sakmann, 1990). They demonstrated an increase in this component until PND21,
however no adult data were reported in comparison. This study gives no indication of
receptor number or affinity, but could be explained by an increase in receptor number as
described here.
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(ii) Postnatal neurotoxicity of EAA's
The toxicity of NMDA and other neurotoxins active at EAA receptors alters
during postnatal development. KA is relatively non-toxic in the immature brain but is a
potent neurotoxin in the adult brain reaching such levels at PND21 (Coyle, 1983).
AMPA and QA both show a transient peak as neurotoxins between PND7 and PND14,
with AMPA being up to 15 times more potent than QA (McDonald and Johnston,
1990a). L-Glutamate also leads to potent neurotoxic effects in the foetal brain when
administered to pregnant mice and monkeys (Toth et al, 1987).
NMDA shows a well defined neurotoxic profile postnatally. This has been
widely investigated in the developing rat by McDonald, Johnston and co-workers.
Direct administration of NMDA (25nmol/0.5|il) into the striatum or the hippocampus at
PND7 resulted in a lesion, 21 times and 16 times respectively, larger than the
corresponding adult lesion. Damage at PND1, 14, 21 and 28 is of a similar degree to
that seen in the adult. Intermediate damage is seen at PND4 and 10 (McDonald et al,
1988). Using a PND7 rat pup model of maximal NMDA toxicity the neuroprotective
effects of competitive, non-competitive and glycine site neuroprotector, antagonists
have been demonstrated, with dizocilpine being the most effective (McDonald and
Johnston, 1990a, 1990b; McDonald et al, 1990a). All were effective after systemic
administration, presumably since the blood brain barrier is not fully formed.
Silverstein et al (1987) has also demonstrated that when rat pups (PND7) suffered an
3
acute hypoxic-ischaemic insult this resulted in a reduction in [ H]-glutamate binding
thereby implicating EAA receptors in the resultant neurotoxic damage.
The present study does not show maximal binding to the NMDA
neurotransmitter site at PND7. In fact quite the reverse is demonstrated since at PND7
3there is no measurable increase in affinity for [ H]CPP binding and no transient peaks
3in binding site densities. In addition, [ H]dizocilpine modulation by L-glutamate
and/or glycine is not enhanced at this age, with the EC^q values for modulation not
showing any increase in potency. Apart from the few studies showing a transient
expression of receptors at early ages which have not been reliably reproduced, receptor
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number and increased receptor affinity would not seem to account for the increased
toxicity of NMDA seen at this early age. However, adult levels of [ H]dizocilpine
binding are reached at PND5-8 in synaptosomal membranes, suggesting the ion channel
2+ 2+is well developed, therefore Ca will be able to easily enter cells. The lack of Mg
block, of NMDA responses at early postnatal ages, and lack of established inhibition
will however allow the receptor to be activated more easily at PND7 thus allowing
2+Ca easy access to the cells. These effects are not however confined solely to PND7
(Morrisset etal, 1990; Bowe and Nadler, 1990; Ben-Ari et al, 1990). Further studies
are required to establish the actual mechanism(s) of neurotoxicity at this particular age.
The mechanisms regulating events occurring after NMDA receptor activation such as
phosphorylation, protease, phospholipase and phosphatase activation which are all
2+initiated upon Ca influx during the cascade of events leading to eventual cell death
(Choi, 1990) are likely to all have individual ontogenic profiles. One or more of these
systems may be maximally expressed at PND7.
Quinolinate an NMDA agonist, does not show the same pattern of neurotoxicity
in the immature brain as NMDA (McDonald and Johnstone, 1990a). This may be
because quinolinate toxicity is mediated via a different pathway to that of NMDA
neurotoxicity. Quinolinate is a week neurotoxin in the immature brain. Alternatively,
this may be further evidence in support of the theory, that NMDA receptor subtypes
exist with different developmental profiles and properties.
The preliminary data presented in this study demonstrated that following an
acute hypoxic-insult in utero, at ED22/PND0, there is no immediate alteration in the
binding of [ HJdizocilpine, or of its ability to be modulated by L-glutamate and glycine.
This binding was performed immediately after the insult (i.e. membrane preparation
began within one hour of the insult). This is probably not enough time for EAA
mediated damage to be manifest, but it is still evidence to support the hypothesis that
the perinatal CNS is relatively resistant to damage produced by excessive EAA receptor
stimulation during a hypoxic-ischaemic insult (Kendall et al, 1991; Cherici et al,
1991). The finding that binding remains unaltered at this age is in agreement with
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biochemical and histological studies performed on tissue obtained at the same time
point. At one hour post-insult the perinatal rat brain shows little signs of having
suffered an hypoxic-ischaemic insult. Damage to the hindbrain however can be
detected histologically after three days survival (Kendall et al, 1991). Due to the
extreme difficulties in maintaining a sufficient number of control and hypoxic rat pups
for any length of time postnatally, further information at present is limited. Binding
studies would ideally be performed on pups from this model at various postnatal time
points, including PND7 and adulthood to discover any postnatal changes in NMDA
receptors which are manifest, as a result of a hypoxic insult over longer time periods.
Autoradiography with competitive, non-competitive and glycine site ligands may prove
to be more productive in this case since discrete alterations in NMDA receptor sites in
isolated nuclei could be examined.
(iii) Neurotrophic role of EAA's
The NMDA receptor has been implicated as having an important role in
promoting the survival of developing cells (Balazs et al, 1988a). NMDA (35fiM)
added to rat cerebellar granule cells (PND7 - 8) cultured in K+ (5-15mM) prevented
nerve cell loss normally seen in the presence of low K+ concentrations. AP5, AP7 and
dizocilpine all blocked this survival effect. AP5 had no effect on control cultures
grown in the presence of 25mM K+ and the absence of NMDA. Non-NMDA agonists
had no effect on the low K+ cultures (5-15mM). They concluded that chronic exposure
of NMDA can promote the survival of nerve cells due to activation of the NMDA
receptor. The extent of the effect was dependent on the concentration of NMDA and
K+ present and the length of time in culture (Balazs et al, 1988a,b; 1989). This
neurotrophic effect involving the activation of the NMDA receptor suggests that
exogenously released L-glutamate acting at the NMDA may be important for cell
survival during development (Balazs et al, 1989). Similar effects were observed in
cultured hippocampal granule cells (Brewer and Cotman, 1989). NMDA (20|iM) and
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L-glutamate (25|iM) were both capable of increasing neurite branching and extension.
Dizocilpine (20pM) blocked these effects thereby implicating the importance of
NMDA receptor activation.
The NMDA receptor therefore has an important role in the development of the
CNS. This explains why receptors are detected at such an early stage of life. Receptor
3 3
number, as measured by [ H]CPP and [ H]dizocilpine binding, may be low to reduce
excessive synaptogenesis during early life which would be wasteful of valuable
resources in the foetus and neonate, or to limit neurotoxicity which may occur due to
overactivation of the NMDA receptor.
A further reason for low receptor number in early life is that endogenous L-
glutamate is also low (Erdo and Wolff, 1990b). Gelbard et al (1990) showed that
depletion of dopamine (DA) in neonatal rats resulted in a significant loss of D^
receptors. They suggest that in the absence of endogenous neurotransmitter receptors
fail to develop adequately. Similar studies to establish the role of endogenous L-
glutamate on receptor development would prove very difficult given the ubiquitous role
of this neurotransmitter.
4.5.7 Cloning of the NMDA receptor
Electrophysiological evidence suggests functional differences between adult and
immature NMDA receptors which may not be identified using radioligand binding or
autoradiography. Cloning the adult and immature receptor, and determining their
respective amino acid structures may reveal differential subunit structures between the
two receptors as has previously been demonstrated for the muscle nicotinic
acetylcholine (nACh) receptor (Mishina et al, 1986).
They demonstrated that the adult nACh receptor had the subunit composition a^
6 e 8 whereas the immature receptor from foetal muscle had the sununit composition o^
B y 8. Before innervation, the foetal receptor predominates, during synapse formation
both receptors co-exist until the foetal receptor is fully replaced by the adult receptor
during later synapse formation (Sakmann and Brenner, 1978). It is certainly possible
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1978). It is certainly possible therefore that the NMDA receptor could be analogous to
the nACh receptor since they are both linked to cation conducting ion channels and that
functionally the NMDA receptor seems to alter postnatally.
Recently a number of reports have appeared describing the cloning of the adult
NMDA receptor. Moriyoshi et al (1991) have cloned a single protein with
physiological and pharmacological properties of the characterised NMDA receptor-
channel complex. Meguro et al (1992) have cloned a different protein, which in
combination with that of Moriyoshi et al (1991) results in a functional heteromeric
NMDA receptor. These proteins show considerable homology with each other and
also with cloned non-NMDA ionotropic receptors (Hollman et al, 1989; Keinanen et
al, 1990). A detailed functional analysis of cloned adult and immature NMDA
receptors may provide information on the nature of receptors from mature and
immature tissue. In addition the existence of receptor subtypes during postnatal
development may be demonstrated.
4.5.8 Therapeutic potential of NMDA antagonists in the immature brain
The presence of NMDA receptors early in life has been demonstrated. This
may provide the opportunity to use NMDA antagonists therapeutically in disorders
resulting from NMDA receptor activation in the neonate (McDonald and Johnstone,
1990a). The problem with this is undoubtedly the potential hazardous side effects.
Acute therapy may be acceptable since the short-term side effects may be masked by
the greater neuroprotective benefit to the patient. Side effects include depression of
synaptic transmission and a transient interference with synaptic development, as well as
a retardation of learning and memory mechanisms. There is evidence that acute
administration of dizocilpine, as a neuroprotectant, may in fact lead to greater neuronal
damage due to NMDA receptor upregulation, a particular hazard in the developing
brain (McDonald et al, 1990b; McDonald and Johnston, 1990a). The potential for
chronic therapy with NMDA antagonists may be extremely limited during postnatal
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development again due to long term interference with synaptogenesis and the resultant
adverse effects on CNS development, learning and memory. Therefore the risks of
chronic treatment may outweigh any potential benefits.
4.6 CONCLUDING REMARKS
The main findings from this study are summarised below:-
3 31. [ H]CPP and [ Hjdizocilpine each bind with high affinity to a single population
of sites in immature and mature rat brain, the NMDA neurotransmitter site and
the ion channel site respectively.
2. Glycine, a full agonist, and HA-966, a partial agonist at the NMDA glycine site
discriminate between the binding of [^H]CPP and [^H]D-AP5. These two
competitive antagonists were previously thought to be binding in a similar
manner to the NMDA neurotransmitter site. HA-966 enhances the binding of
[^H]CPP while it inhibits the binding of [^H]D-AP5. Glycine enhances and
inhibits the binding of [^H]CPP while it only inhibits the binding of [^H]D-AP5.
3. 7-Chlorokynurenate, an antagonist at the glycine site on the NMDA receptor,
does not differentiate between the binding of [^H]CPP and [^H]D-AP5. It
weakly inhibits the binding of both ligands, probably through a direct interaction
at the neurotransmitter binding site and not by an allosteric action at the glycine
site. Evidence from 7-Clkyn actions in the presence of HA-966 however
suggest that 7-Clkyn may bind preferentially to the state of the neurotransmitter
site induced by CPP.
3 3
4. It is suggested that either [ H]CPP and [ HJD-AP5 are binding differently to the
neurotransmitter site and thus inducing different conformational states of the
receptor which are modulated differendy by HA-966 and glycine, or binding of
glycine and HA-966 may be inducing different conformational states of the
glycine site which allow differential binding of ligands to the neurotransmitter
site. These findings could also be explained by the existence of multiple
NMDA receptor isoforms as opposed to one receptor in multiple conformations.
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5. A synaptosomal membrane preparation has been successfully used in an
ontogeny study to demonstrate the postnatal development of the NMDA
neurotransmitter site and associated ion channel.
3 3
6. The binding of [ H]CPP and [ H]dizocilpine during postnatal development
3show different profiles. Adult levels of [ H]dizocilpine binding are reached at
3
an earlier age (PND5-8) than [ H]CPP binding in an identical membrane
preparation (PND21-24).
7. The differences between [ H]dizocilpine binding to whole and synaptosomal
membranes postnatally may be due to different populations of receptors being
measured. Extra-synaptic receptors if they exist may also be measured using
whole membranes.
8. The alterations in all postnatal binding were due to a change in receptor number
rather than to an alteration in receptor affinity.
39. Modulation of [ Hjdizocilpine binding during postnatal development (PNDO-
PND28) by glycine and L-glutamate was similar to that seen in adult tissue.
This suggests that the neurotransmitter site, allosteric glycine site and the ion
channel on the NMDA receptor complex are functionally coupled from an early
stage of development.
Molecular cloning of the NMDA receptor is currently underway. This may
provide evidence for the existence of multiple NMDA receptor subtypes thus
3 3
explaining the differences between [ H]CPP and [ H]D-AP5 binding. In addition, the
structure of the immature NMDA receptor may be revealed to be distinct from that of
the adult. This may explain why mature and immature receptors have different
functional characteristics.
In summary, therefore NMDA receptors are present during development and
antagonists of sites on the complex may have a potential as therapeutic agents for early
postnatal ages. Acute administration may be ethically acceptable if the potential
benefits outweigh the risks. Chronic therapy with such compounds is likely to be
unacceptable during prenatal and postnatal development throughout childhood due to
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the risks of harmful effects on CNS development outweighing any benefits. Further
research is required in order to try and reduce the risks. Different subtypes of NMDA
receptors may have different physiological roles. For example, NMDA receptor
subtypes may be amenable to selective targeting, i.e. a selective "quinolinate receptor"
antagonist may have different properties to NMDA antagonists already characterised.
With the availability of so many sites for therapeutic targeting on the NMDA receptor it
may be prudent to investigate the role of the different sites in NMDA receptor
activation in various pathological states. Site-specific NMDA antagonists may
therefore be useful therapeutically in the treatment of immature seizures, epilepsy and
febrile convulsions, damage due to hypoxic-ischaemic insults, and amino acid
metabolism disorders, non-ketotic hyperglycinaemia and sulfite oxidase deficiency
which ultimately lead to brain damage in the infant due to overactivation of EAA
receptors (McDonald and Johnston, 1990a). Investigation into the events occurring
2+after NMDA receptor activation, and Ca entry, which lead to neurotoxicity and
eventual cell death may prove fruitful in that selective enzyme inhibition may result in
fewer side-effects in the immature and mature brain.
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APPENDIX 1: SURGICAL PROCEDURE TO INDUCE AN ACUTE
HYPOXIC INSULT IN UTERO
Surgery was performed on time mated pregnant Lister Hooded rats. Rats were
used 22 days after pregnancy was confirmed (ED22/PND0). Dams were anaesthetised
using 2.5% isoflurane in a 30% 70% mixture, anaesthesia being maintained,
throughout surgery, with 0.5 - 1% isoflurane.
A midline incision was made to expose one uterine horn. Each utero-placental
blood vessel was clamped with artery clips and replaced in the dam for 30 min. At the
end of the hypoxic episode the artery clips were removed and reperfusion took place.
Pups were rapidly excised, the brains being used for biochemical and histological
studies. Brain tissue used for these binding studies was obtained from pups not
required in this large-scale study. Brain tissue (hypoxic and control) was then
processed in the normal way as already described in Section 2.3 and membranes
prepared. This surgical procedure is routinely used (Kendall et al, 1991).
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